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Preface
The work described in this dissertation was collaborative research conducted in
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Technological University (MTU, MI) with assistance from the Chemical Advanced
Resolution Methods (ChARM) lab at MTU’s Great Lakes Research Center (GLRC) and
the department of Biomedical Engineering at Saint Louis University (MO). The
hypotheses, experimental design, measurements, and analysis mentioned in the
dissertation were developed and written by me with inputs from the collaborators as
mentioned below. Dr. Caryn Heldt did the grant writing and funding acquisition that
supported this work with some help from me on hypothesis formulation and experimental
design.
Chapter 3 discusses the development of the framework by using a phase diagram
to understand virus purification in the aqueous two-phase system (ATPS). The
experiments were designed by me with guidance from my advisor Dr. Caryn Heldt.
Matthew Weiss (undergraduate student) helped me generate the phase diagrams, Michael
Schroeder (undergraduate student) helped me repeat the ATPS formation for porcine
parvovirus (PPV), and GlendyEscalante-Corbin (MiCUP student) helped me with the
ATPS generation for human rhinovirus-14 (HRV). Dylan Turpeinen (Ph.D. Candidate)
helped me perform the dynamic light scattering experiment for the determination of PPV
aggregation in the presence of citrate. I collected and analyzed the infectivity data and
created the figures, under my advisor’s supervision. The chapter was written by me,
reviewed and edited by Dr. Heldt and reviewed by Dylan. The chapter is published in the
Journal of Chromatography B (2019).
Chapter 4 demonstrates the virus purification enhancement by osmolyte addition
in ATPS. I developed the hypothesis and experimental design with insights and guidance
from Dr. Heldt. Undergraduate students Michael Schroeder, Bianca Jones, Audrey
Lyons, and Seth Kriz helped with the generation of phase diagrams, system generation
for the purification of PPV, and enveloped human immunodeficiency virus-group
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specific antigen virus-like particle (HIV-gag-VLP), and physical properties of phases.
The method development and quantification assay for osmolyte detection in the citraterich phases by LC-MS was performed by Dr. Maryam Khaksari (GLRC). All the figure
designs and data analysis were done by me and reviewed by Dr. Heldt. The manuscript is
in preparation for submission in a peer-reviewed journal.
Chapter 5 demonstrates the development of a novel ATPS with inclusion of
affinity peptide ligand for improved specificity and driving forces. The working
hypothesis was generated by me, Dr. Heldt, and Dr. Silviya Zustiak (Saint Louis
University, MO). Half of the work was conducted at Saint Louis University in Dr.
Zustiak’s lab, and the other half was carried out at Michigan Tech in Dr. Heldt’s lab.
Stephanie Kroger from Dr. Zustiak’s lab synthesized and purified the PEG-peptide
conjugate and characterized the polymer to confirm the conjugation and ligand
accessibility. The virus purification, infectivity assay, contaminant partitioning
experiments, and data analysis were performed by me under the guidance of Dr. Heldt.
The majority of the chapter was written by me and reviewed by Dr. Heldt and Dr.
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and acrylamide quenching. The manuscript is in preparation for submission to a peerreviewed journal.
Chapter 6 summarizes the main conclusions from chapters 3, 4, and 5. The
findings of each chapter were interpreted and concluded by me with the guidance of Dr.
Heldt. Dr. Zustiak helped in interpreting the findings of PEG-peptide conjugate
functional analysis from chapter 5. The majority of future works proposed are my
thoughts and initiatives discussed with Dr. Heldt. Some of the hypotheses and directions
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graduate students in Dr. Heldt’s lab and at Clemson University in Dr. Sapna Sarupria’s
lab.
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Abstract
Viral infections regularly pose detrimental health risks to humans. Preventing
viral infections through global immunization requires the production of large doses of
vaccines. The increasing demand for vaccines, especially during pandemics such as
COVID-19, has challenged current manufacturing strategy to develop advanced unit
operations with high throughput capability. Over the decade, the upstream processing
responsible for synthesizing viral products in cell cultures has shown significant success
in yielding high titers of viruses and virus-like particles. The progress in the upstream
stage has now shifted the bottleneck to the downstream processing (DSP). Overlooked
for decades, the DSP responsible for viral product purification from the cell culture
contaminants requires a makeover with the development of new purification strategies
and an upgrade in the traditional unit operations. The current DSP train employing
chromatography and filtration methods have been suboptimal in efficiently processing
comparatively complex and fragile viral particles. Thus, the lack of platform technology
for viral vaccine and biotherapeutic DSP has led to a search for alternative and innovative
methods that have not only high-throughput capabilities but also have potential for
continuous operation.
In the pool of potential technologies, aqueous two-phase system (ATPS) has shown
to be a promising candidate with the numerous advantages over conventional methods.
However, an unambiguous and complex biomolecule partitioning mechanism has
required a large experimental setup for optimizing virus purification. This work focused
on a framework utilizing a phase diagram of a rationalized polyethylene glycol-citrate
system to optimize virus purification. The partitioning behavior of two non-enveloped
viruses, porcine parvovirus (PPV) and human rhinovirus-14 (HRV), were studied in
various system compositions. A tie-line length framework was utilized to define the
systems and relate the partitioning behavior of viruses with different surface
physicochemical characteristics.
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1 Introduction
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1.1 Viruses, infectious disease, and immunity
Pathogens have been disrupting the functioning of living beings for ages. Viruses
are among the five classes of pathogens responsible for causing mild to severe infectious
diseases in animals and humans. These pathogens are essentially small parasites made of
protein cage housing nucleic acids (Figure 1-1) [1]. In some types of viruses, the protein
cage is enclosed in an external lipid bilayer (Figure 1-1) [1]. Viruses are designed by
nature to obligatorily invade a cell utilizing the host cell’s metabolic machinery for their
replication [2]. The shedding of progeny viruses leads to an infection of adjacent cells
that spreads throughout the tissue or organ. During the replication process, viruses seize

Figure 1-1. The structural basis of viruses: non-enveloped virus and enveloped virus.
Virus images were created in BioRender.
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the functioning of the host cells, thereby inhibiting the vital operation of a tissue or an
organ. A human body encounters numerous types of viruses via different routes of
transmission, such as air, water, food, or bodily fluids.
Table 1-1. Human virus species and disease [3]
Virus Species
Structure
Host cell
Influenza A
Human
Immunodeficiency
virus
Hepatitis B

Respiratory cells

Flu

Lymphocytes

AIDS

Liver cells
Lung cells

Hepatitis
Cold sores and
genital herpes
Fever, rash

Intestinal cells
Liver cells
Skin and mucosal
cells
Respiratory cells
Gastrointestinal cells

poliomyelitis
hepatitis
Genital/skin warts,
cervical cancer
Flu
Gastroenteritis

Enveloped

Herpes simplex virus
Measles
Polio virus
Hepatitis A
Human papilloma virus
Human rhinovirus
Rotavirus

Nonenveloped

Disease

Viruses are one of the integral parts of every ecosystem and have played an
essential role in the human evolutionary scheme [4, 5]. However, wild-type viruses are
prominently known for causing diseases (common examples of viruses in Table 1-1).
Woolhouse and coworkers (2012) have listed over 200 viral species known to infect
humans, as of 2005 [6], and the list is expected to expand at a rate of 2 viral species/year
[7]. With the identification of yellow fever virus in 1901 to severe acute respiratory
syndrome virus-coronavirus-2 (SARS-COV-2) in 2019, numerous viruses have been and
are causing life-threatening infections in humans. Some viruses such as influenza or
rotavirus cause acute diseases, which are sudden and severe infections. Other viruses,
such as human immunodeficiency virus (HIV) or human papillomavirus (HPV), tend to
persist in causing long-term or chronic diseases. Viral infections of different virus species
are linked with a characteristic behavior in terms of etiology, pathology, and
epidemiology. Although these areas are a wide field of focus, it is crucial to understand
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the viral infections. Each virus species is addressed to infect a specific type of host cells
which are present in different parts of the body. It is also established in the previous
studies that viral infection vulnerability varies with season [8]. Commonly known
seasonal viruses include influenza and common coronavirus, while some of the viruses
that spread through direct contact such herpes virus, HIV, hepatitis A virus do not have
any seasonal constraints to cause infections.
One of the vital lines of defense is an immune system that is equipped to protect a
body against any foreign antigens. If a virus enters a body, the immune system detects the
structural composition of the virus or the virus-infected cell and responds to inhibit the
viral activity [9]. The immune system operates with two types of responses, i.e., A)
innate immune response and B) adaptive (or acquired) immune response [10, 11].
Initially, the innate immune response is triggered when a foreign body or non-self
molecules are identified by a family of proteins called pattern recognition receptors
(PRR). PRR recognizes a pathogen-associated molecular pattern, such as
lipopolysaccharides of gram-negative bacteria, ds-RNA of viruses, or mannan of yeast,
which are commonly displayed by a group of germlines [9]. The action by the innate
immunity is fast (hours to days). However, the response is generic towards a group of
germlines. Simultaneously, the adaptive immune response is triggered that recognizes
each pathogen family and species, precisely and in detail. The response action to seize the
antigen’s activity and proliferation is highly specific. The virus-infected cells and a
particular type of professional cells display the antigenic information in the form of
epitopes, a small antigenic peptide, on the cell surface. T-cells, a type of immune cell,
detect the antigenic peptide through a complex interaction and undergo functional
transformation known as maturation to eliminate the virus-infected cells.
In addition to the cell-mediated immune response by T-cells, another group of
cells called B-cells, are equipped to synthesize antigen-specific small proteins known as
antibodies [12]. The antibodies are designed to attach to a specific region on the virus
surface to either neutralize the pathogen or disrupt the virus replication cycle [13]. Both
the cell-mediated response by T-cells and antibody-mediated response by B-cells develop
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a prolonged memory to detect and neutralize the re-exposure of the same virus. The
adaptive immune response is highly efficient and robust as compared to the innate
immunity to defend against most viral infections. The response kinetics of the adapted
immunity is as fast as the innate response, reaching the peak within hours to days only if
the acquired immunity is developed prior to the viral infection. The primary response
time is much slower (days to weeks) for the first exposure [10]. The spread of disease due
to the exposure of viruses could be averted or mitigated by inducing a stimulated immune
response through the safe medical intervention of vaccination.

1.2 Overview
Public health can be protected by designing safe and highly immunogenic
vaccines and ensuring a global outreach of the vaccines. A literature review is presented
in chapter 2 on the traditional vaccine designs and the current development in designing
modular vaccines to improve the immunogenicity and safety for strong long-term
protection. Further, the outreach of vaccines depends on the capacity and portfolio
flexibility of a production plant. The chapter reviews the vaccine manufacturing stages
with a focus on the conventional upstream and downstream processing strategies along
with the progress made in each stage to identify and resolve the bottlenecks. As the focus
of the dissertation is the downstream purification of the viruses and virus-like particles,
mechanisms used in the unit operations of the downstream processing stage have been
thoroughly discussed, and the bottlenecks of the conventional unit operations have been
identified. Moreover, a potential and unconventional method, aqueous two-phase system
(ATPS), a liquid-liquid extraction operation, has been reviewed. In the end, gaps in the
understand driving forces of ATPS and optimization framework for preferential
biomolecule recovery in ATPS have been identified.
In chapter 3, a framework is proposed to optimize virus recovery and purity in
aqueous PEG-citrate system. The system is based on a rational selection of processing
parameters and using the phase diagrams consisting of binodal curves and tie lines of
aqueous two-phase systems. The recent evidence of unique virus surface characteristics
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such as hydrophobicity and charge, combined with the phase forming component
characteristics such as polymer amphiphilicity and salting-out ability of ions, were
considered in the system selection. Two non-enveloped virus models – porcine
parvovirus (PPV) and human rhinovirus-14 (HRV) were included in the study. Further,
viral partitioning behavior was studied in the PEG 12kDa-citrate system using a tie line
framework to develop an optimization method. A high PPV recovery (~80%) and purity
were achieved in the PEG-rich phase at the highest tie-line length studied, owing to a
relatively high surface hydrophobicity and net negative surface charge of the virus. The
proposed setup significantly reduced the experimental space required for optimizing the
virus purification, which is one of the hindrances in commercial implementation. Low
recovery of uncharged HRV (~35%), due to the system operated at the isoelectric point
of the virus, indicated the necessity of charge in partitioning. The virus models used
demonstrated not only the dominance of viral surface hydrophobicity but also indicated
the importance of viral surface charge in driving the viral particles to the contaminantpoor phase.
In chapter 4, additives were included in the PEG 12kDa-citrate system to enhance
the driving forces for viral partitioning. Water structure modulator molecules, known as
osmolytes, were used as additives to achieve high virus recoveries and alleviate the
processing conditions such as high system composition and viscosity. Osmolytes glycine,
betaine, TMAO, mannitol, and urea were used in the study. Initially, the influence of
osmolytes on the phase diagrams was studied to elucidate amendments in the phase
characteristics. Further, the efficiency of the osmolyte class on viral partitioning was
screened to identify the influential osmolyte. Two virus models, a non-enveloped PPV
and an enveloped human immunodeficiency virus-group specific antigen virus-like
particles (HIV-gag-VLP), were used to demonstrate the enhanced recovery. The osmolyte
efficiency for improving virus recoveries followed the order glycine > betaine > TMAO
> urea > osmolyte-free control. Overall, >90% virus recoveries could be achieved in
glycine or betaine-containing systems. However, none of the osmolytes affected the
contaminant protein partitioning yielding a pure PEG-rich phase with viruses. Further,
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the tie line framework was employed for each osmolyte-containing system to
demonstrate that high partitioning can be achieved irrespective of the volume ratios of the
PEG-rich phase to the citrate-rich phase. Overall, the study demonstrated a strategy to
enhance virus purification in ATPS and alleviate high concentration processing
conditions that pose challenges in manufacturing.
In chapter 5, the use of a novel affinity ATPS was postulated to improve virus
partitioning by enhancing the affinity of the PEG-rich. The specific binding affinity of a
trimeric peptide WRW towards PPV was harnessed to enhance the virus recovery in the
PEG-rich phase at lower volume ratios, where there are lower PEG-rich phase volumes.
90-100% PPV recovery was obtained in the PEG-rich phase of the systems
complemented with the affinity-peptide ligand, without affecting the contaminant
partitioning. Further, the affinity peptide-PEG conjugate was characterized by acrylamide
quenching that demonstrated the accessibility of the peptide. The accessibility of the
peptide was a significant success as PEG chains have shown to shield smaller affinity
tags in past experiments. Overall, the use of multimodal affinity peptides achieved high
virus recovery in the systems where the PEG-rich phases are the dispersed phase, thereby
alleviating the processing challenges of ATPS.
In the concluding chapter (chapter 6), the impact of the current research on the
biomanufacturing is expressed by discussing the novel findings. In the end, a course of
future work is proposed to gain additional insights into the mechanism of viral
partitioning in ATPS and scale-up implementations.
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2.1 Vaccines and biotherapeutics
One of the ways to protect an individual or public health is to develop an
individual or herd immunity against viral infection through vaccination. As stated earlier,
the immune system generates a robust defense mechanism if it recognizes a generic or
specific component of a virus. This is what the vaccines are intended to do. The main
constituent of a vaccine is a virus component immunogen presented to the body to induce
an immune response against the injected agent. The injected immunogen stimulates an
immune response in the same way as the virus exposure. The adaptive immune system
generates a memorized pathway to inactivate the virus which is undertaken by the innate
immune system in the event of reoccurrence of a similar antigen [1]. The memory of the
immune system results in a short or long-term immunity against the virus exposure.
There are numerous ways to present an immunogen to the immune system.
Conventional vaccines are composed of live attenuated viruses (LAV) and inactivated
viruses. The two types of vaccines are prepared using a whole wild-type virus. The
attenuation of virus is done by passaging the wild-type virus in a novel growth condition
or reassorting the genotypes of virus species [2, 3]. The unfamiliar growth condition
involves a repeated propagation of a wild-type virus in a non-human cell line or an
abnormal growth media and temperature. which renders the virus less virulent or nonpathogenic to the original host [3-5]. The later found reassortment method could be
accomplished by coinfecting multiple viruses of similar family but different serotypes or
subspecies [6-8]. The coinfection results in a mismatch of the interspecies virus genes
producing viruses with structural components of the co-infected viruses. A specific virus
isolate with immunologically relevant segment and attenuating segment is chosen as a
vaccine strain [5]. The second type of whole-virus immunogen is an inactivated vaccine.
The inactivated vaccine type comprises of viruses that have been treated chemically by
formaldehyde, formalin, and β-propiolactone, or physically by gamma irradiation to
disable the infection process [9]. The other types of vaccine designs include presenting a
virus structural fragment such as spike protein and nucleic acid, which are called as
subunit vaccines. The subunit vaccines are the safest of all the types of vaccines,
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however, they provide lowest immunogenicity [10]. Monovalent hepatitis B is one of the
well-established viral subunit vaccines available in the market and approved by the WHO
[11]. A lower immune response by the subunit vaccines require higher amounts of
immune-adjuvants or carriers to optimize the antigen presentation and enhance
immunogenicity [12, 13]. Recent developments in the antigen presentation have used
VLP as a modular vaccine. VLPs are either viruses void of genomes or antigenic proteins
self-assembled to mimic the authenticity of virus structure [14]. Hepatitis B and HPV
vaccines are some of the widely accepted and commercially available vaccines [15, 16].
As the VLP-based vaccines have recently gained attention, there are fewer approved
vaccines than the whole virus vaccines. However, a substantial progress is being done
with more than 20 vaccines approved or in clinical trials [17].

2.2 Viral-based Biotherapeutic Manufacturing
Extensive progress has been made to identify various virus forms as
biotherapeutic modalities to induce immunity and treat pre-existing diseases. However,
the outreach of biotherapeutics across the world is possible only if they can be produced
in sufficient quantities to meet the demand of the ever-growing population and strict
regulatory norms. Manufacturing effective biotherapeutics in large quantities has been a
challenging question for decades due to their complex nature and behavior. Production of
biotherapeutics is majorly divided into three stages (Figure 2-2). The upstream stage that
deals with the synthesis of active biological ingredients through high-level expressing
cell lines, followed by the downstream processing (DSP) to recover and purify the active
ingredient from a complex biological broth, containing contaminants such as host cell
proteins (HCP), nucleic acids, and growth media components. The final stage of
formulation ensures the targeted biologic is suspended in a specifically composed
solution to provide prolonged biotherapeutic stabilization during transportation and
storage. Although the manufacturing stages remain broadly the same, the process design
of the individual stage differs for different viral products due to a high diversity in the
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tropism and physicochemical properties. The current focus of the discussion will be the
upstream and downstream processing of viral- and viral-like particle-based
biotherapeutics and vaccines. The challenges and advances of each stage are explored in
the following sub-sections.

Figure 2-1. General Viral vaccine and biotherapeutic manufacturing scheme

Before understanding the manufacturing strategies of the viral biotherapeutics, it
is essential to grasp the research efforts made in the pre-upstream stage to determine the
feasibility of an appropriate cell platform for viral vaccine production. Various cell lines
are susceptible and permissive for a virus infection. The production of whole virus
vaccines has been mainly focused on mammalian, insect, and chicken embryonic (eggs)
cell lines (Table 2-1). The traditional methods to produce vaccines have utilized chicken
embryonic fibroblast (eggs) cell line [2]. However, the vaccines produced in egg-based
cell line had shortcomings due to lack of egg supply, possible virus strain mutations,
12

difficulty in quick adaptation to produce circulating virus strains, possibility of allergies
and anaphylactic reactions [18-20]. Thus, the newer generation of vaccines are majorly
produced in the primary or diploid cell lines [21]. However, not every cell line has the
potential to produce high titers of virus. Different virus species have different sites of
replication, mechanisms of virus-host interaction, and growth kinetics [22]. Some viruses
require cell nucleus for replication such as influenza virus, herpes simplex virus-1, and
adenovirus [23, 24]. Other viruses replicate in the cytoplasm, such as poliovirus, severe
acute respiratory syndrome coronavirus (SARS-CoV) [24, 25]. Moreover, most viruses
replicate in mitotically functional cells with a few exceptions that can replicate in nondividing cells such as human immunodeficiency virus (HIV) [26, 27]. Progeny viruses
utilize different modes of cell-to-cell transmission, such as extracellular space or cell-cell
direct contact sites [28, 29]. Overall, the factors associated with the host cell
susceptibility and viral life cycle are considered while choosing an appropriate cell
substrate, and even the susceptible cell lines are genetically modified to yield a clone that
increases the viral titer [22].
The current motivation is to design a platform cell substrate for a wide range of
viral vaccines. However, a potential cell line is screened for multiple characteristics such
as the ability to produce high titers of potent viruses, maintain the cell culture stability for
longer passages, and meet the safety guidelines of identity, stability, and purity of master
cell banks [30, 31]. Most manufacturers are currently inclined towards the approved host
cells for a faster commercialization of vaccines due to the strict safety regulations by the
FDA and WHO [32]. In this interest, Vero cell line has been widely accepted in the
industries for the production of vaccines [30, 32-34].
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Table 2-1. Established cell lines currently used in vaccine production and the virus
susceptibility [22].
Cell line
Origin
Virus susceptibility
Poliovirus, influenza A
Vero
Green monkey kidney
virus, respiratory
syncytial virus,
Madin-Darby
Influenza A, influenza
canine kidney
Dog Kidney
B
(MDCK)
Human embryonic
Varicella zoster virus,
MRC5
lung
rabies, hepatitis A
WI-38

Human embryonic
lung

Rubella, adenovirus

A VLP may be a type of subunit vaccines self-assembled to resemble a virus
structure or an empty capsid of wild-type virus void of genetic material, making it a noninfectious antigen. VLP expressions have been successfully demonstrated in a wide range
of cell platforms such as bacteria, yeast, insect cells, mammalian cells, and plant cells
(Table 2-2). However, each of the cell platforms has advantages and disadvantages,
which are mentioned in Table 2-3. The main factors that differentiate between the cell
platforms are feasibility of expression by gene recombination or delivery, expression
levels for higher antigen concentrations, and post-translational modifications for a close
resemblance of a wild-type antigen [17, 35, 36]. Recently licensed VLP vaccines for
HepB virus [37] and Gardasil for HPV [38] have utilized yeast-based cell substrates for
the VLP expressions.
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Table 2-2.Commonly used cell platforms for producing virus-like particles
Commonly used cell platforms for producing virus-like particles
Virus-like particle

Expression system

Cell line

HBsAg*

Yeast

HPV 6, 11, 16, and
18

Yeast

HPV 16 and 18

Baculovirus - Insect

Ebola

Mammalian

HEK-293T

[40]

Zika

Mammalian

Expi293F

[41]

Saccharomyces
cerevisiae
Saccharomyces
cerevisiae
Trichoplusia ni
Rix4446

References
[37]
[39]
[39]

*HBsAg: Hepatitis B surface antigen

Table 2-3. Advantages and disadvantages of cell platforms for VLP production [35]
Cell
Advantages
Disadvantages
platform
• Ease expression
• Improper protein
glycosylation
• Scale-up potential
Yeast
• Inconsistent folding &
• Low production cost
assembly
• Easy expression
• Forbid glycosylation
Bacteria
• Scale-up potential
• Presence of endotoxins
(E. coli)
• Low production cost
• Closely related to natural
• High production cost
Mammalian
host
• Lower titers
Cell
• Appropriate post
translational modifications
• Scale-up potential
• Limited post translational
modification
• High titers of correctly
folded VLP
• Difficult baculovirus
Insect Cell
contaminant removal
• Minimum risk of other
pathogens as compared to
mammalian cell lines

Some of the schemes for viruses and VLP manufacturing are similar in the
upstream and downstream stages if a similar cell platform is used to produce VLP as
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traditional virus vaccine. The current discussion will focus on the infectious virus
production from the mammalian cell platform.

2.2.1 Upstream Processing
The advancements in the host cell screening, and media composition have
contributed significantly towards increasing the throughput of the biotherapeutics and
vaccines at a lab-scale. However, scale-up of biotherapeutic manufacturing is very
challenging as the dynamics of the culture environment changes significantly at larger
scales. The following focus to improve the production capacity of viral vaccines was
shifted to optimize the bioreactor designing and operation to yield highly potent antigens.
Currently, the adherent cell lines, that proliferate when attached to a surface, are
predominantly used in the biotherapeutic manufacturing [42]. Moreover, cells maintain
their productivity in the exponential growth phase and incur a productivity loss when the
growth kinetics reaches equilibrium with the death kinetics due to apoptosis and
autophagy [43, 44]. However, some viruses are produced with a single harvest with
higher cell densities of metabolically active cells with a low multiplicity of infection
(MOI) [45, 46]. The common strategy to scale-up the cultivation is a stepwise increment
in the bioreactor size, which is performed in different formats of bioreactor systems [47].
There are two major types of cultivation methods used for cell proliferation and
virus propagation- static and dynamic systems [48]. The static bioreactors such as Tflasks, cell stacks, and roller bottles are vessels with unagitated culture media. The
dynamic systems such as stirred tank, and wave bioreactors have mechanical agitators to
induce mixing for uniform distribution of the media components. Roller bottles are
preferably employed for small scale cell culturing, seed cells and inoculate viruses. For a
large-scale production, the dynamic systems are used. The systems that achieve higher
cell densities (~106 cell/mL) are of great interest [49]. In this interest, stirred tank
bioreactor is preferentially used in the industries for its expertise in operation and
hydrodynamic modelling [42]. Most cells are adherent cell lines that is they require a
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surface to proliferate except some newly adapted suspension cell lines such as Vero [50,
51] and MDCK [52]. Current operation of stirred tank bioreactors utilizes microcarriers
made of polymers as a substrate for the cells to grow [43, 46]. Trabelsi et. Al. (2012)
were able to achieve 4x106 cells/mL of MRC5 cell lines and produce 106.5 infectious
measles virus/day using a non-porous cytodex 1 microcarrier in 7 L stirred tank
bioreactor. Fixed bed bioreactor is another option being explored for to achieve a high
cell density and higher titer of viruses. A study demonstrated that the iCeLLis Nano, a
packed bed bioreactor with medical grade polyester microfibers by Pall Corporation,
achieved a high cell density of 4x106 cells/mL of Vero cells [53]. Moreover, there was a
significant increase in the hepatitis A and chikungunya viral vaccine doses as compared
to the roller bottle and other undisclosed commercial packed bed bioreactors.
The efforts made to increase the virus production capacity in the upstream sector
are impressive. However, the increased virus titer and higher cell densities increases the
complexity of the culture broth that has pushed downstream sector to purify and recover
high amounts of viruses from a complex HCP profile. Thus, the current bottleneck in the
vaccine manufacturing has been recognized to be the downstream processing and efforts
are being geared towards the recovering viruses from crude stock [54].

2.2.2 Unit Operation Mechanisms in Downstream Processing
A high vaccine production throughput relies on the yield of unit operations
employed to recover viral agents from the contaminants. The purification of viral
particles is crucial as the contaminants from the culture broth are unwanted agents in the
vaccines and biotherapeutics. The regulatory bodies such as the FDA, CDC, and WHO
have imposed stringent guidelines for the industries to evaluate and demonstrate that the
final product has minimal traces of the contaminants. For example, the limitations
suggested on the residual HC-DNA originating from non-tumorigenic continuous cell
lines, e,g, Vero, is less than 10 ng/dose for parental inoculation and 100 µg/dose for oral
vaccines [55]. A robust process design must be implemented to ensure the final products
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are nearly free of contaminants. The purification process exploits the differences in the
surface characteristics of the viral particles and contaminants (proteins and nuclei acids)
to gently separate them without disturbing the structural and functional integrity of the
antigens. However, the virus surface and behavior are very complex, and they share some
physicochemical properties with the contaminants. This makes the purification process
very complicated and thus utilizes a train of unit operations each harnessing a unique
intermolecular interaction to differentially interact with the biomolecules. The
methodology, advantages, and disadvantages of these separation technologies are
discussed below.
2.2.2.1

Conventional Methods and their upgrades

2.2.2.1.1 Size-based separation
One of the characteristic differences between a virus and contaminants is the size.
A typical hydrodynamic diameter of viruses (20-300 nm) is much larger than the
contaminants’ size (< 20 nm). Obviously, the separation of these biomolecules based on
the size differences was the first choice in developing the unit operation. Three types of
methods – filtration, ultracentrifugation, and size exclusion chromatography, have been
developed which use size as the driving parameter. The membrane-based filtration is
used at multiple stages of the downstream processing. The filtration at the clarification
step is used to remove larger contaminant particles such as cell debris and microcarriers,
if used, from the culture broth [56]. Commonly used filtration-based technique utilize a
microfiltration mode with pore sizes ranging from 0.45 µm to 10 µm [57]. This pore size
range retains the larger contaminants on the filter and allows the smaller particles,
viruses, proteins, and nucleic acids, to flow through the filter. This method is widely used
in most of the biotherapeutic manufacturing strategy. The other filtration technique diafiltration is used post-purification step as a buffer exchanger to resuspend the viruses
in the desired solution for the formulation of the vaccines and biotherapeutics.
Diafiltration is a type of ultrafiltration which exchanges the pre-suspended buffer with a
new buffer by mixing the retentate with the desired buffer and repeating the filtration
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again until the pre-suspended buffer dilutes down to an acceptable concentration [58].
The ultrafiltration membranes are rated as the molecular weight cutoff (MWCO), which
retain any particulate with a larger molecular weight than the rated MWCO. A typical
filter used in this step has a MWCO range of 100 kDa (~10 nm) to 1000 kDa (~100 nm).
Appropriately selected membranes yield a high step recovery and high flowrate,
however, are prone to viral losses due to virus-filter non-specific interactions and high
shear rates [57, 59].
The membrane chemistry is an important aspect while selecting a filter, as the
polymers used to prepare the filters affect the separation efficiency. Polypropylene,
regenerated cellulose, cellulose acetate, and polyether sulfone are some of the prevalent
membrane filters used in the biomanufacturing. Viruses adsorb on the filter due to
specific and non-specific interactions with the filter material. Most viruses are negatively
charged at the physiological pH (~7), as the pI of the viruses are generally between pH
3.5-7 [60]. Negatively charged viruses have been shown to adsorb on the positively
charged membranes [61]. Therefore, such membranes might be useful in the antibody
manufacturing where and antibodies are the target product and viruses are contaminants.
Moreover, the hydrophobic membranes, such as polyether sulfone, cause biofouling due
to the virus adsorption by hydrophobic interaction [62]. If the viruses are the target
biomolecules, more hydrophilic membranes with low zeta potentials might be used to
avoid any electrostatic and hydrophobic interactions [63]. Such intermolecular
interactions are easily mitigated by selecting the appropriate buffer compositions and
surface modifications to membrane or inert materials such as polypropylene [64].
However, these interactions are not significant as compared to the fouling and shearing
phenomena that hinders the yield of viruses [65].
Filtration is operated in two modes – dead-end/depth mode and tangential/cross
flow (TFF) mode. The feed flow is parallel to the permeate stream in the depth filtration
mode and tangential in the crossflow filtration (See Figure 2-2). The depth filtration
generally achieves a high purity in the retentate with a decreasing permeate flux. A
higher feed volume leads to membrane fouling due to particulate accumulation at the
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membrane interface causing a high degree of concentration polarization. The plugged
pores cause a high transmembrane pressure that affects the potency of the viral products
due to structural damage, especially enveloped viruses, and aggregation [54, 66]. A TFF
mode is used to alleviate the flux issues and structural damage to viruses. This mode of
operation reduces the concentration polarization along a membrane by sweeping the viral
particles off from the membrane [63]. The flux reduces until an equilibrium concentration
polarization is reached and attains a saturation. However, shear sensitive viruses are still
susceptible for structural damage. Moreover, TFF are more suitable for low cell density
cultures, as TFF is operated at much lower pressures (~0.7 bar) [54, 67]. Among the two
modes of filtration, the tangential flow filtration is commonly used to optimize the
processing capacity and time. Overall, the microfiltration and ultrafiltration techniques
are still highly preferred method for clarification and post-polishing steps due to its ease
of operation, scale-up ability, and versatility.

Figure 2-2. Operating modes of filtration – A) Depth filtration and B) Tangential flow
filtration. This image was created in BioRender.

Another method using size-based separation of biomolecules is the
ultracentrifugation. This centrifugation technique utilizes density gradient mechanism to
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separate viruses from the contaminants (see Figure 2-3). The solutions such as sucrose,
caesium chloride (CsCl) [68], and iodixanol [69] are prepared in graduated
concentrations and layered in a tube with the decreasing concentration from the bottom.
A crude stock applied at the top comprising of the minimum density layer and
centrifuged at high speeds in the range of 30000-300000 x g [68, 69]. Viruses being
denser than contaminant proteins and DNA settle in the heavier layer as compared to the
contaminants (see Figure 2-3). Two types of approaches used to develop a density
gradient are - rate-zonal centrifugation and isopycnic centrifugation. The rate-zonal
separation is a method in which the crude is added to the top layer of the density gradient
and centrifuged for an optimized time. In this method, the density of the media should be
lower than the density of target biomolecule [70]. The biomolecules settle at a different
density layer depending on the characteristic sedimentation rate which is a function of the
size, density, centrifugal force, and the physicochemical profile (density and viscosity) of
the gradient [71]. Segura et. Al. (2006) demonstrated a 36.5% retroviral recovery in 1030% continuous iodixanol gradient [72]. Such a low recovery of the virus in a single step
is not feasible to produce a high throughput of the viral biotherapeutics. On the other
hand, isopycnic centrifugation operated by pre-formed gradients in a tube separate the
biomolecules solely based on the density difference [71]. Gias et. Al. (2008)
demonstrated a 71% recovery of human respiratory syncytial virus in an iodixanol
gradient centrifugation [73]. This recovery is acceptable for a large-scale manufacturing.
The density gradient centrifugation has the capacity to both purify and concentrate the
viral particles in a single step [54]. This is one of the oldest techniques used at a
laboratory scale. However, this method is not feasible to be used at industrial scale
because of the disadvantages of labor-intensive and non-scalable [65].
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Figure 2-3. Principle of virus purification in density gradient centrifugation.
This image was created in BioRender.
The third method of purification that uses differences in the size of biomolecules
is a size exclusion chromatography (SEC). This column chromatographic method is one
of the four modes of chromatography-based separation. A column is packed with beads
having crevices or pores with some rated MWCO as the filters. The separation of
biomolecules depends on the residence time in the column before eluting out of the
column (See Figure 2-4). Viruses are larger than the pore size of the bead crevices and
are thus excluded from the pores. Viruses follow a path of inter-bead void volume to
elute from the column. On the other hand, smaller contaminants diffuse in the pores
which increases their residence time in the column. The viral particles with the lower
residence time elute earlier than the contaminants thereby separating from the
contaminants. However, it has been shown that viruses and other biomolecules might
interact with the packing materials [74, 75], generally composed of agarose gel-based
complexes or synthetic polymers like methacrylate-based copolymers [75]. The
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interaction between the virus and the packing material increases the residence thereby
decreasing the resolution of separation. However, the main disadvantages of SEC are
dilution of the product, low processing capability, and poor distribution of media flow at
larger scales [54]. For the larger scale operations, SEC is possibly replaced by the
ultrafiltration method [54].

Figure 2-4. Principle of size exclusion chromatography for virus purification. A) Column
pores allow diffusion of small contaminant proteins and exclude viruses. B) A typical
chromatogram showing increased residence time of proteins, which elute later than
viruses.

2.2.2.1.2 Charge-based separation
The charge on amino acids determines the net charge of a protein. An amino acid
is negatively charged in a solution with pH higher than the pKa and positively charged if
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the pH is lower than the pKa. However, if the solution pH is identical to the isoelectric
point (pI) of a protein, the net surface charge is zero. Most viruses have a

Figure 2-5. Frequency of isoelectric points of viruses reported in literature. Reprinted
with permission from [71].
pI in the pH range of 2.1 – 8.3 with a mean of 5.0 (see Figure 2-5, [60]), while HCP
impurities can range from 2-11 [76]. The change in the pH away from the pI also changes
the net and relative surface charge of the biomolecules, which is commonly measured
using a bulk characterizing measurements - zeta potential, isoelectric focusing, and
electrophoretic titration curves [65]. The charge distribution on the surface is regulated
by the complex and long sequences of amino acids with varying pIs and electrostatic
interactions with the ions in a solution [77]. The difference in the net charge and the
charge densities between viruses and impurities are utilized to purify viruses.
Ion exchange chromatography (IEC), one of the four modes of chromatography,
is one of the prominently used methods in biotherapeutic manufacturing during the
purification step [78]. The IEX column is packed with resins (stationary phase) carrying
ionic charges, either positive (anion exchanger, AEX) or negative (cation exchanger,
CEX) charges. The electrostatic interaction between the virus and resin is promoted by
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the mobile phase using a pH at which the viruses are oppositely charged. AEX with
quaternary amine or primary amine-functionalized resins are commonly used, as most of
the viruses with pI ≤ 7.4 bind to the positively charged resins. The binding conditions
may allow the majority of the contaminant proteins to elute in the flow-through without
binding to the resin. The differential elution of viruses and some bound protein impurities
can be achieved by varying the pH or increasing the salt concentration [79]. However, the
stability of monodispersed viruses, especially enveloped viruses, persists in a narrow pH
range [65, 80]. Thus, salt gradient, in the range of 100 – 1500 mM, is commonly used in
the virus purification, where the contaminant proteins elute at lower concentrations as
compared to viruses [81, 82]. A careful selection of salt gradient combined with a pH
change can achieve high resolution in the elution profiles, even for closely related
physicochemical properties of virus and protein impurity. However, some of the
challenges faced in this purification method are pore inaccessibility for viruses, low
dynamic binding capacities, mass transfer properties, and limited flow rates [54].
The commercial resins have pore sizes ranging from 30-300 nm, and smaller
proteins with higher diffusion rates occupy these pores, excluding the larger sized, low
diffusive viral particles [83]. The inaccessibility of the surface area for virus-resin
interaction lowers the dynamic binding capacities of the resins [83]. Recent studies
suggest the use of membranes to improve the binding capacities and mass transfer
properties [84]. Mass transport in these setups is regulated by the convection, thereby
overcoming the diffusion limitation in the resin pores [85]. One of the studies explored
the impact of increasing DAAE (diethylaminoethyl) ligand densities to enhance the
recombinant baculovirus yield [86]. However, a lower ligand density demonstrated a
20% increase in the yield as compared to the commercial membrane [86], suggesting that
the optimum ligand density depends on the virus species. One common challenge faced is
that the multiple binding sites with different binding strengths hinder a smooth elution
through the column and add to the shearing of viruses. Moreover, it has been shown that
unwanted interactions, such as hydrophobic interaction of viruses with the resins, also
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makes the choice of elution conditions difficult [87]. Thus, more control over the elution
media and condition needs to be explored to improve the purification efficiency.

2.2.2.1.3

Hydrophobicity-based separation

One of the surface characteristics that differentiate biomolecules is surface
hydrophobicity. A molecular composition with a lower solvent-exposed hydrophilic to
hydrophobic ratio increases the hydrophobicity of a biomolecule. In proteins and virus
capsids, amino acids with aliphatic and aromatic side chains contribute to the
hydrophobicity of the structure. Enveloped viruses have some solvent side glycoproteins
that contribute towards the surface hydrophobicity, while the solvent-exposed lipid
bilayer is extremely hydrophilic due to the polar head group. The detailed surface
characteristics of viruses are not well understood, as this is still a growing area of interest.
However, the differential hydrophobic interactions between viruses or proteins with a
hydrophobic functional group of a third molecule have been studied.
Hydrophobic interaction chromatography (HIC) is a mode of chromatography that
utilizes the differences in the hydrophobic interaction strength of viruses and proteins
with the hydrophobic ligands immobilized on resins. The interaction with the ligands is
induced by loading the crude at high salt concentration [88]. The kosmotropic ions and
biomolecules compete to maintain the hydration shell. The excess ions, beyond the
thermodynamic equilibrium, result in the weakening of the hydration shell of
biomolecules, thereby exposing hydrophobic patches on the surface. The exposure of
hydrophobic components decreases the system entropy and increases the biomolecule
free energy, which promotes the interaction between the hydrophobic patch and
immobilized ligand to reconfigure the hydration shell of the complex. The biomoleculeligand complex strength varies depending on the type and number of hydrophobic
components involved, which is regulated by the ionic strength of the mobile phase.
Lowering the salt concentration of the mobile phase disrupts the hydrophobic interaction,
which allows the biomolecule to elute from the column. Larger viruses contain more
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hydrophobic patches than proteins, the virus complexes are disrupted at much lower salt
concentrations than proteins. Thus, the salt gradient applied in the mobile phase separates
the viruses from the protein impurities.
Various hydrophobic ligands are commercially available, displaying alkyl (butyl,
octyl, ether, and isopropyl) and aryl (phenyl) functional groups [89]. Longer alkyl chains
provide stronger hydrophobic interactions and phenyl groups supplement the
hydrophobic interactions with the π- π interaction [90]. One of the studies showed a 92%
recovery of inactivated foot-mouth-disease virus (FMDV) using butyl Sepharose resin
and 26% recovery with phenyl Sepharose [88]. It demonstrated that the viruses were
bound too strongly at 0.8 M (NH)2SO4 to enrich the product in the elution step using
phenyl Sepharose resin. If the interaction is too strong the recovery and purity both
decreases, on the other hand, if the interaction is too weak viral loss might incur in the
flow-through [91]. Moreover, this study also demonstrated that the HIC (60%) achieved
much higher recovery than IEX (17%) for Mumps and Measles viruses. However, HIC is
seldomly used in industry for vaccine manufacturing. The virus elution from the
stationary phase require high salt concentrations and the column chromatography induces
shear stress, both disrupting the structural integrity of viruses [54].
Recent interest has geared towards the use of ligands utilizing multiple
physiochemical properties (charge, hydrophobicity, and hydrogen bonding) of the
biomolecules to increase the specificity of binding and elution in the chromatographic
methods [92]. The conventional multimodal ligands comprise of small functional
molecules such as octyl amine (CaptoTM Core 700, GE Healthcare), N-benzyl methyl
ethanolamine (CaptoTM adhere, GE Healthcare), and N-benzoyl-homocysteine (CaptoTM
MMC, GE Healthcare). The binding and elution conditions are unique to a given
biomolecule that not only improves the recovery but also enriches the purity of the
vaccine product. However, the binding mechanisms of each virus has to be studied in
detail to understand the optimal processing conditions. The binding studies of phages
PR772, PP7, and ΦX-174 with the Capto adhere showed that the comparatively
hydrophobic phages PR772 and PP7 bound to the resin via synergistic electrostatic and
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hydrophobic interactions as compared, while the less hydrophobic ΦX-174 bound to the
resin only through the electrostatic interaction [93]. This suggests that the process
development of every virus product with Capto adhere resin would need extensive
research. Thus, Capto 700 resin is more frequently being studied as this resin is
developed based on the flow-through mode as compared to the bind-and-elute mode of
other resins. The flow-through mode is when the target viruses are collected in the flowthrough during the loading step, while the impurities bind to the resin [94]. The Capto
Core 700 uses a functionalized core and an unfunctionalized shell that allows smaller
proteins to diffuse into the pores to strongly interact with the ligands [95]. Viruses,
unable to diffuse into the pores due to size exclusion, elute without interacting with any
ligands [95]. Some recent studies showing the efficiency of multimodal chromatography
are shown in Table 2-5.
Table 2-4. Virus and VLP purification in Capto Core 700 multimodal resin
Purity
Virus
Recovery (%)
Reference
(%)
Influenza A VLP

89

60

[95]

Influenza A virus

79

66

[96]

Zika VLP

90

112

[97]

Yellow fever VLP

89

98

[97]

Yellow fever virus

65

99

[98]

Respiratory syncytial virus

100

87

[99]

Rabies virus

87

94

[100]

2.2.2.1.4 Affinity-based separation
The multimodal resins, such as Capto Core 700, have shown promise in the
polishing step but may need additional chromatography steps beforehand to achieve the
desired purity of vaccines [98, 100]. With more steps, higher losses are incurred in the
virus yield [101]. A novel approach to mitigate the footprint of the process equipment has
been the affinity ligand development to increase the specificity in the bind-and-elute
28

mode for viral particles. The affinity ligands explored to date include virus-specific
antibodies [102, 103], protein-based lectin [104, 105], metal ions [106, 107], and
polysaccharide-based heparin and heparan sulfate [108, 109]. The mechanism and
advantages of these ligands are described in Table 2-6.

Table 2-5. Affinity ligands binding mechanisms and processing attributes [110]
Affinity
Binding
Advantages
Disadvantages
ligand
mechanism
• High specificity
• Yields high purity

• High production cost
• Complex molecules
with stability issues

Lectin

Carbohydrate
recognition
domain of lectin
binds to specific
antigen
carbohydrate

• Specific binding to
virus surface
glycoproteins
• Used for intact virus
purification

Immobilized
metals

Metal ions interact
with electro donor
groups on target
virus surface

• Possible affinity to
cell culture-derived
glycosylated proteins
• Lacks consistency
for batch-to-batch
variation in
glycosylation pattern
of contaminants and
target

• High ligand stability
• Low cost

Production issues to
achieve purified tags

Resemble receptor
ligands of host
substrate

• Stable ligand
structure
• High tolerance for
denaturing agents in
process stream

• Promotes nonspecific binding of
contaminant proteins
• Requires high ionic
strength for
dissociation and
elution

Antibodies

Heparin and
heparan
sulfates

Antibodies interact
with specific
antigen domain

Among the above-mentioned ligands, an antigen-specific antibody shows the
highest binding specificity towards viruses, which can yield a high purity of the viral
particles. Due to the antibody production cost and stability issues, the approach has been
directed towards developing short peptides with 3-12 amino acid residues that mimic the
specific interaction mechanism of antibodies [101, 110]. The high affinity peptides can be
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either a closed ring cyclic structure or an open chain linear structure. Ho et al. (2017)
identified cyclic peptides C-WSFFSNI-C and C-WPFWGPW-C that bind tightly to
HBcAg as the previously screened linear peptide LLGRMK [111]. The binding
mechanism of peptides with viruses can vary. The high affinity of cyclic peptide CWSFFSNI-C towards HBcAg was suggested as the hydrogen bonding mechanism while
the other cyclic peptide C-WPFWGPW-C was anticipated to interact with the
hydrophobic regions on the surface [111]. An octamer, DWDLRLLY, identified was
found to bind to the hydrophobic residues of the major coat protein VP1 of murine
polyomavirus like particles [112]. In another study, YKLKYY hexamer binding to the
VP2 capsid protein of porcine parvovirus was suggested to be constrained to the
secondary structure of the hexamer, docking in the capsomere pocket [113]. The large
library of screened affinity peptides has the potential to be included in the purification
step. However, more studies are needed to identify optimal conditions for the processing
of viral particles. Overall, there is still a gap in the comparison studies between the novel
chromatographic modes with traditional methods, and economic feasibility analysis needs
to be evaluated [110].
2.2.2.2 The conventional downstream processing train
The yields obtained in a single unit operation, using any separation mechanism, is
generally not enough to meet the regulatory criteria of purity. Thus, multiple unit
operations functioning with different mechanisms are employed in a series to achieve the
desired purity, final buffer solution, and dose concentration (Figure 2-6). Unlike
antibody production, vaccine manufacturing lacks a platform downstream processing
strategy. Every virus has a unique behavior with a wide range of characteristics. The
virus surface topologies are complex, and studies have employed different mechanisms to
separate viral particles from the different classes of contaminants at each DSP stage
(Figure 2-6). Bandeira et al. (2012) utilized depth filtration for clarification, DEAE AEX
in the purification step, 100 kDa vivaflow ultrafiltration for concentration, and SEC for
the polishing step to develop a DSP train for lentivirus production [114]. The
chromatographic steps were the least yielding unit operations (80% in AEX, and 68% in
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SEC), which achieved a cumulative virus recovery of 36%. In another study of
inactivated HAV vaccine (VAQTA®) production, a long series of the traditional methods
were utilized in the DSP [115]. The clarification was performed using ultrafiltration,
which was followed by Benzonase® treatment. The clarified product was processed
through AEX, followed by PEG precipitation and solvent extraction in the purification
step. The polishing step included AEX followed by SEC. The viral product was then
inactivated using formaldehyde for the vaccine formulation. The use of three
chromatography modes, and a time-consuming laborious PEG precipitation yielded a
final virus recovery of 20% and 99% purity [115].
The strategy to include novel modes of chromatography for increasing the
selectivity and recovery of viral particles has been shown in some studies. One of the
steps where this reform was explored is the polishing step by using a multimodal-based
Capto Core 700 resin in the negative mode chromatography. For example, the proposed
DSP train of inactivated yellow fever virus vaccine included clarification by
microfiltration followed by AEX in the purification step with a final polishing step using
Capto Core 700 [98]. This two-step purification process (regarded clarification as a
midstream stage) yielded an overall 53% virus recovery with ~99% purity. Overall, the
progress is being made rapidly to explore and include novel methods in the DSP train.
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Figure 2-6. Unit operations in the DSP train and their purpose. Reused with permission
from [59]
.
2.2.2.3 Continuous Integrated Processing: Vision for Biotherapeutic
Manufacturing
The rapid growth in the demand for the vaccines and biotherapeutics, along with
the need to reduce the production cost and increase product quality, has motivated
scientists and engineers to explore next-gen strategies [116]. One of the strategies
32

currently being considered to enhance productivity and economic benefits is the
continuous manufacturing capability with integrated processes [117]. Most of the existing
biomanufacturing facilities operate in the batch mode, for which the way to enhance the
productivity is by improving the yield of individual unit operations combined with
scaling up the size of the unit operations. However, an increase in the scale-up not only
increases the facility footprint but might also hinder the flexibility of the product
portfolio [118]. Some studies have evaluated the economic benefits of shifting to
continuous processing and have shown to reduce the costs substantially [119, 120]. The
idea of continuous manufacturing is to integrate the upstream processing and downstream
processing with minimum or no hold up in between each of the unit operations. One
study suggested a hybrid model where some unit operations function in the batch mode
and others in the continuous mode [121]. The combination evaluated for a fed-batch
culture integrated with a continuous capture step and a batch polishing step for
monoclonal antibodies was found to be more economically feasible and flexible for the
companies of all sizes with multiple product portfolios [121]. However, such feasibility
studies have rarely been performed for viral manufacturing. The general vision with the
integrated continuous viral manufacturing is to develop a downsized ballroom like
facility which would still produce the required number of high-quality doses [122, 123].
Focusing on downstream processing, one of the major bottlenecks in continuous
operation is the chromatographic method of separation [124]. Advances are being made
to address this issue. Some strategies recommended to operate a continuous
chromatography included the use of multiple columns to keep a constant output flow
[124]. The concept of using multiple columns is to keep the process steady by utilizing
the columns alternatively in the active and passive state. This is achieved by simulated
moving bed (SMB), which indicates a periodical use of columns for loading and eluting
the biomolecules [125]. However, the use of multiple chromatography columns might
only increase the facility size and is counter-intuitive to the future paradigm of ballroomsized biomanufacturing. Moreover, it has also been shown that an increase in the
chromatography steps increases the process mass index, which is the amount of raw
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materials used per unit mass of active pharmaceutical ingredients [126]. The impact of
increased process mass index was suggested to harm the sustainable and green
biomanufacturing initiative [126, 127]. Some studies have shown that the use of SMB
reduces the processing cost, buffer, and water usage but increases the resin cost, which is
one of the major expenses of the DSP [128]. Thus, some of the groups have been
exploring unconventional methods to potentially substitute for the current challenges of
productivity, cost, time and energy consumption, facility architecture, and environmental
factors in the biomanufacturing.
There is a motivation to improve the DSP by reducing the number of unit
operations and equipment used in the unit operations while increasing the production
capacity. One such method being explored is a liquid-liquid extraction (LLE)-based unit
operation.
2.2.3 Liquid-Liquid Phase Separation
The conventional use of LLE in the petroleum refineries employ organic-organic
or organic-water phases to extract a solute from the mixture into either organic phase or
aqueous phase. However, most organic solvents such as benzene, toluene, and
acetonitrile, etc. are denaturants for biological materials. The discovery of two-phase
systems (ATPS) composing of aqueous solutions, by Beijerinck (1896), opened
opportunities for various applications for the bio micro and macromolecules [129]. The
formation of two incompatible phases was observed after a certain critical concentration
of phase forming components, while the lower compositions yielded a homogeneous
solution. In contrast to the completely immiscible organic-water systems, the aqueous
two-phase systems (ATPS) are partially miscible systems that generate two incompatible
phases. The partially miscible phases signify that a fraction of both the aqueous solutions
is distributed between the two incompatible phases. The component distribution in the
phases leads to one phase being rich in one of the components, and the other phase rich in
the counter component used to form two-phases. The partially miscible aqueous solutions
form two incompatible micro (precipitate and complex coacervate) or macro-phases
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[129]. Two such microphase separation methods are polyethylene glycol (PEG)
precipitation in high ionic strength aqueous solution and colloidal complex coacervation
of oppositely charged polymers in low ionic strength aqueous solution (see Figure 2-7).
The immiscibility of the incompatible aqueous phases is an excellent means to separate
biological materials by preferentially partitioning the target biomolecule in one phase
(preferentially in the microphase) and the contaminants in the other phase. However, due
to their time consuming and labor-intensive operation, they might not be feasible for
large-scale bioprocessing. The use of aqueous solutions that form two macro-phases upon
separating is notable for the downstream processing of biomolecules (see Figure 2-7).

Figure 2-7. Different types of two-phase systems used for biomolecule partitioning. The
image was created in BioRender.
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The macro aqueous t/wo-phase systems (ATPS) were traditionally generated
using aqueous polymer-polymer or polymer-salt pairs (Table 2-7). Polyethylene glycoldextran/dextran sulfate is a commonly used polymer-polymer system. The separation of
two phases yields a PEG-rich phase and a dextran-rich phase with a fraction of the
complementary component in each of the polymer-rich phases. Similarly, a PEG-salt
system yields a PEG-rich phase and a salt-rich phase. The equilibrated two immiscible
phases have been suggested to prevail as hydrophobic-hydrophilic pairs [129]. For
example, the hydrophobic PEG-rich phase is complemented with a hydrophilic dextranrich phase or salt-rich phase. A combination of these phase property differences and
biomolecule surface properties drive the biomolecules either to the top phase (polymerrich phase), the bottom phase (polymer/salt-rich phase), or the interface between the top
and the bottom phase. The variation in the physicochemical characteristics of different
biomolecules decides the target partitioning phase for a given system, which is used to
segregate biomolecules between the two-phases. The partitioning of biomolecules
between the two phases is given by a partitioning coefficient (K), as shown in equation 21 [129]
𝐶𝐶

𝐾𝐾𝐶𝐶 = 𝐶𝐶𝑇𝑇

𝐵𝐵

(2-1)

where, C is the concentration of biomolecule in the top phase (T) or bottom phase (B).
The systems are designed to achieve a distinct partition coefficient for the target
biomolecule and contaminants to achieve separation. Novel phase forming component
pairs such as ionic liquid-salts (Table 2-6) are being investigated for their added relative
deviation in the physicochemical characteristics to achieve better separation of target and
contaminants.
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Table 2-6. Phase forming components for ATPS [130]
ATPS type

Phase forming components
PEG - dextran

Polymer - polymer

UCON - dextran
PEG - sodium polyacrylate
PEG - phosphate

Polymer - salt

PEG - sulfate
PEG - citrate
[N2,2,2,2] Br - citrate

Ionic liquid - salt

[Bmim] BF4 - phosphate
[C4MIM] Br - sulfate

Micellar

Triton X-100 - citrate
PEG - Triton X-100

ATPS has been explored as a potential alternative to conventional unit operations,
mainly chromatography. ATPS consists of water as a major component (>70%), which is
essential for the stability of biological materials. Moreover, the two-phase systems
provide processing advantages such as low-cost raw materials, gentle environments for
biologics, easy scalability, and continuous operation [131, 132]. The phase forming
components such as PEG, dextran, salts are less expensive than the chromatography
resins. A direct comparison of IEX and ATPS for penicillin acylase demonstrated a lower
operational cost and higher recovery of the enzyme in the PEG-phosphate system [133].
Rosa et al. (2011) assessed the operating cost of ATPS and concluded that ATPS would
alleviate the operating cost by 1.5 fold as compared to the protein A chromatography
used for antibody purification [134]. However, such process economic analysis has not
been performed for the viral vaccine manufacturing scenario. Another benefit of ATPS is
easy scalability. The scale-up of ATPS has been shown to yield similar partitioning
behavior of proteins with high recovery [132]. Conventional LLE equipment, such as
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mixer-settler and counter-current partitioning, which are commonly utilized in chemical
industries, can be easily adapted to the bioprocessing [135, 136]. Moreover, ATPS has
been demonstrated to easily adapt to continuous operation and integrate into the
downstream processing at the laboratory scale [137, 138]. Common process design for
continuous operation may include an inline or online static mixer with a tubular separator
or a conventional mixer tank with a separator [138, 139]. These advantages have
motivated the exploration of the potential of ATPS as a purification method for numerous
biological materials.
ATPS has been applied in the purification of numerous biomolecules. However,
many studies have focused on antibody and enzyme purification. Purification of
biotherapeutics using ATPS has been focused on cells, antibodies, nucleic acids, and
viruses. The biotherapeutic applications have targeted the primary clarification and
purification steps of the DSP train [132]. Cell-based regenerative therapeutics have
gained interest in treating diseases such as osteoarthritis, Parkinson’s disease, ALS, and
heart failure [140]. Stem cell therapy involves a differentiated form of the pluripotent cell
and demands the separation of differentiated and undifferentiated cells in the DSP [141].
The antibody therapy, such as monoclonal IgG, targeted to bind an antigen-presenting
cell, are predominantly expressed in mammalian cell lines, such as Chinese hamster
ovary (CHO) [142]. The DSP is intended to purify antibodies from cell culture
contaminants. The novel DNA vaccines produced in various cell platforms have host cell
DNA and RNA contaminants, and studies have explored ATPS as the potential method
for the separation of the therapeutic DNA from HC-nucleic acids [143]. Some examples
of ATPS used for the purification are listed in Table 2-7.
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Table 2-7. Examples of ATPS for purification of different biomolecules
System

Target molecule

Recovery
(%)$

Purity
Reference
(%)

Cells
Ficoll T400 - Dex T70

CD133+ stem cells

59

60

[144]

PEG 8000 - Dex T500

CD11b+ HL-60 cells

93

99

[145]

Proteins
PEG 3350 – citrate

IgG

97

76

[146]

PEG 600 – phosphate

Xylose reductase

117

1.2*

[147]

-

[143]

~100

[148]

Nucleic acids
PEG 8000 –
polyacrylate T240 Plasmid DNA
55
sulfate
PEG 8000 –
DNA fragments
60
polyacrylate T240 (< 6000 bp)
sulfate
$Recovery in the top phase; *purification factor

The inclusion of ATPS for viral-based biotherapeutic and vaccine DSP has
recently gained interest. However, the complex viral tropism and fragile structure had
challenged the method optimization for infectious virus recovery. Some studies have
shown higher recoveries of VLPs (up to 80%) as compared to viruses (Table 2-8). The
VLPs, void of genetic material and replication deficient, are assessed with the major
quality attributes pertaining to the structural integrity and immunogenic glycoprotein
conformation retention [149]. On the other hand, whole virus vaccines and
biotherapeutics such as LAV and gene therapy vectors have comparatively complex
quality attributes. One of the unique critical attributes for LAVs is the potency of the viral
product, which is measured by the infectivity assays (cell-based assay to quantify
infectious dose) and quantitative PCR (counts the number of gene copies) [3]. The viral
infectivity losses incurred during DSP reduces the product yield. This is generally
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observed with the lower virus recoveries measured using the infectivity assays.
Moreover, traditional ATPSs have been utilizing polymer-polymer systems [129, 150,
151]. Recently, PEG-salt systems have been in demand due to lower interfacial tensions,
viscosities, and cost as compared to the polymer-polymer systems [152, 153].

Table 2-8. Virus and VLP recovery in PEG-rich phases of ATPS
System

Virus / VLP

Recovery (%)

Reference

PEG 400 - phosphate

Rotavirus-like particle

60

[154]

PEG 6000 - Dex T500

HIV-1

60

[155]

PEG 1000 - MgSO4

B19 VLP

58 - VP2

[156]

PEG 400 - phosphate

B19 VLP

98

[157]

PEG 400 – phosphate

M13 bacteriophage

83

[158]

2.2.4 ATPS phase diagrams
The experimental design for a given pair of phase-forming components is
governed by a graphical representation of the concentration of the components. The twophase systems formed above certain concentrations of the phase forming solutions are
represented by a binodal curve. The system compositions above a binodal curve form
two-phases upon mixing, and the systems below form homogenous solutions with a
single phase (Figure 2-8). The position of the binodal curve and system compositions
within the two-phase region govern the driving forces for the partitioning of biomolecules
(see Section 2.2.5 for details). The area of the two-phase region is dictated by the type
and characteristics of the phase-forming components such as polymer and salt type,
polymer molecular weight, pH, and temperature [153]. The binodal curves for a given
system, pH, and temperature are generated using a turbidity method [153]. High system
compositions are chosen that form two phases, which is indicated by turbid mixture, and
titrated with water to dilute the systems until the turbidity disappears. The system
compositions calculated at which a bare turbidity is present, form a binodal curve.
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Figure 2-8. Phase diagram demonstrating binodal curve and tie lines for ATPS

The closer the curve is to the origin or axes, the higher the driving forces involved
in the phase formation are. This means that the lower system compositions that can form
two-phases have better immiscibility. In PEG-salt systems, the immiscibility of the
phases is suggested to be the effect of salting-out nonelectrolyte polymer (PEG) from the
salt-rich phase [159]. The salting-out effect of PEG was determined to be in the order of
the Hoffmeister series for anions as phosphate > citrate > carbonate > sulfate > hydroxide
[159, 160]. The salts of anions in the higher order of the Hoffmeister series cause
depression in the binodal curve, resulting in the immiscibility at lower compositions
[160]. The multivalent cations (Mg2+ and Zn2+) have been indicated to favorably interact
with the ether oxygens to form a complex causing a higher salting-in of PEG chains as
compared to the monovalent cations (Na+ and (NH4)+) [159]. However, the depression of
binodal curve has been shown in the order of Na+ > (NH4)+ > Zn2+ >Mg2+ [160]. The
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counter-intuitive effect of the multivalent and monovalent cations was supported with the
complexation ability of the multivalent cations. On the other hand, binodal curve has also
been shown to be affected by the PEG molecular weight. Longer PEG chains have added
hydrophobic character to the polymer due to the increased hydrophobic methyl to
hydrophilic oxide groups. The increased hydrophobicity has been shown to aid in the
salting-out PEG leading to immiscibility at lower concentrations of salt and depression in
the binodal curve [161]. The physicochemical factors affecting the binodal curve changes
the experimental workspace to choose an appropriate system for the partitioning of the
biomolecules.
The other characteristics of the systems are the phase compositions. A set of
systems within the two-phase region separate into two phases with identical equilibrium
phase compositions, which are represented by tie lines (Figure 2-9). While the
equilibrium phase compositions remain the same, the phase volume ratio decreases as the
systems compositions approach the bottom node [153]. The volume ratio is defined by
the ratio of PEG-rich phase volume to salt-rich-phase volume. A tie line is defined by the
length of the tie line (TLL) joining the two nodes on the binodal curve and is expressed
as shown in the equation 2-2 [153]
2
2
𝑇𝑇𝑇𝑇𝑇𝑇 = �∆𝑥𝑥𝑃𝑃𝑃𝑃𝑃𝑃
+ ∆𝑥𝑥𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠

(2-2)

Δx represents the concentration difference of the component (PEG or salt) in the PEGrich phase and salt-rich phase. An increase in the TLL increases the phase concentrations.
The difference in the phase composition is characterized by a tie line slope, which is
expressed as equation 2-3 [153]
𝑇𝑇𝑇𝑇 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 =

∆𝑥𝑥𝑃𝑃𝑃𝑃𝑃𝑃
∆𝑥𝑥𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠

(2-3)

The TL slope is unique for a given system PEG molecular weight, salt type, and pH. For
a given system composition, the TL slope dictates the final composition of the PEG-rich
phase and salt-rich phase. Further, the phase compositions aid in the separation of
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biomolecules (see Section 2.6.6 for details). The phase diagrams are the blueprint of a
given pair of the phase forming components to study the partitioning behavior of
biomolecules. However, the phase diagrams being unique to each pair, the optimization
of the biomolecule purification using ATPS generates an extensive experimental space.
The previous works have used a lab-specific or wide range of phase forming components
varying in PEG molecular weight, salt type, and pH to optimize virus recovery in the
PEG-salt system [154, 156-158]. The goal of current biotherapeutic manufacturing is to
develop a standard method of purification with a minimum variation in the processing
conditions for faster FDA approval. The lack of a standard system or optimization
method for optimization of virus recovery is the bottleneck of ATPS for biotherapeutic
processing applications.

2.3 Biomolecule Partitioning Theories in ATPS
2.3.1 Excluded volume and intermolecular interactions
The commercial implementation of ATPS is lacking due to an ambiguity in
understanding the partitioning mechanism of the biomolecules and lack of expertise in
the process development for large-scale production [162, 163]. There have been
numerous studies to elucidate the partitioning mechanisms of biomolecules in the ATPS.
The two major theories argue the role of excluded-volume effect [154, 158, 164] and
intermolecular interactions [129, 164, 165]. The excluded volume theory states that the
volume occupied by a polymer chain in the polymer-rich phase is saturated with the
polymer chains and hydration molecules [164]. The unavailability of the free volume
leads to a steric hindrance for comparatively larger sized globular biomolecules (proteins,
cells, and viruses), resulting in the exclusion of the biomolecules from the phase [156,
166]. Benavides et al. (2006) demonstrated that the majority of double layer rotaviruslike particle partitioned in the PEG-rich phase when PEG 400 Da was used, and the
partitioning shifted to the interface when the molecular weight was >1000 Da [154]. The
partitioning shift from the PEG-rich phase to the interface was suggested due to the
reduced free volume of the PEG-rich phase with the increased PEG MW supporting
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previous observations of protein partitioning [167, 168]. A similar argument was made by
Gonzalez-Mora et al. (2017) when the partitioning of M13 bacteriophage shifted from the
PEG-rich phase to the interface when the cation type of phosphate salt was changed from
Na+ to K+ in the PEG-salt system [158]. It was proposed that Na+ with more water
molecules in the hydration shell, as compared to the larger sized K+ ion, reduces the
availability of free water molecules for bacteriophage hydration in the PEG-rich phase,
resulting in the interface partitioning [158]. However, the interpretation of the ion effects
on biomolecule partitioning is at the edge of the excluded volume theory and
intermolecular interactions.
Another partitioning mechanism proposed was the net effect of intermolecular
interactions. The driving forces governing the partitioning was proposed to include
hydrophobic interactions, electrostatic interactions, and phase-specific affinity [129, 165].
Over the years, studies have suggested that the hydrophobic interactions of biomolecules
with the PEG-rich phase and electrostatic interactions with the salt-rich phase majorly
influence the partitioning [169, 170]. It has been shown that the hydrophobic patches of
proteins interact with the ethyl groups of PEG [171, 172]. The attractive forces between
some proteins and PEG aids in the preferential partitioning of the proteins in the PEGrich phase. On the other hand, the electrostatic interaction of charged biomolecules with
the ions in the salt-rich phase either helps in salting-out or salting-in proteins [146, 165].
In a way, the principle of hydrophobic interaction of combined salting-out effect and
induced hydrophobic interaction has been suggested to govern the biomolecule
partitioning. The specific affinity of the biomolecules towards the PEG-rich phase in a
PEG-salt system can be interpreted as the interaction of biomolecules, especially
proteins, with the higher molecular weight of PEG (>10 kDa) [172]. However, this effect
may be negligible in the studies that utilized lower molecular weight PEG (< 10 kDa).
The specific affinity has also been shown to supplement the driving force if an affinity
functionalized PEG or affinity ligands are used in the systems to enhance the specificity
of a target biomolecule [173]. Moreover, intermolecular interactions have been shown to
be determinant of the biomolecule size and conformation [129, 165]. The overall
44

partitioning coefficient (K) of a biomolecule is the net effect of these intermolecular
interactions, which was proposed as equation 2-4 [129, 174]
𝐾𝐾 = 𝐾𝐾𝑂𝑂 ∙ 𝐾𝐾𝐻𝐻 ∙ 𝐾𝐾𝐸𝐸 ∙ 𝐾𝐾𝐴𝐴 ∙ 𝐾𝐾𝑆𝑆 ∙ 𝐾𝐾𝐶𝐶

(2-4)

where the subscripts H, E, A, S, and C are the contributions of hydrophobicity,
electrostatics, affinity, size, and conformation to the partitioning coefficients,
respectively. The subscript O represents the miscellaneous contributions affecting the
partitioning of biomolecules as there are other factors that influence the partitioning
[165]. Overall, Grilo et al. (2016) suggested that the influence of excluded-volume
effects, hydrophobicity, and electrostatics depends on the chosen system and target
biomolecule [163].
The biomolecule transport from one phase to another is also governed by the
interfacial characteristics. The characteristics that affect the partitioning are interfacial
tension and electrostatic potential difference [163, 175]. The initial step in phase
partitioning of a biomolecule is the adsorption at the interface. The interfacial tension
governs the free energy profile of biomolecule [176]. If the free energy of a biomolecule
reaches equilibrium at the interface, the biomolecule diffusion across the barrier is seized
[176, 177]. A previous study demonstrated that the partitioning of skin cancer cells was
shifted from the dextran-rich phase to the interface and PEG-rich phase when the
interfacial tension was increased beyond a certain limit [176]. However, the embryonic
stem cells partitioned majorly at the interface without diffusing to the PEG-rich phase,
which was suggested due to the free energy minimization at the interface of stem cells as
compared to the cancer cells [176]. On the other hand, the biomolecule partitioning has
been shown to increase in the PEG-rich phase as the system compositions increase [178,
179]. An increase in the system composition also elevates the interfacial tension [180,
181]. This indicates that interfacial tension aids in the biomolecule partitioning between
the phases until a certain limit, after which it hinders the transport leading to the
interfacial partitioning of biomolecules.
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The other physicochemical characteristics that drive the partitioning behavior of
biomolecules is the electrostatic potential difference between the phases [175]. The
differences in the partitioning of cations and anions in the PEG-dextran system have been
shown to generate a potential difference across the interface [175, 182]. It has been
reported that the PEG-salt systems generate a positive potential difference, typically in
the range of -30 to 30 mV for PEG-phosphate or sulfate systems, measured as the
difference between the top (PEG-rich) and bottom phase (salt-rich) [183]. Sufficient
charge on a biomolecule results in the partitioning behavior that yields a net
electroneutrality of the phases [183, 184].

2.4 Parameters and their effect on driving forces in ATPS
The optimization of a target biomolecule’s recovery in a PEG-salt system
includes designing a system to yield an optimal balance of the driving forces. Previous
studies reported a list of characteristics of the phase forming components that have a
direct effect on the driving forces. The parameters influencing hydrophobic interaction,
electrostatic interaction, and interfacial mass transport properties depend on the PEG and
salt characteristics [183]. These phase forming components directly affect the phase
diagrams yielding different driving forces. The effects of these parameters on the phase
diagrams and driving forces are discussed below.
2.4.1 Phase forming component parameters
2.4.1.1 Polymer molecular weight and concentration
PEG is the most common polymer utilized in ATPS of both polymer-polymer and
polymer-salt system (Tables 2-7 and 2-8). PEG MW significantly affects the phase
characteristics by changing the phase diagrams. An increase in MW has been shown to
reduce the system compositions that form two phases, resulting in depression of the
binodal curve (see Figure 2-9) [161]. It has also been shown that the tie line slope
decreases with an increase in MW [185]. This signifies that for a given system
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composition with a higher PEG MW, the equilibrium salt-rich phase has a lower
composition, and the PEG-rich phase has a higher composition (see Figure 2-10).

Figure 2-9. The binodal curve shift with an increasing PEG molecular weight. Wp and
Ws represents the PEG and salt concentrations. Reprinted with permission from [186].
Copyright (2018) Elsevier.

An increase in the PEG MW has been shown to decrease the partitioning of
proteins to the PEG-rich phase [187, 188]. The reduced partitioning has been argued with
both steric exclusion [154, 187] and hydrophobicity [163] mechanisms. The steric
exclusion was suggested based on the reduced free volume of the PEG-rich phase. An
increase in the PEG MW for a constant PEG concentration reduces the number of
ethylene oxide in the PEG-rich phase, thereby reducing the hydrophobicity of the PEGrich phase [163]. On the other hand, Asenjo et al. (2011) states that for a given polymer,
an increase in the PEG MW increases the hydrophobicity of the polymer due to an
increase in the ethyl to oxygen group ratio [165]. An elevated hydrophobicity of the
higher MW PEG has been shown to favorably interact with the hydrophobic patches of
47

the proteins [172]. Moreover, the PEG-rich phase yields a higher phase composition with
a higher PEG MW for a given system composition that has shown to increase the
partitioning of relatively hydrophobic proteins [165]. The discrepancy in the arguments
of the effect of PEG MW causing steric exclusion and changing hydrophobicity of the
PEG-rich phase needs more characterization of the phases to elucidate the exact
mechanism.
The proposed theory of hydrophobicity as one of the dominant driving forces has
also been studied by increasing the PEG concentration. The increased PEG concentration
increases the number of PEG chains in the PEG-rich phase, thereby dehydrating the
phase and increasing the phase hydrophobicity [165]. However, a study demonstrated
that the PEG concentration does not affect the partitioning of IgG in the PEG-phosphate
system, and the antibodies preferentially partitioned to the PEG-rich phase irrespective of
the PEG and phosphate concentration [189]. In the other study, the α-Lactalbumin
partition coefficient increased up to a certain PEG concentration and then decreased
[190]. While others reviewed that increasing the PEG concentration decreases protein
partitioning in the PEG-rich phase due to steric hindrance exhibited by the increased PEG
chains in the PEG-rich phase [163]. The different partitioning behavior of proteins
demonstrates that the biomolecule characteristics play important role that interact with
PEG-rich phase uniquely.
2.4.1.2 Salt type and concentration
Salts play a significant role as the drivers of electrostatic interactions for
biomolecule partitioning. One of the primary roles of salts is to induce a preferential
salting-out for a target biomolecule. The salting-out ability of different ions studied was
by Hofmeister postulated a kosmotropic series for ions. The anion kosmotropic series for
the salting-out ability was given as PO43- > citrate3- > CO32- > SO42- > Cl- [191]. On the
other hand, the kosmotropic series for cations was given as Na+ > K+ > NH4+ [191]. The
salt type has been shown to modulate the binodal curve and tie line slope. A higher
kosmotropic salt in the series increases the two-phase region by pulling the binodal curve
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closer to the axes, similar to binodal curve behavior shown in Figure 2-9 [192, 193].
However, it was observed that the anion effect on the binodal curve was more influential
and shifted the curve more prominently towards the axes as compared to the cations
[193]. Moreover, the tie line slopes get steeper for higher kosmotropic anions, indicating
that lower salt-rich phase compositions have higher salting-out ability to yield a more
concentrated PEG-rich phase [194]. However, one study demonstrated that sulfate ion
was better at salting-out HIV-GFP-VLP as compared to the phosphate and citrate ions
[195]. There have been some studies indicating that the salting-out effect by anions does
follow the Hofmeister series due to other non-specific interactions of salts with
biomolecules [196]. On the other hand, it has been shown that Na+ salts increase the
relative hydrophobicity of the PEG-rich phase as compared to Mg2+ [197]. Moreover, a
salt of highly kosmotropic ion generates a high electrostatic potential difference, which is
postulated to highly influence biomolecule partitioning to the PEG-rich phase [183].
The kosmotropic anions, such as citrate and phosphate, have been shown to
induce the salting-out effect of biomolecules at much lower concentrations as compared
to the other salts [198]. It has been shown that the preferential hydration ability of
kosmotropes causes an increase in the surface tension near a biomolecule surface that
leads to aggregation and interfacial interactions of biomolecules [146, 199, 200]. In the
ATPS, a kosmotropic salt aids in the interfacial interaction of biomolecules with the
PEG-rich phase caused by the salting-out effect. A previous study showed that, for a
constant PEG molecular weight, porcine parvovirus partition more towards the interface
or PEG-rich phase [178]. In another study, M13 bacteriophage recovery in systems
containing sodium phosphate decreased when crude stock with contaminants was fed as
compared to the pre-purified bacteriophage feedstock [158]. However, the system
containing potassium phosphate demonstrated a similar bacteriophage recovery
irrespective of the feedstock [158]. The authors proposed that as Na+ ions are highly
hydrated as compared to K+ ions, the PEG-rich phase where cations partition is easily
saturated when Na+ ions are used. Overall, the literature demonstrates the effect of
different ion-biomolecule pair for a given system composition and limited studies have
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focused on showing the effect of selecting systems of different salts which yield similar
salt-rich phase composition.
The salting-out ability for a given salt type depends on the ionic strength of the
solution. An increase in the ionic strength by increasing the salt concentration has been
shown to induce the salting-out effect [158]. The salting-out of dlrotavirus-like particles
were shown to recover at the interface but not in the PEG-rich phase [154]. It might be
due to an insufficient hydrophobic driving force that the VLPs did not partition to the
PEG-rich phase at all the PEG MW studied.
2.4.1.3 pH
Ion charge on is one of the influential parameters in governing the driving forces
for biomolecule partitioning, as discussed above. The ionic charge depends on the pH of
the solution, and modulating the pH affects the phase characteristics and biomolecule
partitioning. An increase in the pH causes depression in the binodal curve towards the
axes for a given PEG-salt system [185]. The slope of tie lines increases with an increase
in system pH, indicating lower equilibrium salt-rich phase composition and higher PEGrich phase composition for a given system composition [201].
The change in the phase characteristics due to pH affects the biomolecule
partitioning. An increase in the system pH increases the biomolecule partitioning to the
PEG-rich phase [167, 170]. The partitioning behavior of biomolecules has been
associated with the free volumes of the phases [183, 202]. Oxygen atoms of PEG interact
with metal ions and exclude divalent and trivalent anions, thereby causing the phase
formations. A lower pH decreases the free volume of the PEG-rich phase by reducing the
metal ion availability causing a lower partitioning of the biomolecules in the PEG-rich
phase [167]. Moreover, pH modulates the charge on biomolecules by changing the
protonated to deprotonated sites that supplements the change in the partition behavior of
biomolecules (see Section 2.4.2).
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2.4.1.4 Summary of phase parameters and effects
The driving forces involved in phase formation and biomolecule partitioning have
been discussed as a complex synergy of free volume and intermolecular interactions.
These driving forces are influenced by multiple characteristics of the phase forming
components, and a net effect is provided to allow for biomolecule partitioning in either
phase. In summary, the studies have indicated different theories for which the phase
forming components affect the driving forces which are maintained. Moreover, most of
the studies have been focused on proteins, enzymes. Very few studies were performed to
understand viral behavior in the ATPS, and the studies that were completed focused on
the polymer-polymer systems [150, 151, 203]. Recently, studies are showing interest for
the viral behavior in the PEG-salt systems, but the effects of phase parameters were
correlated with the protein partitioning behavior [154, 156, 158, 195]. Most studies have
reported an experimental design by changing one parameter at a time, such as PEG MW,
PEG concentration, salt type, and concentration by keeping the other factors constant.
However, the conventional setup might not be appropriate to study viral partitioning
behavior in ATPS as the physical characteristics of the phases such as volume ratio, tie
line length, and equilibrium phase compositions, change thereby deviating from the
expected partitioning behavior. While the conventional setup is very crucial for an initial
understanding of viral behavior in the ATPS, this setup is not optimal to develop a clear
picture of the phase parameters as the empirical models have not been validated for
complex structures such as viruses. A systematic approach by understanding the
differences in viral and protein behavior is needed to achieve similar success as
comparatively smaller proteins.
2.4.2 Biomolecule characteristics and the effect on partitioning behavior
2.4.2.1 Surface hydrophobicity
The hydrophobic and electrostatic interactions were shown to be the dominating
driving forces for the biomolecule partitioning. The proteins composed of amino acids
display some amino groups on the solvent accessible side while the rest being solvent
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inaccessible due to secondary and tertiary structures. The solvent accessible amino acids
have a mixture of hydrophobic and hydrophilic side chains, and the ratio of these side
chains determine a net hydrophobicity of proteins. Studies performed with small peptides
with a different number of hydrophobic amino acids have demonstrated, that for a given
PEG-salt system, relatively more hydrophobic peptides readily partition to the PEG-rich
phase [204, 205]. A similar study performed on an array of proteins characterized by the
surface hydrophobicity demonstrated a linear correlation in the partition coefficient with
the surface hydrophobicity in a PEG-citrate system [206]. Thus, the partitioning behavior
indicates a strong relation to the surface hydrophobicity of biomolecules.

Figure 2-10. Comparison of surface hydrophobicity of protein and viruses determined by
the elution salt concentration in hydrophobic interaction chromatography. Reprinted with
permission from [207].

There is growing evidence that viruses are relatively more hydrophobic than
proteins. A study characterized the hydrophobicity of a range of proteins and viruses by a
HIC framework and showed that proteins such as RNase, ovalbumin, and lysozyme
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eluted from the hydrophobic resins at higher salt concentrations as compared to the
bacteriophages such as ΦΧ174, PP7, and PR72 [207]. The mammalian viruses, such as
minute virus of mice, xenotropic murine leukemia virus, reovirus, and pseudorabies
virus, retained on the resin until much lower salt concentrations than bacteriophages,
indicating the higher hydrophobic character of mammalian viruses (see Figure 2-10)
[208]. Most studies have indicated that viral particles are often excluded from the
relatively PEG-rich phase due to the steric exclusion when either PEG concentration or
PEG MW are increased [154, 158]. However, a recent study demonstrated that high
recoveries can be obtained with a higher PEG MW and concentration [178].
2.4.2.2 Surface charge
The other physicochemical characteristic of biomolecules that affect partitioning
behavior is the surface charge. The electrostatic interaction induced by the salt-rich phase
on a biomolecule depends on the pH of the solution. The presence of amine and carboxyl
groups on amino acids have different pKa that are protonated or deprotonated depending
on the solution pH. Thus, a change in solution pH changes the surface charge of the
biomolecule. The pH at which the net surface charge nears zero is determined as the
isoelectric point (pI) of a biomolecule. The surface becomes negatively charged if the
solution pH is above the pI of the biomolecule and carries a positive charge if pH < pI.
Negatively charged viruses effectively partition to the interface or PEG-rich and
positively charged viruses partition to the salt-rich phase [178, 209].
The virus purification has not been studied systematically by relating the phase
characteristics and viral surface characteristics. The viruses are much larger particles as
compared to proteins and their behavior cannot be easily predicted in the two-phase
systems. Maintaining the infectivity of viruses and surface tropism during processing
adds to the challenge and unambiguity in predicting the behavior. Thus, a more studies
need to be conducted to understand the viral behavior in ATPS.
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2.5 Osmolytes
2.5.1 Osmoregulators under environmental stress
Osmolytes are naturally occurring compounds synthesized in most of the cell
types in response to environmental stress [210]. Osmolytes change the water structure in
the environment that allow living creatures to regulate the osmotic pressure and water
content in the cells to survive [210]. Deep-sea fishes habituated in high salt
concentration environment and hydrostatic pressure have known to produce significantly
higher amounts of trimethyl amine-N-oxide (TMAO), a type of osmolyte [211].
Osmolyte production has shown to counteract the hydrostatic pressure, counterbalance
the osmotic stress, and aid in metabolic functioning [212, 213]. On the other hand,
osmolytes are also utilized in the drought conditions by plants [214]. Osmolyte
accumulation has shown to regulate cell protein stabilization to maintain the functionality
under abiotic stress [214].
Different organisms have shown to produce different types of osmolytes in
response to abiotic stress [215]. The osmolytes classes range from amino acids, amino
acid derivatives, polyols, and amine-oxides [210]. However, the osmolytes are further
characterized depending on the effect on proteins - protecting and denaturing. The
osmoprotectants or protecting osmolytes such as proline, glycine, TMAO, and sorbitol,
which are found in the organisms that survive under stress, enhance the protein stability
[216]. Denaturing osmolytes such as urea and guanidinium hydrochloride destabilize the
protein structures by unfolding [216].
2.5.2 Osmolytes in biomanufacturing
The protecting osmolytes are extensively used in the biomanufacturing due to
their ability to promote protein stability [217, 218], and assist protein assembly to capsid
[219]. The prominent use of protecting osmolytes has been shown in the formulation
stage of biomanufacturing. The formulation of biopharmaceutical products involves a
mixture of target biomolecule and compounds such as stabilizers for long term storage
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and adjuvants [220, 221]. The osmolytes are used as stabilizers as they help protect
proteins against unfolding [222]. Commonly used osmolytes as stabilizers are glycine,
trehalose, sucrose, mannitol, and arginine [218]. In one study, glycine was shown to
protect a recombinant protein-based vaccine against antigen modification upon long-term
storage at 37 °C [223]. In the other study, the addition of a combination of the
disaccharide, such as sucrose or trehalose, and glycine was shown to thermally stabilize
the H1N1 influenza subunit vaccine upon freeze-drying for long-term storage and
possibly eliminate the cold-storage [224]. Numerous such osmolytes have been used in
the biopharmaceutical formulations and approved by the FDA [218].
The protein structure stabilization mechanism by protecting osmolytes is still
unclear. However, more studies are being performed both at macro and micro scale to
understand the role of osmolytes in the protein structure fluctuations. A thermodynamic
study suggests that the free energy of unfolded proteins increases in the presence of
osmoprotectants, thus favoring the folded state [225]. A computational study
demonstrated that osmoprotectant, glycine-betaine (commonly known as betaine) has a
high affinity towards water molecules, thereby leading to preferential hydration of selfmolecules in a matrix of proteins, ions, osmolyte, and solvent [226]. The protein
backbone has shown to exclude both osmolyte and water in the case of osmolytes
(betaine, TMAO, and proline) or enrich with osmolyte and water (trehalose and
sarcosine) [227]. Both the cases of exclusion and enrichment have shown to stabilize the
proteins by compaction of the structure.
The effect of osmolytes on viruses has been shown to differ from proteins. Viral
surfaces are relatively hydrophobic when compared to proteins [207, 228]. The
preferential hydration of mannitol and alanine resulted in the viral particle flocculation
[229]. The viral flocculation was suggested to be due to hydrophobic interaction between
the hydrophobic viral surface [198]. The promotion of hydrophobic interaction by
osmolytes has also been demonstrated for a hydrophobic polymer, elastin [230]. Glycine
and betaine partitioned away from the polymer-water interface, thereby promoting the
hydrophobic interaction of the non-polar groups of elastin and causing the polymer to
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collapse [230]. The difference in protein and virus behavior under the influence of
osmolytes can be used in the DSP to upgrade the virus purification methods.
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3 Tie line framework to optimize non-enveloped virus
recovery in aqueous two-phase systems1,2

1

The material in this chapter is published in Journal of Chromatography B.
Full Citation: Joshi, P.U., Turpeinen, D.G., Weiss, M., Escalante-Corbin, G., Schroeder,
M., and Heldt, C.L. Tie Line Framework to Optimize Non-enveloped Virus Recovery in
Aqueous Two-Phase Systems. Journal of Chromatography B, 2019, 1126-1127, 121744.
2

The unpublished extension of the work in this chapter is mentioned in Appendix B.
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3.1 Introduction
The large number of new vaccines and gene therapy vectors coming to market has
spurred growth in viral particle manufacturing. Vaccine manufacturing growth is also
shifting to India and China [1], providing an opportunity to redesign currently approved
processes for traditional vaccines. Since industries have yet to achieve a platform virus
particle process, as has been achieved with antibody manufacturing [2], new unit
operations need to be considered for viral products that can provide virus stability, high
yields, and increased purity. The ultimate goals are to increase throughput, reduce
production cost, and to shift towards continuous processing. Two key attributes are
hindering the manufacturing of viral particles, scale-up difficulties, and low yield. In the
laboratory, ultracentrifugation produces high purity and high concentration viral stocks
[3,4]. However, this extremely manual process is time consuming and expensive. In
addition, co-precipitation has made sedimentation processes discouraging to be used for
large-scale production of vaccines [5,6].
The current race to develop a robust, easy to scale up, environmentally friendly,
and continuous process has led to tremendous research in various chromatography
methods for viral particles. Commonly used chromatography modes for virus and viral
vector processing include size exclusion [7–9], affinity [10,11] and ion exchange [12,13].
Although chromatography is a widely used method for purification of other
biomolecules, low dynamic binding capacities of large biomolecules reduces the
throughput and yield [14,15]. The purification of rhinovirus using anion-exchange
chromatography (AEX) found that only a fraction of viral particles bound to the column,
leading to a high purity but low recovery process [16]. It was also observed that two
peaks of virus eluted from the column, suggesting either different sites on the virus
binding to the column or different sites on the column binding with different strength to
the virus [16]. Issues of yield need to be addressed prior to large scale manufacturing of
these viral particles. A few studies have shown a continuous viral downstream process.

76

Most commonly, a continuous simulated moving bed (SMB) configuration is used
[17,18]. Cell culture-derived influenza virus was purified with a three column SMB
arrangement and a productivity of 3.8 times higher than batch mode was achieved [17].
However, the yield decreased from 80% in the batch mode to 70% in the SMB
configuration and the purity decreased. A two column SMB chromatography system was
used to purify adenovirus serotype 5 with size exclusion chromatography in a
countercurrent configuration [18]. In this case, a higher yield was achieved in the SMB
configuration (86%) as compared to batch mode (57%), with a 6-fold increase in the
productivity. Although the integration of continuous chromatography is likely to reduce
the overall cost and increase the productivity, the challenges pertaining to maintaining
equipment robustness, sterility over long processing times, and real time process
analytical technology (PAT) remain [19]. Due to these problems, the use of multiple
columns still lack integration to the rest of the downstream processing units and is not
currently used commercially [20]. Aqueous two-phase systems (ATPS) are potential
candidates for
virus purification to shorten the number of unit operations needed in the
downstream processing train and provide simple integration into a continuous process.
Unlike other purification methods, ATPS is robust, environmentally friendly,
inexpensive, easy to scale up, and can be operated as a continuous process with short
processing times [21]. ATPS involves mixing two aqueous solutions which produce two
phases when present above a critical concentration. Water is the major constituent of each
phase. Contrary to the high cost of chromatography resins and specialty membranes, the
inexpensive raw materials used in ATPS, along with lower processing time and energy
consumption, makes it a potential method to trim the cost of production for any
biotherapuetic product [22]. A previous study of penicillin acylase purification compared
ion exchange chromatography with ATPS, concluding that ATPS not only reduced the
unit operation number from 7 to 4 but also lowered the gross production cost by 37%.
The findings were obtained considering 100 times re-use of the resin [23]. ATPS
provides a good alternative for integrating clarification and purification for a more
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efficient downstream process. Many types of ATPS have been developed to partition
biomolecules.
Examples include polymer/polymer [24], polymer/salt [25,26], ionic liquid/salt
[27,28], and quaternary ammonium salt/salt [29] systems. The polymer/polymer system,
typically polyethylene glycol (PEG) and dextran, is the classic ATPS. However, high
viscosities, the expense of dextran, and the difficulty in polymer recycling led to the
development of salt-containing systems. Polymer/salt systems have been extensively
studied for protein purification [30–33] and only a few studies have been reported on
virus purification in ATPS. Some viruses and virus-like particles recovered by ATPS are
shown in Table 3-1. Virus-like particles (VLPs) have been studied more often in ATPS
to demonstrate a better downstream process for gene therapy vectors or subunit vaccines
[25,26,34]. VLPs mimic the viral surface immunogenicity but are void of genomes [35].
Maintaining the infectivity of viruses is one of the major challenges in the downstream
processes. This difference can be seen in the higher VLP recoveries as compared to the
lower recoveries of infectious virus (Table 3-1). ATPS have been run in continuous
mode for the processing of protein products [39–41]. The relatively low viscosities and
interfacial tension make the PEG-salt systems the preferred ATPS for scale up and
continuous operation. Various methods to contact the two phases, such as spray columns,
perforated discs, pulsed cap columns, and conventional mixer-settlers have been
suggested to perform continuous ATPS [39]. Mixer-settlers have successfully extracted
monoclonal antibody (IgG1) [41] and an enzyme from spent yeast [40]. Some processing
drawbacks such as flooding and backmixing have been identified [39]. But the problems
are outweighed by the easy adaption of ATPS to continuous processes, as compared to
chromatography. However, the complex partitioning mechanism of biomolecules has
averted the integration of ATPS at an industrial scale. Numerous theories on the
mechanism of partitioning of biomolecules in ATPS have been proposed. The two
leading theories are that the partitioning is, 1) highly dependent on the excluded volume
[30,42–44], or 2) a combination of hydrophobic and electrostatic interactions [38,45–47].
The excluded volume theory suggests that the random distribution of PEG molecules
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results in a geometrically saturated solution, excluding biomolecules from the polymerrich phase due to a lack of space available for the biomolecule to occupy [48]. On the
other hand, the hydrophobic and electrostatic interaction theory argues that the
partitioning of the biomolecules results from the combined effect of the salting-out from
the salt-rich phase and a hydrophobic driving force pulling the biomolecule into the more
hydrophobic PEGrich phase [45]. Our data demonstrated that high MW PEG increased
virus partitioning to the PEG-rich phase which supports the hydrophobic and electrostatic
theory of partitioning [38]. The PEG and the salt composition and concentration control
the hydrophobicity and electrostatics, respectively, in ATPS [49,50]. High MW PEG stay
more globular in solution than lower MW PEG, which are more linear in solution
[49,51]. Linear PEGs have more interaction with water and are better hydrated, whereas
globular PEGs are less hydrated and therefore have more hydrophobic character. Unlike
higher MW PEGs, lower MW PEGs have lower capabilities to provide multiple
hydrophobic binding sites due to fewer of ethylene monomers [49]. For salts, the
Hoffmeister series, which describes the hydration ability of different ions, has been used
to describe the effect of different salts in ATPS [38,52]. A lower concentration of salt is
required to form the twophase region when multivalent salts are used as compared to
monovalent salts [50], demonstrating the importance of ionic strength in the system.
However, there are still many questions as to the driving forces within the ATPS that
govern partitioning. Without a more systematic characterization of the two-phase region,
ATPS will continue to have too many unknown variables that make it too risky to use in
an FDA approved process.
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Table 3-1. Overview of virus and virus-like particles in PEG/salt ATPS.
Target Biomolecule
System
Recovery
Reference
Rotavirus-like particles
HIV-VLP
Bacteriophage M13
Bacteriophage T4
Porcine parvovirus
*partition coefficient

PEG 400/phosphate
PEG 1500/sulfate
PEG 400/ phosphate
PEG 8000/phosphate
PEG 12000/citrate

90%
4.4*
83%
38%
64%

[26]
[34]
[36]
[37]
[38]

This study aimed to determine the effect of PEG and salt concentration on virus
recovery. The model non-enveloped viruses used for this study were porcine parvovirus
(PPV), a single stranded DNA virus with a diameter of 18–26 nm [53], and human
rhinovirus (HRV), a single stranded RNA virus with a diameter of ~30nm [54]. Both
viruses have icosahedral symmetry. Previous work had established that the PEG 12 kDacitrate system could recover PPV in the PEG-rich phase [38]. This particular study
focused on tie line (TL) characterization and its effect on PPV and HRV recovery to
create a stronger theory on the mechanism of partitioning for viral particles in ATPS. TLs
are thermodynamic equilibrium points that form in the two-phase region. Along a TL, the
system separates into phases that have the same concentration, but the volume ratio of the
phases changes. This systematic evaluation of the two-phase ATPS space allowed us to
understand the balance between the salting-out effect of the citrate-rich phase and the
ability of the PEG-rich phase to pull the virus out of the interface and into the PEG-rich
phase by hydrophobic interactions. It is difficult to recover biomolecules from the
interface, so extracting as much virus into the PEG-rich phase was desired. There was a
unique separation behavior observed at each tie line length (TLL). With a matrix
containing TLL and TL ratios, we were able to recover the majority of the infectious PPV
in a PEG 12 kDa-citrate system with high purity. By comparing the PPV recovery to the
HRV recovery, we were able to add to the understanding of viral particle driving forces
in ATPS.
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3.2 Materials & Methods
3.2.1 Materials
Eagle's minimum essential media (EMEM), sodium bicarbonate, phosphate buffered
saline (PBS, pH 7.2), penicillin-streptomycin (10,000 U/ml), and trypsin/EDTA for cell
propagation were purchased from Life Technologies (Carlsbad, CA). Fetal bovine serum
(FBS, Canada origin) was purchased from HyClone™ GE Healthcare (Pittsburg, PA). 2(3,5-diphenyltetrazol-2-ium-2-yl)-4,5-dimethyl-1,3thiazole;bromide (MTT, 98%) was
purchased from Alfa AesarTM (Haverhill, MA) and sodium dodecyl sulfate (SDS,
BioReagent, ≥98.5%) was purchased from VWR (Radnor, PA). Polyethylene glycol with
an average molecular weight of 12,000 (PEG 12 kDa), trisodium citrate dihydrate (ACS
reagent grade, ≥99%), citric acid monohydrate (ACS reagent, ≥99%), and sodium
phosphate dibasic heptahydrate (ACS reagent grade) were purchased from Sigma-Aldrich
(St. Louis, MO). Sodium phosphate monobasic monohydrate (ACS reagent grade) was
purchased from Fisher Scientific (Waltham, MA). All solutions were made with
Nanopure water (Thermo Scientific, Waltham, MA) at a resistance of ≥18 MΩ and
filtered with a 0.2 μm Nalgene (Thermo Scientific) bottle top filter prior to use.

3.2.2 Methods
3.2.2.1 Cell maintenance and virus titration
Porcine kidney cells (PK-13) and H1HeLa cells (HeLa), purchased from ATCC (CRL6489™ and CRL-1958™ respectively), were grown in EMEM supplemented with 1%
penicillin/streptomycin. In addition, the PK-13 cell media was supplemented with 10%
FBS and the HeLa cell media was supplemented with 5% FBS. The cells were incubated
at 37 °C, 5% CO2, and 100% humidity. PPV strain NADL-2 was a generous gift from
Dr. Ruben Carbonell (North Carolina State University, Raleigh, NC), and was propagated
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in PK-13 cells, as described previously [55]. HRV-14 strain 1059 was purchased from
ATCC (VR-284™) and propagated in HeLa cells. Briefly, HRV was infected at 0.001
MTT50/cell after 24 h of HeLa incubation at 70–80% confluency. The infected HeLa
cells were incubated at 35 °C for HRV propagation. The cell lysis was collected 5 days
post-infection.
The titer of PPV and HRV were found by the colorimetric MTT cell viability
assay [56]. Briefly, 96-well plates were seeded with PK-13 or HeLa cells at a seeding
density of 8×104 cells/well. The cells were infected 24 h post-incubation with PPV or
HRV and serially diluted at a 1:5 ratio across the plate. PPV infected PK-13 cells were
incubated at 37 °C and HRV infected HeLa cells were incubated at 35 °C. After six days,
an MTT salt solution was added to each well and both cell lines were incubated at 37 °C.
This was followed by addition of an acidic SDS solubilization solution. The absorbance
was recorded with a Synergy Mx microplate reader (BioTek, Winoski, VT) after 4–12 h.
The 50% infectious dose value of PPV and HRV was determined and reported in the
units of MTT50/ml [55].
3.2.2.2 Construction of binodal curves and tie lines
The binodal curve was generated using the turbidity method with appropriate
stock PEG and citrate concentrations, as described earlier [38]. Briefly, systems were
formed at high concentrations and diluted with water until the turbid systems turned
clear. The tie lines were determined by conductivity measurements of the citrate-rich
(bottom) phase using a VWR® sympHony™ conductivity meter (Radnor, PA), [50] and
intrapolating the citrate compositions from a standard curve. The endpoints of the tie
lines were determined by calculating the remaining amount of citrate in the PEG-rich
(top) phase by completing a mass balance of the system. The tie lines were characterized
by their tie line length (TLL), calculated as [57],
2
2
𝑇𝑇𝑇𝑇𝑇𝑇 = �∆𝑥𝑥𝑃𝑃𝑃𝑃𝑃𝑃
+ ∆𝑥𝑥𝑐𝑐𝑐𝑐𝑐𝑐
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(3-1)

where ΔxPEG is the concentration difference of PEG in the top phase and bottom phase
and Δxcit is the concentration difference of citrate in the top phase and bottom phase. TL
ratios were calculated as
����)
𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙ℎ (𝑇𝑇𝑇𝑇
���� )
𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙ℎ (𝑆𝑆𝑆𝑆

𝑇𝑇𝑇𝑇 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 =

(3-2)

where S is the system composition point, T is the top node, and B is the bottom node (see
Fig. 1). The volume ratios were calculated as
𝑉𝑉𝑉𝑉 =

(𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉)𝑡𝑡𝑡𝑡𝑝𝑝 𝑝𝑝ℎ𝑎𝑎𝑎𝑎𝑎𝑎

(𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉)𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 𝑝𝑝ℎ𝑎𝑎𝑎𝑎𝑎𝑎

(3-3)

After determining the tie lines, TLL 15, 25, and 36 w/w% were chosen for the
study of virus partitioning. ATPSs were made with stock solutions of 30 w/w% citrate
and solutions ranging from 33 to 45 w/w % of PEG. Appropriate amounts of stock
solutions, water and 0.1 g of crude PPV were added to a microcentrifuge tube to
complete a 1 g system. All systems were mixed with a vortex mixer and the phase
separation was carried out in an ST16R Centrifuge (Thermo Scientific, Pittsburg, PA) at
~12,300 xg at 21 °C for 5 min. The recovery of PPV was calculated as
%𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 =

𝑉𝑉𝑃𝑃/𝐶𝐶 ∗𝑇𝑇𝑃𝑃/𝐶𝐶
𝑉𝑉𝑖𝑖 ∗𝑇𝑇𝑖𝑖

∗ 100

(3-4)

where V is the volume of the PEG-rich phase (P), the citrate-rich phase (C) or the initial
stock (i) and T is the titer of one phase expressed as MTT50/ml [38]. The partitioning
coefficient was calculated as
𝐾𝐾 =

𝑉𝑉𝑃𝑃 ∗𝑇𝑇𝑃𝑃
𝑉𝑉𝐶𝐶 ∗𝑇𝑇𝐶𝐶

3.2.2.3 Physical Properties of Systems
The refractive index of the extracted PEG-rich phases was measured with a
Digital Brix/RI-Chek refractometer (Reichert Technologies, Depew, NY), with an
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(3-5)

accuracy of±0.0002. Densities of the PEG-rich and citrate-rich phases were measured by
weighing 1 ml of the phase using a calibrated pipette on a Mettler-Toledo analytical
balance (Columbus, OH), with a readability up to 0.1 mg.
3.2.2.4 SDS-PAGE
The partitioning of the contaminant proteins in the crude lysate was measured
using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with a 4–
12% Bis-Tris NuPage gel and NuPage MOPS running buffer (Life Technologies,
Carlsbad, CA). Benchmark™ protein ladder with a molecular weight range of 10–220
kDa (Life Technologies) was used as the marker. Samples were reduced using
βmercaptoethanol (Sigma-Aldrich, St. Louis, MO) at 7% concentration, and heated to 70
°C for 10 min prior to loading onto the gel. The SDSPAGE was run for 55 min at a
constant 200 V. The gel was loaded at a constant volume so that concentrations of
contaminating proteins could be compared. The gel was stained with the SilverXpress™
staining kit (Life Technologies, Carlsbad, CA).
3.2.2.5 DNA quantification
DNA content in the PEG-rich phase and citrate-rich phase was measured using
the Quant-iT™ PicoGreen® dsDNA kit (ThermoFisher Scientific, Waltham, MA). The
PEG-rich phase and citrate-rich phase were diluted in water to have a final concentration
of PEG and citrate as ≤1 w/w%. The host cell DNA in the crude lysate, PEG-rich and
citraterich phase was measured, as per manufacturer's instruction. The fluorescent
activities (excitation: 480 nm and emission: 520 nm) of the samples were measured using
a Synergy™ Mx microplate reader. DNA recovery was calculated similar to virus
recovery as:
%𝐷𝐷𝐷𝐷𝐷𝐷 𝑟𝑟𝑟𝑟𝑟𝑟𝑜𝑜𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 =

𝐷𝐷𝐷𝐷𝐷𝐷 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑛𝑛𝑃𝑃/𝐶𝐶 ∗𝑉𝑉𝑃𝑃/𝐶𝐶 ∗ 𝐷𝐷𝐷𝐷
𝐷𝐷𝐷𝐷𝐷𝐷 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑛𝑛𝑖𝑖 ∗𝑉𝑉𝑖𝑖 ∗ 𝐷𝐷𝐷𝐷
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∗ 100

(3-6)

where V denotes volume of the PEG-rich phase (P), citrate-rich phase (C) or initial stock
(i) and DF denotes the respective dilution factor.
3.2.2.6 Dynamic Light Scattering (DLS)
Virus aggregates at varying concentrations of citrate were measured by DLS with a
Malvern Zetasizer Nano ZS (Westborough, MA). First, virus was dialyzed in Biotech
cellulose ester 1000 kDa dialysis tubing (Rancho Dominguez, CA) at 4 °C for two days
with two buffer exchanges of 20mM phosphate buffer at pH 7.0 (PB). Then, the dialyzed
virus was further purified in an Econo-Pac 10DG desalting column (Hercules, CA). The
fraction containing the highest titer was used to mix with sodium citrate solution at pH 7
to give different final concentrations of citrate. The hydrodynamic diameter was
measured and the aggregate ratio (AR) was calculated as:
𝐴𝐴𝐴𝐴 =

𝐷𝐷𝐻𝐻,18−26 𝑛𝑛𝑛𝑛
𝐷𝐷𝐻𝐻,18−26 𝑛𝑛𝑛𝑛

(3-7)

where DH,18-26nm is the maximum intensity of the peak at 18–26 nm (the virus
intensity) and DH,>100nm is the maximum intensity of the aggregate peak, which
was>100 nm and became larger as the concentration of citrate increased.

3.3 Results
3.3.1 Model Virus
Porcine parvovirus (PPV) and human rhinovirus (HRV) were chosen as the model
non-enveloped viruses to study the partitioning in ATPS and key properties are shown in
Table 3-2. PPV is a ssDNA virus that is approximately 18–26 nm in diameter [53]. PPV
is a pathogenic agent that causes reproductive failure in swine populations [58,59], and is
a model for the human B19 parvovirus. The capsid of PPV is composed of three proteins,
VP1, VP2, and VP3. VP2 is the major constituent (~80%) of the capsid [60]. Recently, a
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comparative study using computational and experimental methods showed that PPV [61]
and a closely related murine parvovirus, MVM [62], are more hydrophobic than a panel
of proteins. This significant difference in the surface hydrophobicity of PPV and
contaminant proteins is an ideal driving force to develop new purification methods for
viral particles. HRV is a ssRNA virus that is ~30nm in diameter, composed of VP1, VP2,
VP3, and VP4 capsid proteins [64,66]. VP1, VP2, and VP3 are surface exposed antigenic
proteins, whereas VP4 is present in the inside of the capsid and assists in anchoring the
RNA inside the capsid [64]. HRV is one of the agents causing common cold and
exacerbations of asthma in humans, with three main species, namely A, B, and C,
and>100 serotypes identified [67–71]. Despite extensive research, there is no effective
antiviral drug treatment for HRV infections [72]. This virus was used to show the effect
of surface hydrophobicity at net neutral surface charge on virus partitioning in ATPS.

Table 3-2.A brief description and comparison of the model viruses (PPV and HRV)
Model
Related
Size
Genome
Family
pI
References
Virus
Virus
(nm)
18PPV
ssDNA
parvoviridae
B19, AAV
5.0
[60, 63]
26
FMDV,
HRV
(+)ssRNA picornaviridae
6.9
~30
[64-66]
Polio, Hep A
PPV: porcine parvovirus; HRV: human rhinovirus; B19: B19 parvovirus; AAV: adeno
associated virus; FMDV: foot & mouth disease virus; Polio: poliovirus; Hep A: hepatitis
A virus

3.3.2 Binodal curves & tie lines
The ATPS binodal phase diagram separates the homogeneous region from the
two-phase region, as shown in Figure 3-1A. Tie lines were generated to study systems
containing the same concentrations of each component in the PEG-rich and citrate-rich
phases. Tie lines are thermodynamic equilibrium states in the two-phase region,
representing a unique value of Gibb's free energy [57,73]. An increase in the TLL (Eq.
(3-1)) increases the Gibb's free energy, which correlates to the thermodynamic driving
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force [73] and results in higher PEG and salt concentrations in each phase. Additionally,
an increase in TLL also provides elevated hydrophobic interaction from the PEG-rich
phase and effective salting-out of proteins from the salt-rich phase [74]. Increasing the
TLL is hypothesized to provide a larger hydrophobic driving force for the partitioning of
PPV and HRV into the PEG-rich phase. Each system composition is represented by a TL
ratio (Eq. (3-2)). The TL ratio is the ratio of a length of the segment from the system
point to the top node divided by the length of the segment from the system point to the
bottom node of that tie line [57]. The phase volumes change as the TL ratio changes, as
shown in Figure 3-1A.

Figure 3-1. Binodal curve and tie lines. (A) Schematic illustration of ATPS showing
binodal curve separating one-phase region from the two-phase region and set of systems
characterized by tie lines and TL ratios. (B) Experimentally determined binodal curve
and tie lines for PEG 12kDa-citrate ATPS at pH 7.

Earlier studies have shown that a PEG 12 kDa-citrate system was able to separate
and recover 64% of infectious PPV [38]. This is a higher MW of PEG than typically
studied in PEG-salt ATPS. Although higher MW causes an increase in viscosity and
interfacial tension [75,76], it also elevates the hydrophobic driving force in the PEG-rich
phase, which increased the virus recovery [38]. Hence, it was decided to study the PPV
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purification at varying TLL in the PEG 12 kDa-citrate system to better understand the
effect of PEG and citrate concentration on virus recovery.

Table 3-3. Comparison of TL ratio (Eq. 3-2) and volume ratio (Eq. 3-3)
System Composition
Volume
TLL
Citrate
TL ratio
PEG Conc.
(w/w%)
ratio
Conc.
(w/w%)
(w/w%)
30.0

6.4

0.1

7.7

15.0

14.0

1.2

0.9

10.0

16.5

2.3

0.4

18.5

7.5

0.1

3.7

10.3

13.2

1.0

0.5

6.2

16.0

2.3

0.3

13.7

7.5

0.1

0.8

7.4

11.8

1.0

0.4

4.6

13.6

2.3

0.3

36

25

15

Several groups have generated binodal curves for polymer/salt systems [38,77–
80]. The phase diagram was experimentally determined for the PEG 12 kDa-citrate
system and can be seen in Figure 3-1B. Refractive index and density were also used to
confirm the tie lines (see Tables A.1-1 and A.1-2). The densities of the PEG-rich phases
of systems did not differ much with an increasing TLL. On the other hand, the densities
of the citrate-rich phases showed a significant increase with the TLL. Refractive index of
the PEG-rich phases increased linearly with TLL. The binodal curve generated was
similar to previous work [38] and the tie lines determined were parallel, as expected, and
are also shown in Figure 3-1B. The tie lines had an average slope of −1.6 ± 0.2. The PEG
concentrations in the PEG-rich phase was measured by generating a standard curve
(Table A.1-3). The measured PEG concentrations showed a slight deviation from the
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previously determined tie lines using conductivity method. However, the standard curve
was generated without adding citrate salt, which is present when two-phase systems are
formed. Any system composition on a given tie line separates into the same respective
PEG and salt compositions [57], only the volume ratio changes of each system. The TL
ratios were indirectly proportional to the volume ratios (Eq. (3-3)), as shown in Table 3-3
thus suggesting an increase in the TL ratio will decrease the volume ratio.

3.3.3 Effect of tie lines & tie line ratios
Three TLLs and at least three TL ratios were chosen to study the recovery of PPV
and HRV with respect to phase composition and phase volume. The system matrix also
explored the effect of phase composition changes on the partitioning behavior of
contaminants, in particular, host-cell proteins and DNA.
The shortest TLL studied was 15 w/w%. TLL 15 w/w% contained the lowest
concentration of PEG and citrate of those tested. The lower compositions have relatively
low hydrophobic interaction from the PEG-rich phase and low salting-out effect from the
citrate-rich phase. It was observed that PPV highly partitioned to the citrate-rich phase
and very little PPV was recovered in the PEG-rich phase, as shown in Figure 3-2A & B.
Recoveries in the citrate-rich phase started at 100% at TL ratio 0.1 and decreased to 20%
at TL ratio 2.3. Irrespective of the TL ratio, the contaminant proteins partitioned to the
citrate-rich phase, as shown in Figure 3-2C. The PPV concentration is too low to be seen
on an SDS-PAGE. Since there was not enough preferential partitioning of the PPV
particles to the PEG-rich phase, the lower TLL is not suitable for the purification of PPV.
To increase the driving forces (i.e. salting-out of the citrate and hydrophobic
interaction of the PEG) and obtain higher recovery of the viral particles in the PEG-rich
phase, systems on TLL 25 w/w% were studied. As shown in Figure 3-2D, the PPV
recovery in the PEG-rich phase increased almost linearly with the TL ratio. A maximum
of 52% PPV was recovered in the PEG-rich phase at TL ratio 2.3. This corresponded to a
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decrease in recovery in the citrate-rich phase as the TL ratio increased (Figure 3-2E).
However, the recoveries in the citrate-rich phase remained low at<30%. The remainder of
the viral particles are likely aggregated at the interface or have been rendered
noninfectious by the system and are not recoverable, as stated previously [38]. It is most
likely that the virus has been trapped at the interface, since we do obtain high recoveries
at TLLs with both increased and decreased concentrations of PEG and citrate.
Most of the contaminant proteins partitioned to the citrate-rich phase, as shown in
Figure 3-2F. One contaminant protein partitioned along with PPV in the PEG-rich phase
for TLL 25 w/w%, as seen by the band between 50 and 60 kDa. The decreasing band
intensity with an increase in the TL ratio was observed in the citrate-rich phase, the cause
of which might be the decreasing concentration of the proteins with an increasing volume
of the citrate-rich phase, i.e. the citrate is diluting the protein. TLL 25 w/w% provided a
better driving force for the preferential partitioning of PPV to the PEG-rich phase than
TLL 15 w/w%.
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Figure 3-2. PPV recovery in the PEG-rich phase (A, D, and G) and the citrate-rich phase
(B, E, and H) at different TLL. SDS-PAGE of marker (M), starting PPV (S) and the
PEG-rich phase (P) and the citrate-rich phase (C) at different TLL and TL ratios. The
starting titer was log10 6.5 MTT50/ml. Experiments were done in triplicates and the error
bars represent the standard deviation.

Similar studies were performed with HRV to determine the effect of viral surface
charge on the partitioning and recovery of the virus. The recovery of HRV in the PEGrich phase on TLL 15 w/w% remained low, almost 0% (Figure 3-3A). This low recovery
was similar to PPV for TLL 15 w/w%. At the increased TLL of 25 w/w%, the HRV
recovery increased to between 11 and 21%, depending on the TL ratio. Furthermore, TLL
36 w/w% provided an even stronger driving force where the recovery of HRV increased
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to 36% at TL ratio 0.3 (Figure 3-3A). The recovery of the HRV in the PEG-rich phase
showed an opposite trend on TLL 25 w/w% and 36 w/w%. This trend was similar to the
PPV behavior at the same TLLs, as shown in Figure 3-2D & G. Also, the HRV titers
were almost identical to the PPV titers in the PEG-rich phase for all the systems studied
(Table A.1-4) suggesting that the highly hydrated citrate ions dehydrate the HRV surface
which promotes the hydrophobic interaction of PEG-rich phase and dehydrated viral
surface.

Figure 3-3. HRV recovery in the PEG-rich phase (A) and the citrate-rich phase (B) at
different TLL. SDS-PAGE of marker (M), starting HRV (S), PEG-rich phase (P) and the
citrate-rich phase (C) at TLL 15, 25, and 36w/w%. %. The starting titer was log10 6.5
MTT50/ml. Experiments were done in triplicates, and the error bars represent the standard
deviation.

The citrate-rich phase titers were strongly affected by the presence of citrate in the
samples. This is clearly seen in the citrate-rich phase recoveries, where the recoveries at
TLL 15 w/w% and 25 w/w% were>150% at TL ratios>1. These high titers, which then
resulted in high recoveries in the citrate-rich phase, were likely due to the interaction of
the cells with the citrate. Some groups have shown that citrate reduces cell viability [82]
and is cytotoxic to cancer cells [83] at certain concentrations. Reduction of the cell
viability increases the titer in the MTT assay as the virus quantification is based on the
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cell viability. An increase in the titer increases the recovery. The mass balance of viral
particles held true only at TLL 36 w/w% with a total mass balance ranging between 77
and 102%. Overall, the HRV recovery followed the same trends as PPV. At low TLL, the
virus remained in the citrate-rich phase and transitioned to the PEG-rich phase at the
highest TLL studied.
Similar to PPV, the contaminant proteins present in the HRV solution were found
mainly in the citrate rich phase (Figure 3-3C). The bands of the PEG-rich phase and
citrate-rich phase corresponding to all the systems studied were identical. Hence, only
one representative gel comprising of TLL 15, 25, and 36 w/w% at TL ratio 1.2 is shown
(Figure 3-3C). The purity of the PEG-rich phase was similar to PPV. HRV partitioning
demonstrated a high purity but low recovery as compared to the high purity and high
recovery found with PPV.
3.3.4 Effect of increased PPV load
To understand the effect of loading, the initial PPV load was increased from 6.5
log10(MTT50/ml), used in Figure 3-2, to 8 log10(MTT50/ ml). The loading effect was only
performed with PPV as the highest titer of the HRV stock achieved was only 7 log10
MTT50/ml. The PPV partitioning coefficient, K (Eq. (5)), on all three TLLs showed
similar trends for both loadings, as shown in Figure 3-4A & B. TLL 15 and 25 w/w%
showed increasing K values with respect to an increasing TL ratio and exhibited
decreasing K values for TLL 36 w/w%. It was noted that the partitioning coefficient
values are similar or lower for the higher load on all the TLLs. However, the virus titer
increased in the PEG-rich phase by increasing the initial load for all the systems studied
(Table A.1-5). But a respective increase of virus titer in the citrate-rich phase suggested
that a considerable number of viral particles still remained in the citrate-rich phase. This
suggests that all the systems with an initial PPV load of 8 log10(MTT50/ml) have higher
ability than systems with an initial PPV load of 6.5 log10(MTT50/ml) to drive viral
particles in the PEG-rich phase, but the distribution of the viral particles is maintained to
balance the free energy between the two-phases. In the previous studies, the free energy
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has been correlated to the partition coefficient suggesting that for a given system
composition the partition coefficient should remain the same [31,84].

Figure 3-4. Comparison of PPV partitioning at two different loads along (A) TLL 15
w/w%, (B) TLL 25 w/w%, and (C) TLL 36 w/w%. Experiments were repeated in
triplicates and error bars represent standard deviation.
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3.4 Discussion
This study examined the partitioning of PPV and HRV in an ATPS of PEG 12
kDa-citrate. The goal was to determine the influential driving forces in ATPS partitioning
at pH 7. There are two main theories that explain the partitioning of biomolecules in
ATPS, 1) the excluded volume effect [30,42–44] and 2) hydrophobic and electrostatic
interactions [45–47,74]. A previous study conducted for PPV ATPS partitioning using
various molecular weights of PEG, salt types and pHs supported the concept of viral
surface and phase hydrophobicity as the main driving forces [38]. This work supports two
main conclusions, 1) increasing the PEG and citrate concentration, and therefore
increasing the phase hydrophobicity and salting-out effect, increases the PPV and HRV
recovery in the PEG-rich phase at a constant pH and 2) the influence of the electrostatic
interaction is vital in achieving the high recovery of viruses in the PEG-rich phase.
Therefore, the data supports that in a PEG 12 kDa-citrate system, electrostatics and
hydrophobic interactions are the dominant forces.
The current theory for the partitioning of virus in ATPS involve the electrostatic
interaction of the virus with the salt-rich phase and the hydrophobic interaction of the
virus with the water-reduced PEG-rich phase. The first interaction appears to be the
salting-out of the virus from the citrate-rich phase. This is due to the charge repulsion of
the citrate with the virus. PPV is negatively charged at pH 7, and when the salt
concentration is raised from TLL 15 w/w% to TLL 25 w/w%, all of the PPV is salted-out
of the salt-rich phase and is likely at the interface. When the PEG-rich phase
concentration is increased to TLL 36 w/w%, there is enough hydrophobic interaction
driving force from the PEGrich phase to extract the virus from the interface and have it
recovered in the PEG-rich phase. This is illustrated by the recovery map shown in Figure
3-5. This theory is also supported by the data from HRV. HRV is neutrally charged at pH
7, and therefore does not experience the same amount of charge repulsion from the
citrate-rich phase. Since the virus is not driven to the interface, it is not extracted from the
interface by the PEG-rich phase. Therefore, our current hypothesis is that first the virus
must be salted-out by charge repulsion from the salt-rich phase to the interface. Then the
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PEG-rich phase needs to be strong enough to extract the virus from the interface into the
PEG-rich phase. The experiments described here never reached a citrate concentration
that salted-out the contaminating proteins so that they could be extracted into the PEGrich phase. This is preferred because it provides a difference in driving force needed to
purify the viral particles.

Figure 3-5. Schematic PPV recovery map in the two-phase region for (A) PEG-rich
phase and (B) citrate-rich phase.

The salting-out phenomena is the interaction of salt ions (electrolyte),
biomolecules (non-electrolyte) and solvent. At lower salt concentrations, the salt ions
interact with the biomolecules by forming a layer of counter ions around the charged
biomolecule. The counter ion layer increases the water structure stability and decreases
the free energy, therefore promoting biomolecule solubility. An increase in the salt
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concentration, above a critical concentration, causes a high repulsion force to develop
from the development of an electronic double layer and the close proximity of liked
charged ions near the surface of the biomolecule [85]. This high repulsion force increases
the free energy of the biomolecule surface, thereby making the surface
thermodynamically unstable [86].
To test the effect of citrate concentration on the aggregation of PPV, DLS was
measured for PPV in different citrate concentrations. Due to aggregates that were present
in the starting material, an aggregation ratio was used to compare the intensity of the PPV
peak and the aggregate peak. The full calculation is described in Eq. (3-7). PPV particles
started to aggregate at 15 w/w% citrate, with extensive aggregation occurring at 20 w/w%
and above (Figure A.1-1). 20 w/w% citrate and above are close to the citrate-rich phase
compositions of the TLLs, 25 and 36 w/w%, studied (see Figure A.1-1). These results
support the hypothesis that PPV is salted-out at high citrate concentration. Without the
PEG-rich phase present (i.e. citrate only, as was conducted in the DLS experiments), PPV
aggregated. In the presence of the PEG-rich phase, the PPV particles can reduce their free
energy by migrating to the PEG-rich phase. Aggregation was not measured for HRV due
to the low HRV titer available which was not detectable by DLS measurements.
The proposed theory of hydrophobicity as the main driving force in ATPS was
based on recent studies that have shown viral particles to be relatively more hydrophobic
than proteins [61,87]. The PPV surface was shown to be more hydrophobic than the
model proteins BSA, lysozyme, bovine fibrinogen, and human IgG by studying reverse
phase chromatography and ANS fluorescence, and the results were compared with
computationally determined solvent exposed surface area [61]. Another team performed
hydrophobic interaction chromatography (HIC) studies on a variety of enveloped and
non-enveloped mammalian viruses and protein models, where viruses eluted at lower
citrate concentrations as compared to the model proteins, suggesting the relatively
hydrophobic nature of the viruses studied [87]. One of the viruses studied was MVM.
MVM and PPV are both parvoviruses, therefore complementing the idea that PPV is
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hydrophobic. Similarly, the ATPS described here was designed to utilize the hydrophobic
property of PPV to induce preferential partitioning of the virions to the PEG-rich phase.
A few studies have been reported to measure the hydrophobicity or predict the
partitioning behavior based on hydrophobicity of proteins [45], or peptides [47] in ATPS.
The hydrophobic interaction in ATPS is driven by the PEG molecular weight and
concentration. This growing evidence of the hydrophobic interaction as a vital driving
force in ATPS could be reasoned by the molecular composition of PEG. The increase in
the PEG molecular weight and/or concentration increases the number of ethyl groups in
the polymer chain. Ethyl groups are hydrophobic and optimum number of monomers
provide the necessary hydrophobic interaction binding sites to attract proteins or viruses
[49]. The minimization of free energy increase of the biomolecules, from the salting-out
effect, is compensated by the availability of the free energy provided by the amount of –
CH2-CH2– groups in the PEG-rich phase. The high recoveries of virus in PEG-citrate
ATPS is possible by the right balance of salting-out and hydrophobic interaction.

3.5 Conclusion
This study reported the recoveries of PPV and HRV in a PEG 12 kDa-citrate
system at pH 7. The PPV and HRV titers in the PEG-rich phase increased with an
increase in TLL. Most of the viral particles were recovered in the citrate-rich phase at
TLL 15 w/w%, the lowest TLL studied. The PPV and HRV recovery in the PEG-rich
phase increased at TLL 25 w/w%. Across this tie line, the PPV and HRV recovery
increased in the PEG-rich phase as the TL ratio increased. TLL 36 w/w% showed the
opposite trend; the recovery decreased as the TL ratio increased. The highest PPV
recovery of 79% and HRV recovery of 36% was found on TLL 36 w/w% and the lowest
TL ratio studied. An increase in the PPV titer yielded higher titers in the PEG-rich phase.
Overall, this work supported the hypothesis that the main driving forces in viral particle
ATPS are the salting-out from the citrate-rich phase followed by the hydrophobic
interaction of the PEG-rich phase. Therefore, a higher TLL, leading to higher
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concentrations of salt and PEG, is needed for a high virus recovery in the PEG-rich
phase.
The framework in this study achieves high virus recovery in a PEG-citrate system
using known surface properties of the virus. The model viruses used, demonstrated a
need to understand the virus properties to improve virus recovery. By systematically
studying the partitioning and recovery of negatively charged PPV and neutral HRV
across tie lines, it was determined that the surface hydrophobicity and the charge at a
given pH of the virus were key in the selective partitioning of the virus to the more
hydrophobic PEG-rich phase. By combining the study of virus particle surfaces and the
experimental ATPS design space, future correlations can be determined that will reduce
the number of ATPS experiments needed to find an optimal system.
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4 Osmolyte enhanced Aqueous two-phase systems for
virus purification3, 4

3

The material contained in the chapter is in preparation for submission to a peer-reviewed
journal
4

The extension of the material in this chapter is mentioned in Appendix B
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4.1 Introduction
Downstream purification of viral vaccines needs to address the challenges of
yield, purity, scale-up, and robust processing. In addition, continuous processing is also a
future target. To accomplish these goals, we are studying the use of aqueous two-phase
systems (ATPSs) to purify viral particles. The biphasic systems are formed by mixing
two aqueous solutions above certain critical compositions with different phase-forming
components. Typical phase-forming components are polymer-polymer and polymer-salt,
due to their superior biocompatibility and mild, water-based environment. ATPSs have
been mostly studied for therapeutic proteins [1-3] and plasmid DNA [4, 5] purification in
the biotherapeutic area over the decades, with a limited focus on viruses. Viral
purification using ATPS has only recently gained attention, as the onset of new vaccines
and gene therapy modalities create a need to increase capacity and throughput for viral
processing methods. However, this technique still requires extensive study to understand
viral behavior in these types of biphasic systems. Traditionally, viral partitioning has
been studied in a polyethylene glycol (PEG)-dextran system [6-8] and more recent
studies have focused on PEG-salt systems [9-12]. This study explores a PEG-salt system
and ways to enhance virus partitioning to the PEG-rich phase and contaminant retention
in the salt-rich phase by addition of a third component.
Numerous studies have tried to understand the characteristics of ATPSs that lead
to biomolecule partitioning. A comprehensive review suggests that the partitioning of
biomolecules is synergistically influenced by the excluded volume theory, electrostatic
interaction, and hydrophobic interaction [13]. However, recent reports have demonstrated
critical contributions from the electrostatic and hydrophobic interactions in a PEG-salt
system for virus purification [12, 14], with a contradictory contribution of the excluded
volume theory. The virus prefers the PEG-rich phase once it is salted out of the salt-rich
phase. This is accomplished by employing a stronger kosmotropic salt, such as citrate, for
salting out, and a higher molecular weight PEG to provide hydrophobic interaction. One
could also operate the ATPS at higher system compositions, which will create a higher
ionic strength of the salt-rich phase and an increase in relative hydrophobicity of the
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PEG-rich phase, thus promoting virus separation [12]. However, the hydrophobic
interactions are relatively weak in a PEG-salt system as compared to a conventional
hydrophobic interaction chromatography using phenyl-based resins. Due to this, a higher
ionic strength might be detrimental to the virus structure and functional stability. On the
other hand, higher compositions of the PEG-rich phase, needed to achieve high
recoveries, generate a viscous solution which pose a processing challenge. Moreover,
with an increasing array of viruses used in biotherapeutics that have a wide variety of
surface characteristics and stability, there is a need to look for driving force enhancers
that will preferentially increase the virus partitioning at milder system compositions.
Osmolytes are a class of molecules that occur naturally and are used by cells to
compensate for changes in osmotic stress [15, 16]. Osmolytes have been divided into two
groups based on the nature of their interaction with the protein backbone; 1)
osmoprotectants or protecting osmolytes and 2) denaturing osmolytes. Osmoprotectants,
such as betaine and trimethylamine N-oxide (TMAO), help in stabilizing protein
structures [17]. Denaturing osmolytes, such as urea and guanidinium chloride, have been
shown to unfold and destabilize protein structures [18, 19]. Numerous applications of
osmoprotectants have been reported in the life sciences and biomanufacturing. Osmolytes
function as water structure modulators, either to maintain osmotic balance [20, 21] or
induce intramolecular or intermolecular interactions that stabilize proteins during osmotic
stress [22]. Osmoprotectants have been utilized to induce intramolecular interactions to
stabilize biologics in the formulation of biomolecules [23, 24]. Conversely, osmolytes
have been shown to induce intermolecular interactions to flocculate viruses [25], which
aided in the development of filtration-based method for virus purification. The exact
mechanism of osmolyte function in protein stabilization or viral flocculation, however, is
not clearly understood.
A few studies have used osmolytes as additives in ATPS. However, most of them
have reported the effects in polymer-polymer systems on small organic molecules or
protein partitioning (Ferreira, Fan [26], [27, 28]). This study explores the effect of
osmolytes on two virus models in a PEG 12kDa-citrate system. Our previous study
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showed that negatively charged non-enveloped viral particles partition to the PEG-rich
phase only at higher system compositions [14]. It was hypothesized that a high salt
concentration was needed to salt-out the virus to the interface. Then a high PEG
concentration was needed to draw the virus out of the interface and into the more
hydrophobic PEG-phase. To decrease the concentration of salt and PEG needed in the
system, we added osmolytes and explored the partitioning of two viruses. The use of
additives demonstrated preferential enhancement of partitioning at lower system
compositions. This was likely by improving the hydrophobic interaction of virus and
VLP with the PEG-rich phase. Moreover, the efficiency of osmolyte type to improve
virus recover in the hydrophobic PEG-rich phase has led to theories on the mechanism of
osmolyte action. Understanding the mechanism driving partitioning has direct correlation
not only in the viral purification, but also in understanding the differential action of
osmolyte towards biomolecules.

4.2 Materials and Methods
4.2.1 Materials
Eagle's minimum essential media (EMEM), sodium bicarbonate, phosphate
buffered saline (PBS, pH 7.2), penicillin-streptomycin (pen-strep) (10,000 U/ml), fetal
bovine serum (FBS, USDA approved) and trypsin/EDTA for cell propagation were
purchased from Life Technologies (Carlsbad, CA). 2-(3,5-diphenyltetrazol-2-ium-2-yl)4,5-dimethyl-1,3thiazole;bromide (MTT, 98%) was purchased from Alfa AesarTM
(Haverhill, MA) and sodium dodecyl sulfate (SDS, BioReagent, ≥98.5%) was purchased
from Sigma Aldrich (Radnor, PA). Polyethylene glycol with an average molecular weight
of 12,000 Da (PEG 12 kDa), trisodium citrate dihydrate (ACS reagent grade, ≥99%),
citric acid monohydrate (ACS reagent, ≥99%) were a generous gift from MilliporeSigma
(Burlington, MA). Osmolytes glycine (BioUltra, ≥99.0%), betaine (BioUltra, ≥99.0%),
trimethylamine N-oxide (TMAO) dihydrate, D-mannitol, and urea were purchased from
Sigma-Aldrich (St. Louis, MO). Stable isotopes glycine (1-13C, 99%), betaine (D-11,
98%), TMAO (D9, 98%), and D-mannitol (U-13C6, 99%) were purchased from
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Cambridge Isotope Laboratory (Tewksbury, MA). All solutions were made with
Nanopure water (Thermo Scientific, Waltham, MA) at a resistance of ≥18 MΩ and
filtered with a 0.2 μm Nalgene (Thermo Scientific) bottle top filter or 0.22 µm cellulose
acetate syringe filters (VWR, Radnor, PA) prior to use.
HIV-VLP crude stock was a generous gift from Esperovax (Plymouth, MI). HIVVLP with genetically infused green fluorescent protein (GFP) were expressed in
Saccharomyces cerevisiae with a proprietary method.
4.2.2 Methods
4.2.2.1 Cell maintenance, virus propagation and virus titration
Porcine kidney cells (PK-13, CRL-6489TM) purchased from ATCC were cultured
in EMEM pH 7.1 supplemented with 10 v/v% FBS and 1 v/v% pen-strep. The cell
cultures were grown by incubating at 37°C, 5% CO2, and 100% humidity. Porcine
parvovirus (PPV) strain NADL-2, gifted by Dr. Ruben Carbonell (North Carolina State
University, Raleigh, NC), was propagated in PK-13 cells as described previously [29].
PPV titration was performed by a colorimetric cell viability assay using MTT salt as
described previously [14].
4.2.2.2 Generation of binodal curve and tie lines
Binodal curves were generated using the turbidity method [12] with 50 w/w%
PEG and 35 w/w% citrate, and 0.5 M osmolyte stocks. Titration was done using 0.5 M
osmolyte solutions to maintain the osmolyte concentration in the systems until the
systems turned clear.
The tie lines were determined using the conductivity measurements of the citraterich phases as described previously [14]. The conductivity contribution of osmolytes was
measured and determined to be negligible as compared to the conductivity of citrate. The
osmolyte concentration was disregarded in the calculation of the citrate concentrations in
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the citrate-rich phase. The tie line length (TLL) and tie line ratios (TLR) were calculated
as mentioned previously [14].
4.2.2.3 Osmolyte detection and quantification
Osmolyte in the citrate-rich phases were quantified using LC-MS. A Thermo
ScientificTM UltiMateTM 3000 HPLC (Thermo Fisher Scientific, Waltham, MA) was
coupled with an Orbitrap Elite mass spectrometer (Thermo Fisher Scientific) with an
electrospray ionization capability. Separate LC-MS/MS methods were developed for
detection and quantification of glycine, betaine, TMAO, and urea. For each method, a
corresponding isotope was added to all the calibration solutions and samples at the same
concentration as the internal standard were used to compensate for instrument
fluctuations. The analytical column used was an Ascentis Express HILIC 15 cm x 2.1
mm, 2.7 micron (Sigma Aldrich). Eluent A was acetonitrile (HPLC grade, Fisher
Scientific) and eluent B was 0.1 v/v% formic acid (98-100%, Sigma Aldrich) in HPLC
grade H2O (Fisher Scientific). The LC-MS/MS conditions used for each osmolyte are
listed in the Table A.2-1 in the appendix. For quantifications, standard curves were
generated by with the measuring the elution curve area of osmolyte and corresponding
internal standard at different concentrations detected by the mass spectrometry. For mass
spectrometry, selected ion monitoring (SIM) of the parent ion [M+H]+, or the selected
reaction monitoring (SRM) of the suitable fragmentation ion were used. For SRM, the
transitions used for parent ion and fragment ion used for each osmolyte are reported in
the Table A.2-1.
4.2.2.4 Virus and virus-like particle partitioning
Two phase systems were prepared with 50 w/w% PEG and 35 w/w% citrate.
Appropriate stock concentration of each osmolyte was used to maintain a concentration
of 0.5 M in the total system. Appropriate amounts of stocks with 0.1 g crude virus were
added to a microcentrifuge tube to total 1g systems. The rest of the procedure was similar
to our study reported earlier [14]. The virus and VLP recoveries and partition coefficient
(K) were calculated using equations 4-1 and 4-2, respectively.
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% 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 =
𝐾𝐾 =

𝑉𝑉𝑃𝑃/𝐶𝐶 ∗𝑇𝑇𝑃𝑃/𝐶𝐶
𝑉𝑉𝑖𝑖 ∗𝑇𝑇𝑖𝑖

𝑉𝑉𝑃𝑃 ∗𝑇𝑇𝑃𝑃

∗ 100

𝑉𝑉𝐶𝐶 ∗𝑇𝑇𝐶𝐶

(4-1)
(4-2)

where V refers to the volume of either PEG-rich phase (P), citrate-rich phase (C), or
initial stock (i) and T refers to the titer of the virus or virus-like particle in either phases
or initial stock. PPV titer was expressed as MTT50/mL. HIV-VLP titers were expressed as
relative fluorescent unit (RFU)/0.1 mL, as measured with a Synergy Mx microplate
reader (BioTek, Winoski, VT) at an excitation wavelength of 485 ± 9 nm and emission
wavelength 509 ± 9 nm with 80% sensitivity and 10 mm probe offset in black 96-well
plates (VWR).
4.2.2.5 SDS-PAGE for protein detection
The contaminant protein partitioning was detected using sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) with a 4–12% Bis-Tris NuPage gel and
NuPage MOPS running buffer (Life Technologies, Carlsbad, CA). SeeBlue Plus2 prestained protein ladder (molecular weight range: 14–191 kDa, Life Technologies) was
used as the marker. Samples were reduced using 7 v/v% βmercaptoethanol (SigmaAldrich, St. Louis, MO) and heated to 90 °C for 10 minutes prior to loading onto the gel.
The SDS-PAGE was run for 55 min at a constant 200 V. The gel was loaded with a same
volume of the samples. The gel was stained with the SimplyBlue Safe stain (Life
Technologies, Carlsbad, CA) as per the manufacturer’s protocol.
4.2.2.6 DNA Quantification
Host cell dsDNA content was measured using the Quant-iT™ PicoGreen®
dsDNA kit (ThermoFisher Scientific, Waltham, MA) as per the manufacturer’s protocol.
The PEG-rich phase and citrate-rich phase were diluted in water to a final concentration
of PEG and citrate ≤1 w/w% to reduce the interference with the assay. The fluorescence
(excitation: 480 nm and emission: 520 nm) of the samples were measured using a
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Synergy™ Mx microplate reader. A DNA partition coefficient was calculated similar to
virus partitioning using equation 4-3
𝐾𝐾 =

𝑉𝑉𝑃𝑃 ∗ 𝐷𝐷𝐷𝐷𝐷𝐷 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑛𝑛𝑃𝑃 ∗ 𝐷𝐷𝐷𝐷

(4-3)

𝑉𝑉𝐶𝐶 ∗ 𝐷𝐷𝐷𝐷𝐷𝐷 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑛𝑛𝐶𝐶 ∗ 𝐷𝐷𝐷𝐷

where V denotes volume of respective phases and DF denotes respective dilution factor.

4.3 Results
4.3.1

Effect of osmolytes on two-phase behavior
In this study, both protecting and denaturing osmolytes were used to study the

partitioning of viruses in ATPS. Protecting osmolytes modulate the water structure in the
solution due to their strong solvation ability, denoted by the hydration number. The
classification and characteristic hydration number of osmolytes in the concentration range
used in this study is listed in Table 4-1. The osmolytes affected the two-phase systems
by changing the threshold compositions of immiscibility and/or altering the equilibrium
phase compositions.

Table 4-1. Osmolytes and their characteristics
Molecular mass
(g/mol)

Hydration number
(Concentration,
mol/L)*

References

75..07

7

[28, 30]

117.15

31 (0.1 - 1)

[31]

182.17

NA
22.6 - 23
(0.9 - 0.46)
~1 - 1.8 (0.5 - 1)

[27, 32]

Osmolyte

Class

Glycine

Mannitol

Amino acid
Modified
amino acid
Sugar alcohol

TMAO

Amine oxide

75.11

Urea

Carbamide

60.06

Betaine

[33]

*Values in the parenthesis denote the range of concentrations for which the hydration
numbers were determined
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Binodal curves generated with the addition of 0.5 M osmolyte in the PEG-citrate
system changed the two-phase formation. Osmoprotectants demonstrated a shift of the
two-phase region (Figure 4-1A), whereas the denaturant urea did not show considerable
change in the separation between the homogeneous and heterogeneous region. The
addition of osmoprotectants shifted the binodal curve towards the citrate axis, indicating
an increase in the salting-out behavior of the citrate-rich phase. The incompatibility of the
phases is driven by the salting-out ability of salt-rich phase towards the ethylene oxide
groups in the PEG chains [34]. On the other hand, the system formed with urea did not
demonstrate a significant shift in the binodal curve as compared to the osmolyte-free
binodal curve. It is likely that a high concentration of urea is required to make significant
change in the phase behavior as studied previously [35].

Figure 4-1. (A) Binodal curves and (B, C, D) tie lines for PEG 12kDa – citrate systems
in presence of various 0.5 M osmolytes. Denaturing osmolyte – (B) urea and protecting
osmolytes – (C) mannitol, TMAO, (D) betaine, and glycine.
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The other important characteristic of two-phase systems are tie-lines,
representing the set of systems at thermodynamic equilibrium with identical final phase
compositions. The slope of a tie-line determines the equilibrium system compositions.
The change in the TL slopes due to addition of osmolytes is compared to the osmolytefree system in Table 4-2 and shown in Figures 4-1(B-D). Osmoprotectants betaine,
TMAO, and mannitol showed a negative change in the TL slope (in that order) as
compared to the osmolyte-free system, thus showing an increase in the PEG
concentration and a decrease in citrate concentration as compared to a common point on
that TL for the no osmolyte control. Glycine did not significantly change the slope. The
denaturant urea demonstrated a positive change in the slope. If the altered equilibrium
compositions generate an optimum balance between the hydrophobic and electrostatic
interaction for the preferential partitioning of biomolecules, higher recovery and yield
could be achieved. In this regard, mannitol, a polyol, demonstrated the largest increase in
the PEG-rich phase composition and the largest decrease in the citrate-rich phase
composition followed by TMAO (see Figure 4-1 and Table 4-2).

Table 4-2. Changes in the TLL and TL slope with addition of osmolytes
t-test values of Δ TL
Osmolyte
Δ TLL
Average TL Slope
Δ TL Slope
Slope
(w/w%)
-

Deg (rad)

Deg (rad)

P

-1.48 ± 0.05

Glycine

10.4

-1.54 ± 0.12

-0.06

0.4688

Betaine

9.5

-1.95 ± 0.18

-0.47

0.0121

TMAO

7.8

-2.23 ± 0.11

-0.75

0.0004

Mannitol

13.8

-3.33 ± 0.11

-1.85

0.0001

Urea

2.3

-1.33 ± 0.07

+0.16

0.0392

Note: Mannitol was not used to generate TL at high TLL
Δ = control - osmolyte
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The osmolytes affected the interactions by variably partitioning between the two
phases. Osmoprotectants preferred the citrate-rich phase, whereas the urea highly
partitioned to the PEG-rich phase (Figure 4-2A). Almost 100% of the glycine was
recovered in the citrate-rich phase at all TLL. Glycine partitioning to the citrate-rich
phase shifted the binodal curve towards the citrate axis and increased the length of tielines, without affecting the tie-line slope, as compared to the osmolyte-free system.
Betaine, TMAO, and mannitol demonstrated similar partitioning behavior. 60% recovery
was observed for these osmolytes in the citrate-rich phase at the lowest TLL and
increased up to 80% recovery at the higher TLLs (Figure 4-2B). Only 40% of urea was
recovered in the citrate-rich phase at all TLL. Overall, the degree of osmolyte partitioning
to the citrate-rich corresponded to the shift of binodal curve away from the osmolyte-free
system.

Figure 4-2. Partitioning of the osmolytes at common compositions of ATPS with
increasing TLL represented as (A) ln (K) and (B) % recovery in the corresponding
citrate-rich phases.

4.3.2 Model viruses
Two virus models - porcine parvovirus (PPV) and human immunodeficiency virus-group
specific antigens virus-like particles (HIV-gag VLP) were used to determine the effect of
osmolytes on the partitioning within an aqueous two-phase system. The structural and
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physiochemical characteristics of PPV and HIV-gag VLPs are compiled in Table 4-3.
Essentially, PPV used in this study is a non-enveloped infectious virus and comprises of
three capsomeres VP1, VP2, and VP3, assembled in an icosahedral geometry [36]. HIVgag VLP is an enveloped, non-infectious, virus-like particle comprised of Gag
polyproteins self-assembled in spherical particles and enclosed in the envelope derived
from S. cerevisiae cell membrane [37] These two models were used to determine the
osmolyte action to modulate the partitioning of both non-enveloped and enveloped
virus/VLP in the PEG-citrate system.

Table 4-3. Biophysical and biochemical characteristics of model virus/VLP
Size
Model
family
Cell origin pI
genome Structure
Ref
(nm)
NonPPV
Parvoviridae Mammalian 5 18-26 ssDNA
[36, 38]
enveloped
HIVRetroviridae
80gag
(Original
Yeast
?
Enveloped proprietary
120
VLP
virus)
PPV: porcine parvovirus; HIV-gag-VLP: human immunodeficiency virus-group specific
antigen-virus like particle

4.3.3 Influence of osmolyte class on virus partitioning
Initially, three global compositions having similar osmolyte concentrations were
studied to understand the efficacy of different osmolyte classes to modulate virus
partitioning in the PEG-citrate system at pH 7. Previous studies have shown that the
negatively charged PPV partitions to the PEG-rich phase only at high system
compositions. This is hypothesized to be due to the need to salt-out the virus from the
citrate-rich phase to the interface. Then, the virus is pulled from the interface at high PEG
concentrations due to the hydrophobic interaction between the amphiphilic PEG [14].
Here, the objective is to determine the additive that could enhance the purification at
lower PEG and citrate concentrations, thus reducing viscosity and ionic strength of the
system.
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Figure 4-3. Effect of different osmolytes on (A) PPV and (B) HIV-gag VLP partitioning.
Biomolecule portioning upon addition of 0.5 M protecting (glycine, betaine, and TMAO)
and non-protecting (urea) osmolytes are compared to osmolyte-free (control) system.
Experiments were performed in triplicates and the error bars represent standard deviation.

The zwitterionic osmolytes glycine and betaine had most significantly altered the
binodal curve as compared to the other osmolytes used (Figure 4-1A), indicating
elevated driving forces for phase separation. A similar effect was observed for the viral
partitioning, whereas addition of glycine and betaine significantly improved the PPV and
HIV-VLP partitioning to the PEG-rich phase (Figure 4-3). Glycine-containing systems
were able to enhance the partitioning of PPV at the lowest composition studied, yielding
about 95% PPV recovery in the PEG-rich phase as compared to ~0% with the osmolytefree systems (Figure A.2-11A in Appendix). The other two higher systems compositions
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both yielded ~100 % recovery of PPV when glycine was added. Betaine improved the
PPV partitioning slightly at the lowest composition studied, whereas TMAO did not
change the partitioning behavior as compared to osmolyte-free system. However, most of
the viral particles still partitioned to the citrate-rich phase in both betaine and TMAOcontaining systems, exhibiting a lack of salting-out (Figure 4-3). Interestingly, ureacontaining systems demonstrated a similar effect on the partitioning behavior of PPV as
TMAO. It should be noted here that most of urea partitioned to the PEG-rich phase as
compared to the citrate-rich phase partitioning of TMAO (Figure 4-2).
A similar study was performed to determine the effect of osmolytes on the
enveloped HIV-VLP. At the lowest system composition, the glycine-containing system
demonstrated an insignificant increase in the partition coefficient and betaine and TMAO
reduced the partitioning of the VLP in the PEG-rich phase, as compared to the control
(Figure 4-3B). The partition coefficient elevated significantly at the mid-system
composition containing glycine, betaine, and TMAO, yielding 92% VLP recovery in the
PEG-rich phase (Figure 4-3B and Figure A.2-11C). The highest system composition
containing glycine demonstrated an increase in the partition coefficient as compared to
the osmolyte-free system but yielded 83% recovery (Figure 4-3B and Figure A.2-11C).
On the other hand, betaine and TMAO-containing systems did not show any significant
differences in the partition coefficients (Figure 4-3B).
In both model viruses, osmolyte systems with betaine and TMAO recovered a
lower number of viral particles in the PEG-rich phase when compared to glycinecontaining systems of the same composition. This difference is likely due to the osmolyte
partition in the citrate-rich phase, where glycine is recovered at >80%, and
betaine/TMAO are recovered at ~60% (Figure 4-2). Although the hydration number of
glycine is almost three-fold lower than betaine and TMAO (see Table 4-2), it is likely
that the higher concentration of glycine in the citrate-rich phase compensates for the
lower hydration number. It has been also shown that glycine is more kosmotropic as
compared to betaine and TMAO [39]. Now, the same study suggested that betaine is less
kosmotropic than TMAO which also correlated with the change in the TL slopes in our
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study (Table 4-2). However, this kosmotropic difference was not translated to the virus
partitioning, which showed similar salting-out effect by betaine and TMAO, but higher
hydrophobic interaction to draw the virus into the PEG-rich phase by betaine than TMAO
(Figure A.2-11A & B). Secondly, as the TLL increases with osmolyte-containing
systems, the recovery is lower at low TLL compared to higher TLL. However, at the midTLL, the system reaches a maximum PEG-rich phase virus recovery meaning the
addition of more osmolyte no longer increases virus recovery. This is hypothesized to be
due to the salting-out effect of the citrate itself being the dominant driving force to saltout virus from the citrate-rich phase, regardless of osmolyte concentration. A common
trend of driving force enhancement for non-enveloped PPV and enveloped HIV-VLP
recovery appears to follow the order glycine > betaine > TMAO > Urea ~ osmolyte-free.
4.3.4 Influence of osmolyte class on protein and HC-DNA partitioning
Depending on the class, the osmolytes in the previous section demonstrated an
elevated partitioning of virus and VLP. It is essential to see if a similar effect is observed
on the proteins which would lower the purity of the virus recovered PEG-rich phase.
As glycine and betaine had demonstrated the most improvement in the virus
partitioning, host cell proteins (HCP) and host cell DNA (HC-DNA) were tracked only in
these systems. The HCP were only detected in the citrate-rich phase, except at the highest
TLL in which one band at 51 kDa appeared in the PEG-rich phase (Figure 4A & B).
Also, all the contaminant proteins from HIV-VLP crude partitioned to the citrate-rich
phase (data not shown). It is noted that the lower TLLs were of primary interest, as the
glycine and betaine additions were able to recover most of the viral particles in the PEGrich phase (Figure A.2-11). The partitioning of proteins in the citrate-rich phase is likely
because the osmolytes stabilize the protein structure. Stabilization causes intraparticle
interactions [22, 25] and likely does not induce interaction between the proteins and the
PEG-rich phase. These results correlate with the previous studies that have shown
osmolytes to induce only structural changes in the flexible proteins, whereas the
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comparatively rigid viral particles experience interparticle interactions or flocculation in a
single-phase solution [25, 40].
The HC-DNA partitioned to the citrate-rich phase at the lower TLLs of both the
glycine and betaine-added systems (Figure 4-4C& D). At the highest TLL, glycine, but
not betaine, enhanced the HC-DNA partitioning to the PEG-rich phase. This indicates
that either glycine enhances the hydrophobic interaction of DNA with the PEG-rich phase
or induces interaction between viral particles and DNA causing DNA to attach to the
viral particles and co-partition in the PEG-rich phase. Overall, the lower TLLs with lower
PEG and citrate compositions achieved a very high yield and purification of the viruses in
the PEG-rich phases when glycine or betaine were used as additives.

Figure 4-4. Contaminant protein (A & B) and HC-DNA (C & D) partitioning at varying
TLL in presence of 0.5 M glycine or betaine. Contaminant protein partitioning were
visualized on Coomassie stained SDS-PAGE and HC-DNA were quantified using QuantiTTM PicoGreen® dsDNA assay. The error bars in the DNA partitioning figures represent
standard deviations from the experiments done in triplicates.
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4.3.5 Effect of tie-line framework on virus partitioning
Tie-lines guide the volume ratio of the phases, providing opportunity to recover
viral particles in the PEG-rich phase having low volume. However, the system
characteristic changes at the phase inversion point where the dispersed phase changes
from the citrate-rich phase to PEG-rich phase as the TL ratio increases [41]. The phase
inversion dictates if the viral particles directly partition to the bulk PEG-rich phase or
accumulates at the interface of the dispersed PEG-rich phase to coalesce. This study was
performed only with PPV to evaluate the phase inversion effects. The partition
coefficient of PPV increased with the increasing TL ratio at lower TLLs and remained
constant at the highest TLL (Figure 4-5A). This indicates that at the lower TL ratio,
where the citrate-rich phase is the dispersed phase, there is no salting out of the viral
particles. The increase in the TL ratio, where the PEG-rich phase is the dispersed phase,
resulted in a slightly higher partition coefficient. PPV still partitioned to the citrate-rich
phase at the lower TLL. However, more PPV was in the PEG-rich phase than the citraterich phase at the mid-TLL which indicates that the salting-out effect caused the viral
particles to partition at the interface and coalition of the PEG-rich phase droplets
collected the viral particles from the interface. At the highest TLL studied, PPV clearly
exhibited hydrophobic interaction with the PEG-rich phase as the partitioning trend
flattened. The PPV partitioning not only demonstrated a flat trendline in the systems
containing glycine but also demonstrated that most of the viral particles partitioned to the
PEG-rich phase at all TLLs (Figure 4-5B). This trend was observed at the mid and
highest-TLL in the systems containing betaine or TMAO (Figure 4-5C&E).
Interestingly, urea containing systems demonstrated similar trend as osmoprotectants
(Figure 4-5D). However, the partition coefficients were lower than glycine and close to
betaine and TMAO (Figure 4-5B-E). The systems containing mannitol demonstrated a
reverse trendline as compared to the osmolyte-free system where the partitioning
coefficient decreased with the TL ratios (Figure 4-5F). The overall trend of PPV
partition coefficients implies that the osmolytes, except mannitol, provide consistent
partitioning of viral particles across the tie line on contrary to the osmolyte-free systems.
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Figure 4-5. Partition coefficient of PPV in the systems (A) without osmolyte and systems
enhanced with 0.5 M protecting osmolytes (B) glycine (C) betaine (D) TMAO (E)
mannitol. Experiments were done in triplicates and the error bars represent the standard
deviation.

The effect of osmolytes on the interaction of PPV and either phases is too
complex to just be explained by the partition coefficients. Glycine containing systems
yielded high PPV titers in the PEG-rich phase at all the TLL and TL ratio (Table A.2-2).
However, the titers dropped with the increasing TLL in the citrate-rich phase. Similar
trend was observed for betaine-containing systems, except the PPV titers in the PEG-rich
phase were slightly lower than glycine. On the other hand, both TMAO and ureacontaining systems demonstrated an increasing PPV titer with increasing TLLs, but the
actual titers were much lower than glycine and betaine. The significantly different titers
in the PEG-rich phase followed a decreasing order as glycine > betaine > TMAO > urea.
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4.3.6 Effect of pH on virus partitioning
Surface charge of the viruses plays a vital role in the paritioning between the PEGrich and citrate-rich phases. Negatively charged viruses experience repulsion effects by
citrate ions, causing the salting-out effect. The repulsion effect decreases at the isoelectric
point of the virus, causing the majority of viruses to partition to the citrate-rich phase [14,
38]. PPV has a pI near 5, thus it has a net neutral charge at that pH [38]. The systems
containing the osmolytes glycine, betaine, or TMAO at pH 5 seem to have no effect on
the interaction between PPV and the PEG-rich phase, as the systems infused with either
of these osmolytes resulted in similar partitioning (Figure 4-6). However, an increase in
the TLL increased the partitioning of the PPV, which is likely due to an increase in the
ionic strength of the citrate-rich phase. This is a preliminary, yet significant observation,
and more studies need to be performed to fully understand the effect of osmolytes on
biomolecules at their pI.
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Figure 4-6. PPV partitioning at varying TLL in presence of (A) 0.5 M glycine, (B) 0.5 M
betaine, and (C) 0.5 M TMAO maintained at pH 5 and 7. The error bars represents
standard deviation of experiments done in triplicates.

4.4 Discussion
The partitioning of biomolecules in the PEG-salt systems is suggested to be
highly affected by the balance of electrostatic and/or hydrophobic interactions [42]. The
goal of this study was to improve the virus recovery in the PEG-rich phase at lower TLL
where high recoveries were not achieved without additives. Osmolytes are known to
modulate solvent properties and induce hydrophobic interactions in aqueous solutions
[43, 44]. Changes in electrostatic and hydrophobic interactions can result in either
intraparticle or interparticle interactions. The flexible smaller proteins are known to
undergo conformational changes (intraparticle interactions) in the presence of
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osmoprotectants [17, 18] and comparatively rigid viruses have been shown to flocculate
(interparticle interactions) [25] in the presence of similar osmolytes. In this study, the
osmolytes induced interfacial interactions between virus particles and the PEG-rich phase
to improve virus recovery. This is an interesting observation in that the addition of
protecting osmolytes yielded a high selectivity, as there was no interaction between the
contaminant proteins and PEG-rich phase. It is likely that the osmolytes only affected the
conformation of proteins.
The mechanism of protecting osmolytes glycine, betaine, and TMAO to stabilize
the proteins structures and flocculate viruses is still unclear. In one study, the stabilizing
effect of glycine and betaine disrupted the hydrogen bond network of elastin-like
polypeptide with water [39]. The changes in the water structure was caused by osmolytes
partitioning away from the polypeptide. On the other hand, TMAO was observed to
favorably interact with the backbone of a collapsed protein and a hydrophobic
homopolymer [39, 45]. Among the three osmolytes, TMAO was least recovered in the
citrate-rich phase and this might indicate an interaction with the globular PEG molecules
in the PEG-rich phase. Moreover, in this study, glycine and betaine (in that order)
induced hydrophobic interactions between the virus models and PEG-rich phase to
improve the partition coefficient (Figure 4-3). TMAO did not seem to improve the
hydrophobic interaction, as previously shown [46] and shown here.
The enhancement of the driving forces at lower TLL also signifies comparatively
easier processability of the phases, as the high recovery of biomolecules are obtained at
lower phase compositions. The concentrated PEG-rich phase is viscous, which might
pose challenges towards phase handling. The osmolytes recovered viruses at lower
compositions that have lower viscosities of the PEG-rich phase as compared to osmolytefree systems (Table A.2-3). Also, lower ATPS concentrations have a lower ionic
strength. A lower ionic strength is highly preferred to maintain the stability of the viral
particle function for use as a vaccine or gene therapy.
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4.5 Conclusion
This study reports the use of osmolytes to modify the partitioning behavior of
PPV and HIV-gag-VLP. Glycine followed by betaine, among the zwitterionic osmolytes,
demonstrated an increase in the salting-out ability of the citrate-rich phase and an
increase in the phase hydrophobicity of the PEG-rich phase. The elevated driving forces
improved the recoveries of viruses at lower TLLs, where the systems without osmolytes
are insufficient to induce the needed electrostatic and hydrophobic interactions to cause
preferential virus partitioning. TMAO increased the ability of two-phase formation at
lower system compositions, but it did not increase the hydrophobic interaction of viruses
with the PEG-rich phase at lower TLL. ~100% of PPV and 90% of HIV-gag-VLP were
recovered using glycine at the lowest TLL studies. The order of efficiency of osmolytes
to enhance the driving forces was determined to be glycine > betaine > TMAO > urea.
High recovery and purity of viral modalities in the PEG-rich phase implied that
osmolyte addition enhances the interfacial interactions for comparatively hydrophobic
and rigid viruses as compared to the intramolecular interactions for flexible proteins. The
HC-DNA partitioned to the citrate-rich phase at low TLL but increased towards the PEGrich at higher TLL in presence of glycine and betaine. This study provides evidence that
osmolyte addition not only improves the recovery, but also alleviate the challenges of
high concentration ATPS processing. Moreover, this study showed that the effect of
osmolytes on virus is drastically different than a protein, which is essential to develop a
robust and versatile downstream process for viral particle manufacturing.
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5 Affinity aqueous two-phase system using multimodal
peptide ligand for virus partitioning5

5
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5.1 Introduction
Aqueous two-phase systems (ATPS) formed by partially miscible aqueous
solutions (polyethylene glycol-salt) have shown a great potential to be used in the
downstream processing of viral vaccines and biotherapeutics [1-3]. However, our
previous studies have shown that higher viral recoveries are obtained in the systems that
have higher PEG-rich phase volume [4]. When the PEG-rich phase volumes are higher
than the salt-rich phase volume, the PEG-rich phase acts as a continuous phase with the
dispersed salt-rich phase [5]. The PEG-rich phase being viscous, the processing of ATPS
becomes difficult. Moreover, the separation of viral particles from the PEG-rich phase is
challenging. The possible strategy to reduce the processing burden is to operate the twophase systems with the compositions that yield continuous salt-rich phase and dispersed
PEG-rich phase is limited by the virus partitioning at the interface [4, 6]. This problem of
lower virus recovery with lower PEG-rich phase volumes needs to be to addressed by
developing novel systems that improve the affinity of the PEG-rich phase to allow higher
virus partitioning.
ATPS composed of different phase forming components such as polymerpolymer (polyethylene glycol-dextran) and polymer-salt (polyethylene glycolsulfate/citrate/phosphate) have found numerous applications in bioprocessing and
biotechnology. The common application of ATPS in biotherapeutic field has been in the
recovery and purification of cells [7-9], antibodies [10, 11], viruses [12-14], and nucleic
acids [15, 16]. The advantages of ATPS as a potential alternative to the conventional
downstream processing unit operations are high target biomolecule yield, inexpensive,
easy-to-scale up, and continuously processable unit operation. However, in the early
days, the unambiguity in understanding the partitioning behavior of biomolecules
between the two phases hindered the potential use of the mild biphasic systems. Various
studies point to the following factors affecting the partitioning behavior: hydrophobicity,
electrostatics, and volume-exclusion [17, 18]. These interactive forces are influenced by
the phase-forming component and biomolecule structural and physicochemical
properties. The insight into the driving forces has been used to investigate ATPS as a tool
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in the surface physicochemical characterization of biomolecules [19, 20], developing
assays for molecular recognition [21-23], and producing microspheres for protein and
drug encapsulation [24, 25].
There has been a significant advancement in designing and synthesizing
molecules to enhance the affinity for biomolecules. The affinity ligands are made from
peptides [26, 27], aptamers [28, 29], proteins [30], and polysaccharides [31]. These
ligands have been utilized in the affinity and multimodal chromatography for purification
of a target biomolecule. Protein A, used for the affinity purification of immunoglobulin G
(IgG), is expensive, labile, and requires harsh elution conditions. One way to alleviate the
disadvantages of Protein A is to design short peptides to mimic the protein A binding to
IgG [32, 33]. A hybrid ligand composed of a trimeric peptide FYE conjugated with a
hydrophobic charge-induction group provided a comparable purity and recovery of IgG
with a milder elution condition than protein A [34]. The design of appropriate ligands to
alleviate harsh processing conditions has helped to improve the downstream processing
of biologics [35, 36].
While similar strategies have been used to select ligands with a high affinity
towards viral particles, the diversity in the viral surface composition and physicochemical
characteristics makes the use of appropriate ligands difficult. Ligands for viral processing
has come in the form of antibodies [37, 38], protein-based lectin [36, 39], metal ions [40,
41], and polysaccharide-based heparin and heparan sulfate [42, 43]. A more robust
method suggests the use of multimodal ligands that use a combination of electrostatic
interaction, hydrophobic interaction, and hydrogen bonding mechanisms [44, 45].
Synthetic peptide libraries are also being explored as the potential sources of multimodal
ligands. Zheng and coworkers (2017) demonstrated that the peptide motif
YHDCFSAGFCIG presented a high affinity with a dissociation constant of 98 nM
towards porcine circovirus type 2 Cap protein [46]. The other study found that the
peptide sequence CAAALAKPHTENHLLT, selected by phage-display, was able to bind
to retrovirus virus-like particle expressing Ampho4070A protein and recovered 90% viral
particles with a mild elution condition [47]. However, such peptides not only depend on
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the amino acid sequence to harness the molecular interactions but also on the spatial
orientation of the peptide to dock in a targeted pocket of the viral proteins [48]. The
peptide ligands could also be designed to preferentially interact with viral proteins based
only on the molecular interactions without requiring a constrained structural
conformation of amino acid residues. This was achieved previously by limiting the
number of residues where trimeric peptides were found to bind porcine parvovirus and
the binding was not improved by adding more amino acids, which likely resulted in
secondary structure of the ligand [49].
Affinity ligands have also been used in ATPS to improve the specificity and
processing abilities for biomolecule partitioning. The affinity ligands are generally
conjugated with the polymer and attract the target biomolecule to the polymer-rich phase.
Polyethylene glycol has been modified to present electrophilic, nucleophilic, or
hydrophobic end groups [50]. Ligands were either small organic molecules, such as
benzoyl or dinitrophenyl, or biospecific proteins or enzymes such as avidin or antibodyhorse radish peroxidase. However, there have been hardly any studies performed with the
inclusion of small peptide ligands in affinity ATPS. The challenge of using a PEGylated
ligand is the long PEG tail may hinder the accessibility of the active site of the ligand
[51]. The conjugation of a small antimicrobial peptide with PEG inhibited the
antimicrobial activity and was hypothesized that the PEG chain interfered with the
functioning of the active sites [52]. The presence of PEG functionalized with the cell
adhesion domain (RGD) did not induce cell adhesion as the peptide was surrounded by a
PEG shell [53]. However, the masking of the active domains by PEG chain could be
averted by utilizing an optimum molecular weight of PEG that increases the flexibility of
the polymer and provides steric hindrance for nonspecific interactions [54].
In this study, a non-enveloped porcine parvovirus (PPV) partitioning behavior
was studied in the PEG-citrate system in the presence of peptides conjugated to PEG
10kDa. A trimeric multimodal affinity region WRW was chosen due to its high affinity
towards PPV [55]. With the growing interest of determining if the active sites of ligands
are accessible upon conjugation, the target peptide with the WRW region was
136

characterized using the fluorescence quenching method. High solvent accessibility of the
target multimodal region favored the PPV partitioning into the PEG-rich phase. The
improved PPV partitioning was suggested to be the result of either direct binding with the
PPV capsids or enhancing the hydrophobicity and electrostatic potential of the PEG-rich
phase. The use of multimodal peptide ligand demonstrated that the virus partitioning
could be enhanced at lower phase composition and lower volumes of the PEG-rich phase.

5.2 Materials & Methods
5.2.1 Materials
Eagle's minimum essential media (EMEM), sodium bicarbonate, phosphate buffer
saline (PBS, pH 7.2), penicillin-streptomycin (pen-strep) (10,000 U/ml), fetal bovine
serum (FBS, USDA approved) and trypsin/EDTA for cell propagation were purchased
from Life Technologies (Carlsbad, CA). 2-(3,5-diphenyltetrazol-2-ium-2-yl)-4,5dimethyl-1,3thiazole;bromide (MTT, 98%) was purchased from Alfa AesarTM
(Haverhill, MA) and sodium dodecyl sulfate (SDS, BioReagent, ≥98.5%) was purchased
from Sigma Aldrich (Radnor, PA). Polyethylene glycol with an average molecular weight
of 12,000 Da (PEG 12 kDa), trisodium citrate dihydrate (ACS reagent grade, ≥99%), and
citric acid monohydrate (ACS reagent, ≥99%) were a generous gift by Millipore Sigma
(Burlington, MA). Monofunctional methoxy-polyethylene glycol-vinyl sulfone (mPEGVS) (PEG molecular weight: 10000 Da) was purchased from Creative PEGworks
(Chapel Hill, NC). Peptide ligands GRCDGGWRW, GRCDGGGGG, and
GRCDGGAAA (98% purity) were purchased from Peptide 2.0 Inc. (Chantilly, VA).
Acrylamide solution (40% w/v) was purchased from Bio-Rad Laboratories (Hercules,
CA). Triethanolamine (TEA) was purchased from Thermo Fisher Scientific (St. Louis,
MO). Phosphate buffer saline (PBS) was obtained from HyClone Laboratories (South
Logan, UT). Dialysis tubing (MW cutoff 3.5 kDa) and black-walled, glass-bottom 96well plates were purchased from Thermo Fisher Scientific (Waltham, MA). Solutions
were prepared with Nanopure water (Thermo Scientific, Waltham, MA) at a resistance of
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≥18 MΩ and filtered with either a 0.2 μm Nalgene (Thermo Scientific) bottle top filter or
0.22 µm cellulose acetate syringe filters (VWR, Radnor, PA) before use.

5.2.2 Methods
5.2.2.1 Cell culture, virus propagation, and titration
Porcine kidney cells (PK-13, CRL-6489) purchased from ATCC (Manassas, VA)
were maintained in EMEM pH 7.1 mixed with 10 v/v% FBS and 1 v/v% pen-strep as
described previously [4]. Porcine parvovirus strain NADL-2 (PPV) was a generous gift
from Dr. Ruben Carbonell (North Carolina State University, Raleigh, NC) and was
propagated in PK-13 cells, as described previously [56]. PPV was quantified by titration
using MTT salt-based colorimetric cell viability assay [4].
5.2.2.2 Functionalized PEG conjugation and purification
The functionalization of PEG with peptide ligands was carried out by reacting
vinyl sulfone on mPEG(10 kDa)-VS with the thiol group of cysteine on the peptide
sequence GRCDGGXXX, where XXX represents GGG, AAA, or WRW (Figure 5-1).
Each peptide (WRW, GGG or AAA at 12 mM) was reacted via Michael-type addition
with mPEG-VS (10 mM) in 0.3 M triethanolamine (TEA) pH 7.4 at a molar ratio of 1.2
peptide:1 PEG in an incubator at 37 °C for 30 minutes. The solution was removed from
the incubator and dialyzed in dialysis tubing of molecular weight cut-off 3.5 kDa in
deionized water with convective mixing at 200 RPM. The water was replaced 3 times in
the first hour and once a day for two more days. The solution was then aliquoted, frozen
at −80 °C for ~1 hour and lyophilized overnight. The resulting functionalized mPEGVSpeptide was stored in a desiccated container at −20 °C until use. The average product
yield was ~90% and the average derivatization was >95% as confirmed by proton nuclear
magnetic resonance (1H NMR): the product was dissolved in deuterated chloroform
(CDCl3) and the disappearance of peaks at 6, 6.5, an 7 ppm confirmed successful mPEGVS functionalization.
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Figure 5-1. Synthesis flow diagram of functionalized PEG-peptide conjugates. A linear
PEG-vinyl sulfone is covalently functionalized with a cysteine terminated peptide.

5.2.2.3 Steady-state fluorescence quenching
To determine whether derivatization with PEG ‘buried’ the peptide, GRCDWRW
peptide and mPEGVS-WRW were dissolved in PBS at a final concentration of 1200 nM.
Acrylamide solutions of 0.8 M, 0.6 M, 0.4 M, and 0.2 M were prepared in PBS by serial
dilution. Next, 50 µL of GRCDWRW or mPEGVS-WRW solutions were added in
triplicate to a black-walled, glass-bottom 96-well plate and 50 µL of acrylamide solution
was added to each well for a total of 100 µL volume per well. Fluorescence of the
tryptophan amino acid (W; excitation at 280 nm/emission at 350 nm) was then recorded
using a spectrophotometer (SpectraMax i3, Molecular Devices, Sunnyvale, CA).
Fluorescence quenching experiments were performed by measuring the fluorescence
intensity loss of the free GRCDWRW peptide or conjugated mPEGVS-WRW as a
function of acrylamide concentration. Acrylamide quenches the fluorescence of W, where
quenching kinetics depends on W accessibility. Fluorescence quenching data were fitted
to the Stern-Volmer equation [57]:
𝐹𝐹0 ⁄𝐹𝐹 = 1 + 𝐾𝐾𝑆𝑆𝑆𝑆 [𝑄𝑄]
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(5-1)

where 𝐹𝐹0 and 𝐹𝐹 are the fluorescence intensities in the absence and presence of the
quencher, 𝑄𝑄, and 𝐾𝐾𝑆𝑆𝑆𝑆 is the Stern-Volmer quenching constant.
5.2.2.4 Virus Partitioning and Recovery

1 g two-phase systems were prepared by mixing appropriate amounts of 45 w/w%
PEG and 35 w/w% citrate stocks along with 0.1 g crude PPV stock to a non-stick 1.5 mL
microcentrifuge tube (VWR, Radnor, PA) for systems without affinity ligands [4]. The
systems with affinity ligands were prepared by maintaining a 7:3 mass ratio of PEG to
PEG-peptide, and the rest of the components remaining identical to the ligand-free
systems. A 7:3 mass ratio of unfunctionalized and functionalized PEG was maintained by
an appropriate amount of 45 w/w% PEG-peptide stock. The virus partitioning procedure
was similar to the previously described study [4]. The PPV partitioning (K) and recovery
were calculated using equations 2 and 3, respectively.
𝐾𝐾 =

% 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 =

𝑉𝑉𝑃𝑃 ∗𝑇𝑇𝑃𝑃
𝑉𝑉𝐶𝐶 ∗𝑇𝑇𝐶𝐶

𝑉𝑉𝑃𝑃/𝐶𝐶 ∗𝑇𝑇𝑃𝑃/𝐶𝐶
𝑉𝑉𝑖𝑖 ∗𝑇𝑇𝑖𝑖

(5-2)
∗ 100

(5-3)

where V and T are the volume and PPV titers of the PEG-rich phase (P), citrate-rich
phase (C), or initial stock virus (i). PPV titers are expressed as MTT50/mL

5.3 Results
5.3.1 Virus partitioning in the presence of affinity ligand
Aqueous two-phase systems are defined by a binodal curve and tie lines (see
Figure 5-2A). The binodal curve defines the two-phase region and tie lines represent the
thermodynamic equilibrium of the system, where any system on a tie line will separate
into two phases containing the concentrations found by the intersection of the tie line and
the binodal curve. Previous work has shown that high PEG and salt concentrations (i.e.
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longer tie line lengths) are needed to partition viral particles to the PEG-rich phase [3, 4].
Also, virus partitioning increases with higher volume ratios or lower tie-line ratios (TLR)
[4]. Since partitioning is an equilibrium process, virus titers in each phase were similar at
different volume ratios, but when taking volume into account, yield was higher in the
PEG-rich phase when there was more PEG-rich phase volume (i.e. lower TLR). A nonenveloped porcine parvovirus (PPV) comprised of capsid proteins VP1, VP2, and VP3 is
used as a model virus in this study [58]. A multimodal peptide-based affinity ligand was
used in this study to enhance the PPV partitioning at lower volume ratios in the PEG
12kda-citrate systems at pH 7.
Two TLR at three different tie-line lengths were selected (Figure 5-2A) such that
the volume ratios of the equilibrium PEG-rich phase to the citrate-rich phase volumes
were < 1 (Table A.3-1). These represent cases where there is low virus partitioning to the
PEG-rich phase without affinity ligands present. WRW peptide has been shown to
display high affinity towards PPV with a combined hydrophobic and electrostatic
interaction of WRW with the PPV capsids [49]. Thus, this peptide was used as the
primary affinity ligand in this study. As controls to the multimodal WRW ligand, GGG
and AAA were used to evaluate the specificity of the virus partitioning. The effect of a 30
w/w% replacement of PEG with functionalized PEG can be found in Figure 5-2B & C.
At the TLR of 1 (Figure 5-2C), PEG-WRW increased the PPV partitioning to the PEGrich phase significantly at all tie-line lengths, as compared to the unmodified systems
(ligand-free systems). However, most of the PPV particles still partitioned to the citraterich phase at the tie-line length 15 w/w%, and the significant increase by was observed at
the tie-line length 36 w/w%. On the other hand, control ligands demonstrated the
opposite trend. The PPV partitioning was not significantly affected by GGG and AAA at
the tie-line lengths 15 and 36 w/w%. The PPV partitioning was pushed to the citrate-rich
phase at tie length 25 w/w%. The WRW ligand is likely attracting viral particles to the
PEG-rich phase if the viral particles are at the interface, and the control ligands seem to
push the viruses away from the interface to the citrate-rich. An increase in the TLR to 2.3
only increased the partition coefficient at the tie-line length 15 w/w% of the PEG-WRW
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containing systems, whereas, the other two tie-line lengths did not show any significant
change in the virus partitioning (Figure 2C). Even though the equilibrium PEG-rich
phase composition remains the same for each tie line length, a lower number of affinity
ligands were added to the system due to the overall lower PEG mass in the system. On
the other hand, the control ligands (GGG and AAA) had no significant effect on the virus
partitioning at the tie-line length 15 w/w%. However, the control ligands reduced the
virus partitioning at tie-line length 25 and 36 w/w% even more than the addition of PEGWRW. It is likely that PEG-WRW makes the PEG-rich phase more hydrophobic and
positively charged than the unmodified systems, thereby elevating the negatively charged
virus partitioning towards the PEG-rich phase. The control polymers PEG-GGG and
PEG-AAA may make the PEG-rich phase more hydrophilic, thereby suppressing the
virus partitioning to the PEG-rich phase.
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Figure 5-2. Effect of TLL and TL ratios on PPV partitioning with an inclusion of affinity
ligand mPEGVS-WRW. (A) Six systems were selected on three different tie-lines and
two TLR. The partitioning coefficients in the presence of 30% PEG-peptide doping are
demonstrated at (B) TLR:1 and (C) TLR:2.3 on all the three TLL along with systems
without the affinity ligand doping. Experiments were conducted in triplicates and the
error bar represents standard deviation. *p-value < 0.05 using Student’s t-test as
compared to the ligand-free system.
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Another way to assess the effect of viral behavior at the interface and determine
the ligand efficiency is to explore the recoveries of the viral particles in each equilibrium
phase. The viral transport through the interface was traced by determining the viral
recovery (Figure 5-3A and B) in the PEG-rich and citrate-rich phases of the systems
studied in Figure 5-2. The PPV recovery in the PEG-rich phase was higher at the TLR
2.3 as compared to the TLR 1 with the inclusion of PEG-WRW (Figure 5-3C and D). It
is likely that the increased volume of the citrate-rich phase was able to induce an
interaction of additional number of the viral particles with the PEG-rich phase, as a lower
PPV recovery was observed in the citrate-rich phase of the TLR 2.3 compared to the TLR
1 (see Figure 5-3E and F). The PEG-WRW containing system at the TLR 2.3 was able
to recover the virus at the interface in the PEG-rich phase due to the high affinity towards
PPV. The ligand-free system was incapable of transporting a similar number of salted-out
PPV to the PEG-rich phase. The system at TLR 1 was able to recover only 10% of PPV
as most of the viral particles were not salted-out (Figure 5-3C and F). However, this
effect is more prominently observed at the tie-line length 15 w/w% because the citraterich phase composition is insufficient for the driving force to act upon all the viral
particles. The tie line lengths 25 and 36 w/w% demonstrated that most of the viral
particles salted-out of the citrate-rich phase at both the TLRs. The PPV recoveries in the
citrate-rich phases ranged between 0-5% in the unmodified and PEG-WRW systems (See
Figure 5-3E and F). A similar effect was observed in the PEG-rich phase at the tie line
length 25 w/w% where the system at TLR 2.3 was able to recover more PPV as
compared to the TLR 1 (Figure 5-3C and D). The control ligands GGG and AAA
demonstrated a similar high PPV recovery of 80-90% in the citrate-rich phase at TLR 1
of the tie line length 15 w/w% as compared to the ligand-free system (Figure 5-3E).
However, similar viral particles were still recovered in the citrate-rich phase as compared
to a relatively lower recovery in the ligand-free and PEG-WRW systems at the TLR 2.3.
On the other hand, the PPV recoveries in the PEG-rich phases were minimal, indicating
that the viruses do interact with the PEG-rich phases. The increased concentration of
control ligands in the systems at tie-line length 25 w/w% showed a comparatively higher
PPV recovery in the citrate-rich phase at TLR 1 and a similar recovery at TLR 2.3 as the
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ligand-free systems (Figure 5-3E and F). A slight increase in the PPV recovery was seen
at the TLR 2.3 than the TLR 1, but most of the PPV appears to be stuck at the interface
(Figure 5-3C and D). The tie line length 36 w/w% demonstrated a similar low PPV
recovery in both the citrate-rich phase and PEG-rich phase as the ligand-free system
indicating that the viruses partitioning to the interface. In general, PEG-WRW enhanced
the virus recovery at TLR 2.3 on all the tie lengths and likely improved the virus
partitioning by directly attaching to PPV capsids or increasing the affinity of the PEGrich phase for PPV partitioning.

Figure 5-3. PPV recovery comparison at (A&B) the three TLL and two TLRs in the
(C&D) PEG-rich phase and (E&F) citrate-rich phase. Three separate ligands (AAA,
GGG, and WRW) were added individually in each system at a 7:3 ratio of PEG 12 kDa to
PEG-peptide conjugate and compared with the ligand-free control systems. The error bars
represent the standard deviations from three individual experiments.
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5.3.2

Efficiency and characterization of PEG-peptide conjugation
The conjugation of PEG-peptide was confirmed using the 1H NMR spectra of the

polymers. The disappearance of the peaks at 6, 6.5, and 7 ppm (orange box) after
functionalization of mPEG-VS indicates that functionalization had successfully occurred
(Figure 5-5A-D). This absence of peaks, which corresponded to the unreacted VS group,
indicated a successful conjugation of PEGVS and peptide at the thiol group of the cystine
terminal [59]. The conjugation of PEG-WRW was further confirmed as PEG-peptide and
free WRW peptide demonstrated a similar fluorescence profile with a peak at 310 nm
(Figure A.3-1A). Lastly, a high absorbance of PEG-WRW between 210-280 nm as
compared to a no absorbance of unfunctionalized PEGVS further confirmed successful
conjugation (Figure A.3-1B).

Figure 5-4. Conjugation confirmation of mPEGVS and peptides represented as 1H NMR
spectra of (A) mPEGVS, (B) mPEGVS-AAA, (C) mPEGVS-GGG, and (D) mPEGVSWRW. The orange box at 6, 6.5, and 7 ppm indicates the vinyl sulfone peaks, whose
disappearance shows that the reaction between the mPEGVS and the peptides had
occurred.
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The affinity of WRW towards PPV was possible only if the target peptide was
accessible in the aqueous solution. It was possible that the WRW peptide would be buried
by the PEG polymer. However, WRW was found to be accessible as acrylamide highly
quenched the fluorescence intensity of PEG-WRW as compared to the unconjugated
WRW peptide (Figure 5-6). The Stokes-Volmer coefficient (KSV) was found to be 13.5
for PEG-WRW as compared to only 5.1 for the free WRW. This indicated that the PEG
conjugation made the peptide more accessible to the quencher as opposed to less
accessible.

F0/F at 350 nm
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Figure 5-5. Acrylamide quenching of free WRW peptide and mPEGVS-WRW
fluorescence. Fitting of data points to the Stern-Volmer equation yields KSV values of
5.1 ± 0.8 and 13.5 ± 1.1 M-1 for free WRW and mPEGVS-WRW, respectively.
Experiments were conducted in triplicates and the error bars represent standard
deviations.

5.4 Discussion
Aqueous two-phase systems have been widely utilized for developing an
alternative to the conventional downstream processing unit operations. The new
generation applications have focused on the various biotechnology applications such as
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drug encapsulation, delivery, and model bio-compartmentalization [24, 60, 61]. These
applications have recognized the potential of affinity ligands to improve the specificity
and partitioning of target biomolecules [50, 61, 62]. In this study, PEG conjugated with
the multimodal affinity ligand WRW demonstrated an enhancement in the virus
partitioning, which provides an opportunity for various applications stated above.
However, the changes to virus partitioning depended on the bioavailability of the peptide
upon conjugation. The PEGylation of peptides has shown to alter the peptide
conformations depending on the physicochemical characteristics of the peptide and the
PEG chain length [63, 64]. A molecular simulation study showed that the cationic
residues of the peptides interacted favorably with the PEG oxygen atoms and the
hydrophobic residues interacted with non-polar ethyl regions of the PEG subunits [64].
The favorable interactions of the peptide residues with the PEG chain led to a shielding
effect by PEG, thereby reducing the solvent-accessible surface area of α-helical peptides.
A similar study showed that charged and polar smaller peptides had higher solventexposed structures than hydrophobic peptides [63]. The same study demonstrated that
PEG has an insignificant effect on the conformation of neutral peptides. In another study,
a specific PEG chain length has shown to display a shielding effect for peptides with a
specific amino acid number [65]. Specifically, PEG 10kDa has shown to have the
shielding of the electrostatic potential of the peptide with a maximum of eight amino acid
residues. In this study, the biologically active region WRW of the nine amino acids
peptide, with both hydrophobic and positively charge amino acids at physiological pH
(Table 5-1), was found to be solvent accessible upon conjugation (Figure 5-6). It is
highly possible that the tendency of hydrophobic residues to avoid exposure to the polar
solvent was comprised of the highly charged peptide or the hydrophilic PEG chain length
resisted the structural change of small peptide due to the hydrophilic and neutral spacer
region (GRCDGG). It has been shown previously that the preferential partitioning of
PPV to the PEG-rich phase in a PEG-salt system is driven by electrostatic and
hydrophobic interactions [3, 4]. The accessible bioactive region WRW likely improved
the virus partitioning through the charge and hydrophobic interactions with the PPV
capsid. It is also possible that the WRW increased the biospecific affinity of the PEG-rich
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phase towards negatively charged PPV by increasing the positive charge density of the
phase as the neutrally charged slightly hydrophobic ligand AAA did not improve the
virus partitioning (Figure 5-2).
Previous studies have shown that the high virus partitioning is achieved at lower
TLR where the PEG-rich phase volumes are higher than the salt-rich phase volumes [4,
6]. The addition of hydrophobic and positively charged peptide containing WRW
residues improved the virus recovery in the PEG-rich phase at the higher TLR with lower
volumes of the PEG-rich phases. The enhanced recovery at higher TLR is beneficial for
the downstream processing of biomolecules. The high TLR systems fall in the regime of
continuous citrate-rich phases, which have higher settling kinetics, lower dependence of
viscosity, and low volume of target biomolecule containing PEG-rich phase [5]. Further,
the high partitioning of the viruses in low PEG-rich phase volumes may be desired to
generate droplet hydrogels or microgels for drug encapsulation and compartmentalization
studies. Overall, the two-phase system designs with conjugated multimodal affinity
peptides, having balanced physicochemical characteristics to preserve the accessibility
for a target biomolecule, suggests various advantages in bioprocessing and biomedical
applications.
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Table 5-1. Hydrophobic and charge characteristics of peptides
Avg.
molecular Theoretical
Attributes at
Peptide
Peptide
Hydrophobicity
weight
pI
pH 7
use
sequence
(g/mol)
Hydrophilic
Spacer
GRCDGG
563.59
6.1
1.28
and neutral
charge
Hydrophobic
and positive
GRCDGGWRW 1092.21
9.0
20.70
charge
Hydrophobic
This
GRCDGGAAA
776.32
6.1
2.93
and neutral
study
charge
Hydrophilic
GRCDGGGGG
734.75
6.1
1.37
and neutral
charge
Hydrophilic
and negative
EEGEEG
648.58
3.0
1.16
charge
Hydrophilic
KKGKG
644.81
11.0
0.86
and positive
Adapted
charge
from
Hydrophobic
[63]
YGSLPQ
663.73
5.9
12.30
and negative
charge
Hydrophobic
VFVVFV
708.42
6.0
33.13
and negative
charge
The pI and hydrophobicity measures were determined using the peptide analyzer tool
from ThermoFisher Scientific [66].

5.5 Conclusions
This study demonstrates the potential use of peptides as multimodal affinity
ligands in the PEG-salt system for virus purification. The partitioning behavior of PPV
significantly improved in the presence of the multimodal ligand GRCDGGWRW. The
affinity ligand-induced biospecific affinity through hydrophobic interaction and charge to
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drive the PPV particles to the PEG-rich phase at lower TLR generating lower PEG-rich
phase volumes than the citrate-rich phases. The control hydrophobic peptide containing
AAA residues with a neutral charge did not improve the virus partitioning, confirming
that the multimodal effects of WRW were influential in the virus partitioning. The
inclusion of affinity ligand did not seem to affect the salting-out ability but only the
ability to extract the viral particles residing at the interface into the PEG-rich phase. This
suggests that the multimodal ligand only changes the physicochemical environment of
the PEG-rich phase.
The conjugation of peptides with PEG generally affects the bioactivity of the
peptides by either increasing or decreasing the accessibility of the biologically active
domain [67]. Through fluorescence quenching, we demonstrated that the accessibility of
the WRW domain was retained upon the conjugation to PEG. This unique combination of
ligand accessibility and high virus partitioning improve the downstream processing of the
viral vaccines and biotherapeutics.
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6.1 Conclusions
Aqueous two-phase systems (ATPS) have emerged as potential alternatives for
the purification of biomolecules that is easy-to-scale-up and can be run continuously. A
few studies performed on the separation of viruses using ATPS have shown discrepancies
in the proposed partitioning mechanism. Some argue that the main driving force is
volume exclusion [1-3], while others interpret the mechanism to be a mixture of
intermolecular interactions based on hydrophobicity and electrostatics [4]. The lack of
understanding of the viral behavior and interactions with the phases have led to a large
experimental design to optimize the virus purification. The tie-line framework (chapter 3)
presented in this dissertation supported the intermolecular interaction theory. The
combination of high PEG-rich phase hydrophobicity combined with the salting-out
ability of the salt-rich phase could achieve the high virus recoveries. However, the tie line
framework demonstrated the desired virus recovery in the higher system compositions
that are not optimal for processing. The motivation to reduce the system concentrations
led to the use of osmolytes in the systems (chapter 4). The osmolytes enhanced the
driving forces to achieve higher virus recoveries at lower system compositions. Along
with the osmolytes, multimodal peptides were explored as the alternatives to improve the
specificity and affinity of the PEG-rich phase to viruses (chapter 5). The affinity peptide
demonstrated the potential to recover viruses at lower system compositions having lower
PEG-rich phase volumes.
The optimization of virus recoveries was performed in the PEG 12kDa-citrate
system using a tie-line framework. Non-enveloped porcine parvovirus (PPV) and human
rhinovirus 14 (HRV) were used as model viruses. The framework comprising of three tieline lengths (TLL) and tie-line ratios (TLR) were used to study the viral partitioning
behavior. The negatively charged PPV (pI ~5) at pH 7 demonstrated that the virus
partitioning shifts from the citrate-rich phase to the PEG-rich phase with an increasing
TLL. The PPV partitioning at the highest TLL demonstrated similar virus titers in the
PEG-rich phase irrespective of the TLR leading to lower recoveries in the PEG-rich
phase with the increasing TLR. Overall, 80% PPV recovery and high purity were
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achieved at the lower TLR. An increased PPV load demonstrated a similar pattern of
virus partitioning along the TLL and across TLR. However, a lower recovery of ~40%
was achieved in the system that yielded a high recovery with a lower load. The PPV
partitioning behavior strongly supported the intermolecular interactions (hydrophobicity
and charge) to be the dominant forces in the virus partitioning. The neutrally charged
HRV (pI~6.9-7) in the systems operated at pH 7 demonstrated a high recovery in the
citrate-rich phase leading to a low recovery in the PEG-rich phase at all the TLL. Overall,
36% HRV recovery was achieved in the PEG-rich phase in the system that yielded a high
PPV recovery. The HRV behavior suggested inefficiency of the citrate-rich phase in
salting-out and inducing hydrophobic interaction with the PEG-rich phase for viruses
with a net neutral charge. Overall, the framework aids in the high-throughput
optimization of virus recovery.
Naturally occurring osmolytes were used as the additives in the PEG 12kDacitrate systems to enhance the driving forces for virus partitioning. The objective was to
improve the virus recovery at higher virus loadings, and system compositions that yield
lower PEG-rich phase compositions and volume. PPV and human immunodeficiency
virus-group specific antigen virus-like particles (HIV-gag-VLP) were used as the model
viruses. Different osmolytes, glycine, betaine, TMAO, mannitol, and urea were added to
the system components. The effect of each osmolyte on the system characteristics was
analyzed by the changes in the phase diagrams comprising of the binodal curve and tie
lines. The effect of osmolytes on the binodal shift away from the control system was
observed in the order of glycine > betaine > mannitol > TMAO > urea. A similar effect
on the virus partitioning was observed. The highest recoveries of PPV and HIV-gag-VLP
were observed in the systems-containing glycine and betaine. ~ 100% PPV and 80%
HIV-gag-VLP recoveries were obtained in the PEG-rich phase with glycine and betaine
containing-systems. The high recoveries were obtained in the lower system compositions
that yield a lower PEG-rich phase composition and viscosity. The contaminant
partitioning was unaffected upon the addition of osmolytes. Overall, the use of osmolytes
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not only enhances the virus recovery but also will reduce the processing challenges in
scaled-up manufacturing.
The affinity of the PEG-rich phase towards viruses was enhanced using a
multimodal peptide ligand. The goal was to improve virus recovery in the PEG-rich
phase of the systems at lower volume ratios of the PEG-rich phase to citrate-rich phase.
Systems were chosen that would have virus partition to the interface or citrate-rich phase
when the affinity peptide was not present. The multimodal affinity peptide WRW was
used in conjugation with PEG 10kDa to drive PPV to the PEG-rich phase. A 30%
replacement of the unfunctionalized PEG with PEG-WRW showed a significant increase
in the PPV recovery in the PEG-rich phase at higher TLR. The control hydrophobic
trimer AAA did not show improvement in the PPV partitioning; instead, it decreased the
partitioning. The multimodal nature of WRW displaying hydrophobic and positive charge
characteristics was regarded as the driving force to capture hydrophobic and negatively
charged viral particles in the PEG-rich phase. Moreover, the citrate-rich phase being the
continuous phase at the higher TLR provides an ATPS that is easier to process as the
system viscosity decreases as compared to the lower TLR with continuous PEG-rich
phase. The PEG-conjugate structure analyzed by acrylamide quenching demonstrated the
accessibility of WRW, supporting the enhanced specificity of the PEG-rich phase
towards PPV. Overall, this was the first study reported in the ATPS literature to utilize
affinity peptides to enhance virus partitioning.
The framework demonstrated in this dissertation allows for the rapid
optimization of viral product purification. The reduced experimental framework will aid
in faster process development of vaccines and viral biotherapeutic. Moreover, the highthroughput recovery of ATPS will help in producing higher number of vaccine doses
required for global outreach. The rationale of selecting the phase parameters and the use
of specific enhancers will help platform the ATPS as the unit operation for viral
processing in the near future.
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6.2

Future work

6.2.1 Viral behavior at interface and mathematical model validation
The partitioning of viruses to the PEG-rich phase from the citrate-rich phase
depends on the viral ability to crossover the interface. Very few studies have been
reported characterizing the biomolecule behavior at the interface [5, 6]. The transition of
biomolecules from the interface to the PEG-rich phase has been shown to be related to
the surface energy of the biomolecules [6]. The surface energy of the viral particles can
be determined through a single particle measurement technique using atomic force
spectroscopy (AFM) [7]. The AFM setup could include a two-phase droplet system, and
the force measured to pull or push the virus through the interface could be translated to
the free energy transfer of viral particle across the interface.
A bulk method using a microfluidic device can be used to determine the diffusion
coefficient of viral particles across the interface [8]. Relating the equilibrium phase
properties such as viscosity, electrochemical potential difference, and interfacial tension
with the diffusion coefficient will yield a better understanding of the local effects of the
interface as compared to the bulk phases. Moreover, previous studies have proposed
empirical models to predict protein and peptide partitioning by relating biomolecule
surface properties and phase properties [9-11]. The ability to measure single particle and
bulk surface characteristics of viruses could be potentially used to validate the models for
prediction of the partitioning.
6.2.2 Expanding the viral database
The current work showed a proof-of-concept for the optimization of viral
recovery in the PEG-salt system. A database of model viruses with different viral surface
characteristics and their partitioning behavior needs to be studied. The enveloped viruses
are comparatively more prone to aggregation and inactivation than non-enveloped viruses
due to high ionic strength of citrate-rich phase and osmotic pressure of the PEG-rich
phase. Different enveloped viruses such as herpes simplex virus (HSV), bovine viral
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diarrhea virus (BVDV), and influenza B virus need to be evaluated for the deviation in
the partitioning behavior and stability to design appropriate systems. Novel ATPS needs
to be developed with lower phase compositions and higher driving forces, as shown with
the osmolyte addition (chapter 4). The diversity in viral surfaces has been characterized
based on morphology [12], hydrophobicity [13], and charge [14]. The relation between
viral surface and phase characteristics will help generate a hierarchical model that will
help in generalizing the systems for a group of virus models. Neither a single
combination of the system parameter nor the extensive variation in the optimized systems
is the solutions for platforming ATPS in biotherapeutic manufacturing. The database
generated might be used to predict and narrow the search for the virus recovery
optimization.
6.2.3 Back-extraction of viral product
The inclusion of ATPS in the DSP train would require a follow-up back
extraction stage to separate viral products from the PEG-rich phase. Various methods to
extract viral particles from the PEG-rich phase needs to be evaluated for their
applicability in the high-throughput production and continuous operation strategy. Some
of the methods considered for this process are ultrafiltration, ATPS re-extraction, and
steric exclusion chromatography. Ultrafiltration with a membrane pore size ranging from
50 kDa to 500 kDa MWCO needs to be evaluated to retain the viral product and allowing
PEG chains in the permeate. The tie-line framework showed that the viral particles
partition to the citrate-rich phase at lower TLL (chapter 3). This information can be used
to develop a system by mixing a fresh citrate stock with the virus-containing PEG-rich
phase to shift from the high TLL to low TLL, which will promote virus partition to the
citrate-rich phase. A novel chromatography method using the steric exclusion principle
can be used by loading the column at high PEG concentration (PEG-rich phase) and
eluting at low PEG concentration [15].
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6.2.4 Scale-up and sustainability analysis of ATPS
The implementation of ATPS at an industrial scale needs extensive expertise in
the hydrodynamic behavior of the phases [16], and their effects on viral partitioning. We
are currently exploring the challenges of the ATPS scale-up and its implementation of the
continuous operation for viral processing. The shear effects of mixing hydrodynamics on
viral stability need to be evaluated. The viral partitioning effects on the phase separation
kinetics need to be assessed.
There is a green manufacturing initiative call for the biomanufacturing industry to
prevent environmental risk posed by a high process mass intensity (PMI) [17]. PMI is the
mass ratio of consumables to active pharmaceutical ingredient. A previous study has
shown that increasing the number of chromatography steps increases the PMI, mainly
due to the high consumption of water. PMI needs to be assessed for the proposed DSP
train with the inclusion of ATPS and back extraction. The relative intensity index could
be assessed by comparing an industry-standard DSP train with the optimized ATPSincluded DSP train on a case-by-case basis. The evaluation will guide the industrial
implementation of ATPS in the viral vaccine and biotherapeutic manufacturing.

6.3 Dissertation Summary
The work presented in this dissertation helped gain crucial insights into the viral
partitioning behavior in the PEG-salt ATPS. The framework to narrow down the
experimental space for optimization, and enhancers to aid in the higher throughput of
viral particles suggested a promising future of ATPS to improve viral based vaccines and
biotherapeutic manufacturing. However, additional knowledge is still needed before
commercial implementation. Partitioning behavior of an extensive virus library,
interaction of viruses with the phase components at molecular level, and hydrodynamic
behavior of phases at large scales are some of the missing pieces to the puzzle. The
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deeper understanding of these pieces would elevate the confidence in implementing the
ATPS in the industrial processes.
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A

Supplementary information

A.1

Tie-line framework for virus optimization

Table A.1-1. Physical Properties (density and refractive index) of the systems at TLL 15,
25, and 36 w/w%
PEG-rich phase
Citrate-rich phase
TLL
TL
density
density
Refractive index
(w/w%) Ratio
(g/mL)
(g/mL)
Average Std Dev Average Std Dev Average Std Dev
15

25

36

0.3

1.0675

0.0080

1.0889

0.0142

1.3690

0.0030

1.2

1.0627

0.0051

1.0895

0.0040

1.3709

0.0029

2.3

1.0667

0.0125

1.0939

0.0092

1.3731

0.0008

0.3

1.0685

0.0044

1.1071

0.0056

1.3755

0.0017

1.2

1.0630

0.0131

1.1115

0.0033

1.3799

0.0020

2.3

1.0741

0.0055

1.1248

0.0120

1.3828

0.0012

0.1

1.0646

0.0099

1.1456

0.0140

1.3902

0.0058

0.3

1.0671

0.0066

1.1413

0.0129

1.3897

0.0048

0.6

1.0755

0.0091

1.1507

0.0096

1.3879

0.0049

1.2

1.0700

0.0182

1.1459

0.0148

1.3889

0.0034

2.3

1.0513

0.0361

1.1366

0.0114

1.3886

0.0024

Experiments were conducted in triplicate and the standard deviations were calculated for
those three trials
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Table A.1-2. PEG concentration in the PEG-rich phase at different TLL using refractive
index
Refractive Index
PEG
(RI)
TLL
concentration
(w/w%)
Std
(w/w%)
Average
Dev
36

1.3891

0.0009

36

25

1.3784

0.0037

30

15

1.3710

0.0020

26

PEG concentrations in the PEG-rich phase were calculated from known PEG
concentrations found in Table S3. Experiments were conducted in triplicate and the
standard deviations were calculated for those three trials.

Table A.1-3. Standard Refractive Index of increasing concentration of PEG
PEG
Citrate
Refractive Index
Density
Density
Conc.
Conc.
(RI)
(g/mL)
(g/mL)
(w/w%)
(w/w%)
Std
Std
Std
Average
Average
Average
Dev
Dev
Dev
0

1.3330

0.0017

0.9933

0.0036

5

1.3386

0.0055

1.0144

0.0088

5

1.0255

0.0014

10

1.3456

0.0009

1.0189

0.0104

10

1.0417

0.0151

15

1.3517

0.0012

1.0166

0.0120

15

1.0876

0.0169

20

1.3585

0.0028

1.0398

0.0155

20

1.1132

0.0077

25

1.3662

0.0023

1.0152

0.0113

25

1.1467

0.0010

30

1.3735

0.0028

1.0410

0.0142

30

1.1817

0.0043

50

1.4159

0.0006

1.0785

0.0136

Experiments were conducted in triplicate and the standard deviations were calculated for
those three trials
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Table A.1-4. HRV titer in the PEG-rich phase and citrate-rich phase as a function of TLL
and TL ratio
Initial Titer
TLL
(w/w%)
15

25

36

6.7 ± 0.4 log10 MTT50/mL

TL ratio

PEG-rich
phase titer

Citrate-rich
phase titer

0.3

3.4 ± 0.4

6.4 ± 0.4

1.2

3.3 ± 0.5

6.4 ± 0.4

2.3

3.7 ± 0.9

6.2 ± 0.3

0.1

4.4 ± 0.5

6.2 ± 0.0

1.2

4.9 ± 0.8

6.2 ± 0.2

2.3

5.2 ± 1.3

6.0 ± 0.4

0.3

5.4 ± 0.4

5.8 ± 0.5

1.2

5.3 ± 0.6

5.8 ± 0.3

2.3

5.1 ± 0.6

5.7 ± 0.2

Data is the average of experiments performed in triplicates and the error represents the
standard deviation
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Table A.1-5. PPV titer in the PEG-rich phase and citrate-rich phase as a function of TLL
and TL ratio
PEG-rich phase titer
Citrate-rich phase titer
Initial Titers
TLL
6.4 ± 0.2
8.3 ± 0.2
6.4 ± 0.2
8.3 ± 0.2
(w/w%)
TL ratio
15

25

36

0.3

3.1 ± 0.9

4.8 ± 0.4

5.7 ± 0.4

7.7 ± 0.3

1

3.7 ± 1.1

5.1 ± 0.3

5.4 ± 0.1

7.4 ± 0.2

2.3

4.4 ± 0.4

6.1 ± 0.9

5.1 ± 0.3

7.2 ± 0.1

0.1

4.1 ± 0.8

5.2 ± 0.3

5.3 ± 1.0

6.5 ± 0.3

1

5.2 ± 0.6

6.7 ± 0.3

3.9 ± 1.0

5.4 ± 0.9

2.3

5.9 ± 0.1

7.4 ± 0.6

3.4 ± 0.8

5.9 ± 0.8

0.3

5.2 ± 0.2

7.1 ± 0.7

*2.8 ± 0.1

5.7 ± 0.2

1.2

5.2 ± 0.3

7.0 ± 0.5

*2.7 ± 0.0

5.9 ± 0.3

2.3

5.3 ± 0.2

7.5 ± 0.1

*2.6 ± 0.1

4.8 ± 0.6

*limit of detection. All the titers are expressed log10 (MTT50/mL)
Data is the average of experiments performed in triplicates and the error represents the
standard deviation

Figure A.1-1. Aggregate ratio of 8 log10 MTT50/ml PPV at varying citrate
concentration. Aggregation ratio compares the intensity of the PPV peak to the intensity
of the aggregate peak in DLS and can be found in Eq. 3-7. The open bars represent the
lack of a PPV peak. Experiments were conducted in triplicate and the error bars represent
the standard deviation.
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A.2

Osmolyte-containing aqueous two-phase systems

Table A.2-1. Description of the LC-MS method development parameters for osmolyte
detection and quantification. Corresponding stable isotopes of each osmolyte was used as
the internal standard.
Osmolyte
MS
Internal
LC Gradient
Quantification Ion
polarity
standard
Glycine
Glycine-C13
Betaine
Betaine-D11
TMAO
TMAO-D9
Mannitol
Mannitol-U-13C6
Urea
Urea-C13-2N15

positive

SIM of m/z 76

positive

SIM of m/z 77

85/15 to 50/50 A/B in 6
min at 0.4 mL/min

positive

SRM of m/z 118 --> 59

positive

SRM of m/z 129 --> 68

85/15 to 50/50 A/B in 6
min at 0.6 mL/min

positive

SRM of m/z 76 --> 59

positive

SRM of m/z 85 --> 68

85/15 to 60/40 A/B in 4
min at 0.4 mL/min

negative

SRM of m/z 181 --> 101

negative

SRM of m/z 187 --> 105

positive

SIM of m/z 61

positive

SIM of m/z 64

85/15 to 50/50 A/B in 6
min at 0.4 mL/min

85/15 to 70/30 A/B in 5
min at 0.2 mL/min

SIM: selected ion monitoring; SRM: selected reaction monitoring
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Figure A.2-1. LC-MS profile of glycine. (A) The area under the elution curve of
showing(A) was used in relation to the elution area of glycine-C13 internal standard
(Figure A.2-2) to form a standard curve and (B) MS peak used to detect glycine, operated
with conditions shown in table A.2-1.

172

Figure A.2-2. LC-MS profile of glycine-C13, used as the internal standard for glycine.
(A) The area under the elution curve of glycine-C13 was used in relation to the elution
area of glycine (Figure A.2-1) to form a standard curve and (B) MS peak used to detect
glycine C-13, operated with conditions shown in table A.2-1.
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Figure A.2-3. LC-MS profile of betaine. (A) The area under the elution curve of betaine
was used in relation to the elution area of betaine-D11 (Figure A.2-4) to form a standard
curve and (B) MS peak used to detect betaine, operated with conditions shown in table
A.2-1.
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Figure A.2-4. LC-MS profile of betaine-D11 used as the internal standard for betaine.
(A) The area under the elution curve of betaine-D11 was used in relation to the elution
area of betaine (Figure A.2-3) to form a standard curve and (B) MS peak used to detect
betaine-D11, operated with conditions shown in table A.2-1.
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Figure A.2-5. LC-MS profile of TMAO. (A) Area under the elution curve of TMAO
was used in relation to the elution area of TMAO-D9 (Figure A.2-6) to form a standard
curve and (B) MS peak used to detect TMAO, operated with conditions shown in table
A.2-1.
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Figure A.2-6. LC-MS profile of TMAO-D9 used as internal standard for TMAO. (A)
Area under the elution curve of TMAO -D9 was used in relation to the elution area of
TMAO (Figure A.2-5) to form a standard curve and (B) MS peak used to detect TMAOD9, operated with conditions shown in table A.2-1.
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Figure A.2-7. LC-MS profile of mannitol. (A) Area under the elution curve of mannitol
was used in relation to the elution area of mannitol-U-13C6 (Figure A.2-8) to form a
standard curve and (B) MS peak used to detect mannitol, operated with conditions shown
in table A.2-1.
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Figure A.2-8. LC-MS profile of mannitol-U-13C6, used as the internal standard for
mannitol. (A) Area under the elution curve of mannitol-U-13C6 was used in relation to
the elution area of mannitol (Figure A.2-7) to form a standard curve and (B) MS peak
used to detect mannitol-U-13C6, operated with conditions shown in table A.2-1.

179

Figure A.2-9. LC-MS profile of urea. (A) Area under the elution curve of urea was used
in relation to the elution area of Urea-C13-2N15 (Figure A.2-9) to form a standard curve
and (B) MS peak used to detect urea, operated with conditions shown in table A.2-1.

180

Figure A.2-10. LC-MS profile of urea-C13-2N15, used as the internal standard for urea.
(A) Area under the elution curve of urea-C13-2N15 was used in relation to the elution
area of urea (Figure A.2-9) to form a standard curve and (B) MS peak used to detect
ureaurea-C13-2N15, operated with conditions shown in table A.2-1.
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Table A.2-2. Average of PPV titers across TL ratio and TLL in osmolyte-containing
ATPS.
Glycine
TLL

Avg. Top Titer

Avg. Bottom Titer

Low

7.7 ± 0.5

6.7 ± 0.4

Mid

8.0 ± 0.3

5.8 ± 0.6

High

8.1 ± 0.2

4.3 ± 0.9

Avg. Top Titer
7.9 ± 0.4

Betaine
TLL

Avg. Top Titer

Avg. Bottom Titer

Low

7.1 ± 0.5

7.8 ± 0.4

Mid

7.7 ± 0.3

5.7 ± 0.5

High

7.6 ± 0.2

4.8 ± 0.3

Avg. Top Titer
7.5 ± 0.4

TMAO
TLL

Avg. Top Titer

Avg. Bottom Titer

Low

5.0 ± 0.4

7.4 ± 0.2

Mid

6.8 ± 0.4

5.6 ± 0.5

High

6.9 ± 0.3

4.9 ± 0.3

Avg. Top Titer
6.3 ± 0.9

Urea
TLL

Avg. Top Titer

Avg. Bottom Titer

Low

5.4 ± 0.9

7.3 ± 0.5

Mid

6.3 ± 0.7

5.1 ± 0.5

High

6.6 ± 0.4

3.5 ± 0.9

Avg. Top Titer
6.1 ± 0.9

All titer values are represented as log10 (MTT50/mL) measured using MTT assay.
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Figure A.2-11. PPV and HIV-gag VLP recoveries in (A & C) PEG-rich and (B & D)
citrate-rich phases, at three common global compositions in presence of different
osmolytes. The open columns indicate 100% recovery in the represented phase. The error bars

represent standard deviation of experiments done in triplicates. The high error bars are because of
the sensitivity of the MTT assay measured in log and converted to percentages.
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Table A.2-3. Viscosities of the PEG-rich phase with and without addition of osmolytes
of systems at different TLL
Osmolyte
None

Glycine
Betaine
TMAO
Mannitol
Urea

TLL

Viscosity (mPa-s)

Low

31 ± 6

Mid

122 ± 41

High

221 ± 7.8

Low

97 ± 21

Mid

265 ± 87

Low

73 ± 17

Mid

239 ± 76

Low

71 ± 17

Mid

221 ± 79

Low

94 ± 25

Mid

279 ± 85

Low

27.2 ± 5

Mid

110 ± 34

Low: system composition of 10 w/w% PEG and 10 w/w% citrate
Mid: system composition of 10.3 w/w% PEG and 13.2 w/w% citrate
High: system composition of 15 w/w% PEG and 14 w/w% citrate
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A.3

Multimodal affinity ligand based aqueous two-phase
system for virus purification

Table A.3-1. Correlation of tie-line ratio and volume ratios of the selected systems on
different tie-line lengths
Tie-line length (w/w%)

Tie-line ratio

Volume ratio

1

0.6

2.3

0.3

1

0.5

2.3

0.3

1

0.8

2.3

0.5

15
25
36

Figure A.3-1. Conjugation confirmation of mPEG-VS and GRCD-WRW by (A) relative
fluorescence spectra comparison of free WRW peptide and PEGVS-WRW and (B)
absorbance spectra comparison of free mPEGVS and mPEGVS-WRW in 1x PBS, pH
7.4. The presence of fluorescence at 310 nm and a high relatively absorbance between
210-280 nm confirms the successful attachment of PEGVS to the peptide with the target
sequence of WRW
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B

Enveloped virus partitioning in ATPS
Aqueous two-phase system (ATPS) has been identified as a potential candidate

for virus purification in the downstream processing of viral products. However, the lack
of partitioning mechanisms and experience with the viral behavior in ATPS leads to a
large experimental space to optimize the recovery process. The viral partitioning studies
must be expanded to familiarize the influence of viral structural characteristics on the
partitioning. A systematic study that involves the viral partition behavior in a pre-defined
standard system needs to be conducted to develop empirical prediction models. The
standard system can be defined with a set polyethylene glycol (PEG) molecular weight
and salt type operated under similar process conditions such as pH and temperature. A
database of the relationship between the viral partitioning deviations from a model virus
behavior and differences in the structural and physicochemical characteristics could yield
a better design for the high-throughput screening of the optimal system.
The standard system determined from the tie-line framework proposed in Chapter
3 can be used to understand viral partitioning behavior of other viruses. Our previous
work developed a tie-line framework to study the partitioning behavior of porcine
parvovirus (PPV) in a PEG 12 kDa-citrate system at pH 7 (refer to Chapter 3 for details).
PPV was a non-enveloped virus model sized 18-26 nm in diameter with a pI ~5. In the
framework, most of PPV was recovered in the citrate-rich phase at the lowest tie-line
length (TLL). PPV salted-out from the citrate-rich phase with an increasing TLL.
However, the viral particles accumulated at the interface due to the lack of driving force
to cross the interface. It was at the highest TLL studied where the salted-out PPV
partitioned to the PEG-rich phase. This partitioning behavior of PPV can be compared to
more virus models with varied structural features to get a better understanding of the
partitioning mechanism.
The previously developed tie-line framework was extended to an enveloped virus
model, herpes simplex virus -1 (HSV) to add to the partitioning behavioral database.
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HSV is a dsDNA virus, 200-250 nm in diameter, with a pI ~5. The envelope presence
makes a virus more fragile and susceptible to structural disintegration under
environmental stress as compared to a non-enveloped virus. The partitioning behavior of
infectious HSV was studied in the pre-defined PEG-citrate system.

Figure B-1. HSV-1 partitioning behavior studied with the tie-line framework. (A)
Partitioning coefficient of HSV at increasing TLL and TLR. Recovery of HSV-1 in (B)
PEG-rich phase and (C) citrate-rich phase. The experiments were performed in
triplicates, and the error bars represent standard deviation.

An overall increase in the HSV partition coefficient trend was observed with an
increasing TLL (Figure B-1A). However, the partitioning coefficients were < 1,
indicating lower partitioning to the PEG-rich phase. HSV was salted-out of the citraterich phase with the increasing TLL, as demonstrated by the lower recoveries in the
citrate-rich phase, but not recovered in the PEG-rich phase (Figure B-1B and C). The
lower recoveries of salted-out HSV in the PEG-rich phase likely signifies two
possibilities. First, HSV partitioned to the PEG-rich phase but was rendered non187

infectious. Second, HSV partitioned to the interface due to ineffective driving forces.
Additional non-infectivity assays, such as ELISA, or DLS, are required to evaluate the
possibilities of the presence of the inactivated virus or aggregated viral particles.

Figure B-2. Effect of osmolytes on the partitioning coefficient of HSV in PEG 12kDacitrate pH 7 systems. The experiments were performed in triplicates. The error bars
represent the standard deviation.

To evaluate the possibility of ineffective driving forces, previously used
protecting osmolytes, glycine, betaine, and TMAO were added to the system (see
Chapter 4 for details on PPV). The osmolyte addition increased the overall HSV partition
coefficients in the order of glycine > betaine > TMAO as compared to the osmolyte-free
systems (Figure B-2). The most substantial increase in the partition coefficient by
glycine did not yield a higher HSV recovery in the PEG-rich phase (Figure B-3A).
Addition of glycine increased the salting-out ability of the glycine-containing citrate-rich
phase (Figure B-3B). The other osmolytes showed a similar enhanced salting-out ability
in the order mentioned above without increasing the HSV recovery in the PEG-rich
phase. On the other hand, the same osmolytes used in this study increased the recovery of
the enveloped HIV-VLPs (see Chapter 5 for details). All three virus models, PPV, HSV,
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and HIV-VLP were negatively charged, which enabled a better salting-out ability of the
citrate-rich phase. However, the interface and PEG-rich phase interaction with the viruses
differed. Thus, additional work needs to be performed to understand the enveloped virusPEG interaction and virus-interface interaction.

Figure B-3. Effect of osmolytes on HSV recovery in (A) PEG-rich phase and (B) citraterich phase. The experiments were performed in triplicates. The error bars represent the
standard deviation.
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Figure 4.(b) Elution salt concentration and relative
hydrophobicity to the Phenyl as compared to RNase,
calculated using the fraction containing the highest titer.
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